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Study rationale: Managing patients whose disease has become unresponsive to anticancer 
treatment confronts oncologists with major stressors which may range from the management 
of distressing physical symptoms to complex psychosocial issues. These sets of circumstances 
prompted the undertaking of this study: An evaluation of the current practices followed by 
oncologists in private practice in Cape Town, South Africa, in the management of patients with 
advanced cancer which no longer responds to anticancer treatment and the identification of 
the needs associated with such management. 
Method: A descriptive qualitative study was selected for data collection. Cross-sectional, in–
depth semi structured face to face interviews were conducted with fifteen radio-oncologists 
working in five satellite units of a private oncology company in Cape Town. The interviews were 
conducted with the aid of a topic guide.  The process of coding was employed to organise and 
manage the collected data.  
Results:  The following six themes which had a bearing on the main topic were distilled from 
the data: Oncologists’ experiences pertaining to the management of patients with advanced 
disease; the difficult discussion necessary when a patient’s disease  became incurable and when 
it had to be decided whether anticancer treatment should be stopped; the decision to stop 
anticancer treatment; advance directives; oncologists’ burnout and the palliative care team 
approach.  
Discussion and conclusion: A description of challenging aspects associated with the 
management of terminally ill cancer patients is given. Identified needs include training of staff 
in palliative care; guidance for oncologists regarding the discussion of and the decision to stop 
anticancer treatment; implementation of advance directives; the development and 
employment of a multidisciplinary approach to provide palliative care; and support for 
oncologists facing burnout. Recommendations were made pertaining to appropriate training in 
the field of palliative care; the development of guidelines to aid oncologists in the discussion of 
and decision to stop anticancer treatment and the implementation of advance directives; the 




palliative care physician; and external support which should be provided by the oncologists’ 




CHAPTER 1: BACKGROUND 
1.1 Introduction     
The management of patients with advanced cancer which does not respond to anticancer 
treatment is often a major challenge for oncologists. Patients may present with a variety of 
problems ranging from distressing physical symptoms to complex psychosocial and spiritual 
issues.  The complex care they need due to their advanced disease puts a great deal of stress on 
their families and on healthcare resources.1 Despite the availability of palliative care services 
and the benefit of the palliative care approach in complex problems associated with patients 
suffering from advanced disease, the utilisation of palliative care services by their treating 
physicians remains low.2 As a result the patients involved are deprived of the benefits of 
palliative care, such as the efficient treatment of depression, fewer hospital admissions, 
improved quality of life and even a substantial survival advantage. This was evident in the 
findings of the study undertaken by Temel et al. They confirmed that patients with metastatic 
lung cancer who received palliative care in the early phases of  their disease, showed 
improvement in quality of life, experienced less depressive symptoms, required less aggressive 
end of life care and had a longer median survival when compared with patients who received 
only standard oncology care.3 
1.2 Importance of advanced cancer care 
 The incidence of cancer is globally on the rise. The World Health Organization estimated that 
by the year 2020 more than 15 million people worldwide will have cancer.  Of those, 10 million 
will die each year which will represent a 60% increase in deaths.101  Although 50% of patients 
with cancer are not cured, early detection and advanced cancer treatments result in patients 
living longer despite their advanced disease. These patients can experience profound 
distressing symptoms and psychosocial issues associated with advanced disease. Additionally, 
in view of the general aging of the population, these patients are usually older and thus at risk 
of developing co-morbidities and chronic diseases which will make their health needs much 
more complex.4 However, by combining palliative care with oncology treatment in the 




can be considerably enhanced. This was shown in the results of a randomised controlled trial 
conducted by Bakitas et al. The trial demonstrated that the quality of life and mood of patients 
with advanced cancer who received nurse led intervention focused on palliative care improved 
noticeably when compared with those of patients who received usual oncology treatment.5 
Such relief of complicated symptoms and other distressing factors associated with advanced 
cancer, brought about by the early implementation of palliative care, strongly emphasises the 
value of such an approach.    
1.3 Caring for patients with advanced cancer  
Patients suffering from advanced cancer present with distressing physical symptoms as well as 
complex psychosocial and spiritual issues. Such issues, which need to be identified and 
appropriately managed by the treating oncologist, include the following: 
1.3.1 Pain and associated physical  symptoms 
Pain caused by advanced cancer is often complex and chronic.6 It is present in all phases of 
cancer and the assessment and treatment thereof is of utmost importance.7 In addition it may 
cause psychological symptoms, decline in performance status, spiritual or existential distress 
and social disruption. All of these may affect the quality of life of the patients and families.8 Yet 
studies have shown that pain suffered by cancer patients is still not adequately treated.7 
Although pain is commonly associated with advanced cancer, other physical symptoms can also 
contribute significantly to the discomfort suffered by cancer patients. Fatigue and anorexia are 
the two most common symptoms associated with emotional and physical distress with pain 
ranked third. Other common symptoms frequently coupled with pain are dyspnoea, dizziness, 
tenesmus, nausea, constipation, delirium and confusion which all affect quality of life 
negatively.9   
The early identification and impeccable assessment and treatment of pain and other distressing 
symptoms should therefore be a priority in the management of patients whose disease is no 
longer responding to active treatment. This can usually be achieved through a direct organised 
approach. Good pain management requires that the patient receives a thorough pain 




effectiveness of the regime. Good communication between the oncologist and the patient is 
essential.10 All treatment options, questions and concerns regarding pain control and general 
measures and advice to reduce pain should be discussed with and explained to the patient and 
family. The management of nonpain symptoms in advanced cancer patients includes 
identification and treatment of possible underlying causes by means of proper historical, 
physical and laboratory assessment as well as alleviation of the symptoms. As in the case of 
pain management, frequent evaluation and good communication is vital for proper symptom 
control.9     
1.3.2 Psychosocial issues 
It is well recognised that the diagnosis and treatment of cancer impact severely on the lives of 
patients and their families. Studies have shown that cancer patients experience a great deal of 
psychosocial symptoms and distress. Not only does the disease and its treatment cause physical 
distress but it also triggers emotional issues, role limitation and lack of social activities.11 It has 
also been indicated that 35% of cancer patients present with psychological symptoms of 
anxiety, depression and changes of mood.11 The quality of life of cancer patients suffering of 
depression is markedly affected. Their cancer tends to progress more rapidly and their cancer 
related symptoms, especially pain, tend to be more severe.12 Psychological responses to major 
losses, such as loss of independence and loss of physical health, are also more prominent in 
advanced cancer patients. These responses are often seen at the time of or shortly after the 
initial diagnosis has been made, at the time of the first disease recurrence and as death 
approaches.13  
Psychosocial issues associated with patients with advanced cancer are currently managed 
through adjunctive programmes such as psychotherapy, support groups and psycho-education. 
These services are usually provided by social workers, chaplains and counselors and should be 
in conjunction with medical care.12 Modern medical practice has also recognised the 
importance of applying a patient centered model of care. In the fields of both oncology and 
general medicine approaches such as these, where physicians are encouraged to communicate 
in a patient centered way, have resulted in improved patient outcomes and recovery.11   
4 
1.3.3 Spiritual issues 
Spirituality and religion becomes highly significant when a patient approaches the end of his 
life. It is well recognised that spirituality and religion can affect a patient’s quality of life, quality 
of care and satisfaction.14 Spiritual pain can be defined as a conflict situation that occurs 
between a person’s belief structure and his current reality. It is experienced when there is 
conflict and disharmony between a person’s hopes, beliefs and values and his personal 
experience with life. It often has its origin in a traumatic life shattering incident which 
influences a person’s current life perspectives and purposes. This may cause disparate states 
like distress, loss, frustration, sorrow, disbelief and discomfort which, in turn, may trigger a 
poignantly painful condition.15 Studies have shown that a high prevalence of spirituality, 
religiosity and spiritual pain is observed in patients with advanced cancer who are receiving 
palliative care. Importantly, such patients regarded these issues as markedly significant which 
either improved or worsened their physical and psychological symptoms. Spiritual pain was also 
found to be associated with a decreased spiritual quality of life. Evidence showed that the 
addressing and supporting of patients’ spiritual issues could lead to improvement in quality of 
care, higher hospice utilisation and less aggressive terminal care. Therefore, it is important to 
perform regular spiritual assessments to identify spiritual needs that ought to be addressed 
appropriately.14 
1.3.4 A multidisciplinary team approach 
The optimal management of the distressing symptoms and psychosocial issues associated with 
patients with advanced cancer requires a multidisciplinary team approach. The palliative care 
team and the treating oncologist are integral components of such a multidisciplinary team. 
Physical symptoms, psychosocial stress and spiritual issues may present at any time in the 
course of the illness. Hence it is essential to implement palliative care as soon after the 
diagnosis as possible to ensure proper management of needs and quality of care.16 By following 
a multidisciplinary approach, the treating oncologist may benefit from the wisdom and support 
of fellow team members. A successful team may possess a combination of strengths and skills 
which will not be available should the oncologist be functioning alone.17  With the support of 




the disease while the palliative care team will concentrate on symptom management and 
psychosocial issues.   
The palliative care team should be familiar with the role of the oncologist in the team and must 
be informed about the cancer which is treated as well as of the effectiveness and side effects of 
the treatment. They should also be aware of any symptoms shown by the patient that may 
benefit from anticancer treatment. Such a case should be referred to the oncologists for 
consideration. Although palliative care teams are more likely to be involved in caring for 
patients with advanced and incurable cancers, patients with early or curable cancer in the 
adjuvant setting may also benefit from their expertise.16  
1.4 Attitudes of treating oncologists 
A survey regarding the attitudes of oncologists toward palliative care for patients with 
advanced and incurable cancers was performed by the European Society of Medical Oncology. 
This survey recognized the importance of palliative and supportive care of patients with 
incurable cancers. It was also found, regrettably but not unexpectedly, that most oncologists 
did not receive adequate training in palliative care during their residency training. Consequently 
and inevitably this leads to suboptimal levels of participation by oncologists in palliative care 
programmes later in their careers.1  
Oncologists are trained to treat aggressively and to cure where possible. If regular curing of 
patients is not accomplished, this mind-set can cause a great deal of stress for and even 
burnout of the oncologist. Contributing to this perception of failure is the pressure of the  
patient’s and family’s unrealistic expectations which often are in stark contrast with the reality 
of what can be achieved with the treatment of an advanced disease.18 In addition, continued 
exposure to the demise of patients with whom the oncologist has developed a relationship, was 
involved with their emotional conflicts and was expected to absorb their and their families’ 
emotions of grief and anger can inflict major stresses on the treating oncologist.13 
1.5 The cost of cancer care 
Major advances in the understanding of cancers and the treatment thereof have led to a 




with substantial cost increases.  These increases add considerably to the financial burden on 
patients and their families and to the demands on national health care resources. Studies have 
shown that even patients with health insurance are negatively affected by the increase in 
treatment costs.  Of these patients 25% were compelled to deplete their financial reserves to 
pay for oncology treatments while 33% struggled to such an extent to pay their health bills that 
they are faced with financial ruin.19  
Treating oncologists are in a position to directly or indirectly influence the costs of cancer care. 
Their choice of treatment options or drugs, usage of imaging and special investigations, types of 
supportive care and decisions on hospital admissions substantially affect cancer care costs. 
Amongst the suggestions made to mitigate the impacts of increased cancer care costs was to 
better integrate palliative care into standard oncology care. Randomised trials have shown that, 
when compared with standard oncology care alone, the effective combination of palliative care 
with standard oncology care not only leads to longer survival by patients and enhanced patient 
and family satisfaction but also to meaningful cost savings. Furthermore, by applying better 
integrated palliative care, a patient’s fear of abandonment can be reduced and his quality of life 
and life expectancy can be improved.20 
1.6 The role of chemotherapy in advanced stage disease 
Progress in cancer related therapy has brought about significant improvements in overall 
survival of cancer patients as well as in response to treatment and toxicities. However, these 
treatments are associated with distressing side effects. Although some of these side effects are 
reversible, they can still undermine the patient’s psychological well being and have a negative 
effect on his quality of life.21 This notwithstanding, chemotherapy remains the foundation of 
treatment of patients with advanced cancer in developed countries. The main aim of treatment 
is to prolong survival and to palliate symptoms.22  
The prevalence of chemotherapy related side effects, which influence the patient’s quality of 
life, sometimes makes continuation of treatment unacceptable especially if the aim of 
treatment was palliation of symptoms. Appropriate cessation of chemotherapy plays an 




as a bench mark in quality assurance and improvement in clinical practice. The accepted 
approach is that chemotherapy should be stopped in the final two weeks of life. Usually less 
than 10% of patients receive chemotherapy during this period.22 
When chemotherapy is applied when death is certain and imminent, the question needs to be 
asked whether one is prolonging life or prolonging the process of dying. In some cases serious 
side effects associated with chemotherapy, such as neutropaenic sepsis, bleeding due to 
thrombocytopenia or bowel perforation, could be fatal and can then be regarded as hastening 
death. Therefore, a decision needs to made if continuing chemotherapy in this scenario is 
appropriate or aggressive.23 The following has been identified as markers for aggressive 
chemotherapy:  The overuse of chemotherapy near the time of death; high rates of emergency 
unit visits; ICU admissions and hospitalisations of terminal patients as a result of chemotherapy 
related side effects; and underuse of hospice facilities due to lack of or late referrals of terminal 
patients.25  
Many reasons are presented for continuation of potentially futile treatment. Studies have 
shown that the treating oncologist plays an important part in this situation. Overestimation of 
prognosis and lack of important information provided to the patient and his family by the 
treating oncologist can lead to inappropriate continuation of treatment and may create a sense 
of false hope for the patient.22 When it does not acknowledge the reality of an imminent death, 
such false hope can lead to inadequate end of life arrangements and added suffering by 
patients and their family members.24 Another possible cause for continuation of potentially 
futile treatment could be the recommendation of another line of lucrative chemotherapy to 
avoid the difficult discussion of cessation of treatment and implementation of palliative care.22  
On the other hand the prolongation of chemotherapy at the end of life may be insisted on by 
the patient and/or his family. This may be caused by a personality trait to persevere and to 
keep on fighting in hope for a cure or for the improvement of the chances of survival. Although 
continuation of treatment will give the patient a feeling of control over his disease and a sense 
of hope, it may delay acceptance of his preterminal condition and deny him and his family to 




Therefore, with the emphasis on quality of life, the treating oncologist should discuss openly 
with patients and families the prognosis of their disease and the desirability of further 
treatment. In such a discussion the efficacy and benefits of further chemotherapy treatment 
and the possible adverse effects and symptoms that may be experienced must be addressed 
frankly and it needs to be clearly stated that the chemotherapy is not going to effect a cure.  
Patients need to be made fully aware of the aggressiveness of cancer treatments and of the 
impact it may have on their lives and the lives of their family members. New approaches within 
the field of oncology and especially palliative care, which focuses mainly on enhancement of 
quality of life, should continuously be integrated in the care of patients suffering from advanced 
cancer.21   
1.7 The role of the oncologist treating patients with advanced cancer 
Globally, cancer is a major public health problem. It is responsible for more than 25% of all 
adult deaths in the United States. According to the latest cancer statistics the overall cure rate 
for cancers are less than 60%.26 It is therefore no surprise that many patients may perceive 
cancer as a chronic disease that ultimately causes their deaths. These patients regard issues 
pertaining to quality of life as essential, irrespective of the illness trajectory and duration of 
survival.  Therefore, their care should provide for quality of life dimensions by combination of 
disease specific treatment and palliative care according to the patients’ clinical circumstances 
and their own priorities and preferences. In these cases the role of the treating oncologist is 
that of primary cancer caregiver and coordinator of clinical services. This can be very 
demanding and may be associated with complicated challenges which require a fair amount of 
cognitive, interpersonal and clinical skills.27 
The clear division of cancer care into two parts starting with disease specific anticancer 
treatment followed by symptom control and palliative care in the advanced stage is no longer 
appropriate. The treating oncologist’s responsibilities towards his patient should not only 
comprise the provision of anticancer treatment but also the management of psychosocial, 
spiritual and clinical issues during all phases of care until the final phase of life. To accomplish 




neoplastic therapy but also to provide appropriate palliative care. Obtaining palliative care 
training and training in the utilisation of specialised palliative care teams is necessary to enable 
oncologists to manage terminally ill cancer patients more efficiently.28  Familiarisation with the 
field of palliative care will extend the oncologist’s therapeutic range and will diminish the stress 
associated with treating patients with incurable disease and, consequently, will improve patient 
outcomes and will provide new avenues for clinical research and reward.27 
1.8 Communication in advanced cancer treatment 
Diagnosis of cancer is often associated with feelings of fear, anxiety and uncertainty 
experienced by patients while questions about issues regarding mortality are also triggered. 
Consequently, cancer patients are also subjected to a fair amount of stress. Such stress can 
affect their ability to interpret and integrate complicated medical facts and information which 
underpin the difficult life changing medical decisions that need to be taken. These experiences 
are more intense in patients with advanced cancer where the balance between hope and 
despair in the search of a possible cure can cause great tension.29 The quality  of the care for 
patients in this situation is dependent on effective oncologist-patient communication, 
especially in patients with intense suffering and emotional stress. Patients who are given the 
opportunity to disclose their fears and concerns tend to cope with their circumstances better.30 
Despite the above, doctors and nurses sometimes are inclined to censor the information they 
disclose to their patients.  Disturbing facts are withheld as an effort to prevent harm. Such less 
than honest disclosures of information usually occur when the patient first reports suspicious 
symptoms; at the confirmation of a diagnosis; when assumed benefits of disease specific 
therapy are discussed; at disease relapse or progression or at the end of life. By protecting the 
patient from the truth, well meant as it may be, more harm than good is often done. 
Furthermore it can lead to inconsistent messages given by other members of the multi-
disciplinary team.  Although the provision of these ambiguous or misleading messages may 
render some short term benefits while things are still going well, the occurrence of negative 




A patient who suffers from a life limiting disease needs time and space to adjust to and to come 
to terms with his disease. Realistic hope can only be given and reasonable objectives can only 
be set with honest disclosure of information.31 In this context the treating oncologist should 
ascertain from the patient what he defines as hope and what he hopes for in his particular 
situation. In the case of incurable disease, the oncologist should gradually guide the patient to 
let go of unrealistic particular hope for cure and progressively adopt more generalised forms of 
realistic hope.  More rational aims that could be strived for may include  a remaining life 
without pain and suffering; the presence of loved ones  at the patient’s death bed; personal 
matters that are in order; the reaching of spiritual peace and assurance that family members 
and children will be well cared for after the patient’s death.24  
It is well known that an open and sensitive discussion on end of life issues with patients 
generally leads to less aggressive end of life treatment and enhanced quality of life in the days 
preceding death.24 Therefore, effective and honest communication between a patient with 
advanced cancer and his oncologist or healthcare worker must be a priority. 
1.9 Patients’ preferences for prognostic information about their disease 
Surveys have indicated that most patients want extensive information on their prognosis. The 
kind of prognostic information required is usually influenced by the patients’ cultural 
backgrounds, their views on hope and their acknowledgment or not that information on a poor 
prognosis can influence psychological processes.32 In some cases discrepancies can occur 
between the information given by the oncologists and their patients’ understanding thereof. 
Medical information is often poorly absorbed and communication is often affected when 
patients are confronted by an incurable disease. Patients are prone to misinterpret the given 
information usually more positive than it was intended to be.33 This can lead to unrealistic 
hope, for instance that a patient with a 10% chance  to survive five years might regard himself 
to be in the 10% group.    
It has further been reported that the manner in which prognostic information is given to 
patients can affect patients’ satisfaction, depression, anxiety, hope and the patients’ views on 
the possibility of applying alternative therapies. Most patients require information about life 
11 
expectancy, the extent of disease progression, how the cancer will affect their lives and on the 
possible side effects of disease specific treatment. It has also been shown, however, that most 
patients want their oncologists to request their permission before discussing such information 
and that the information is given in a direct and honest manner.  Patients prefer that their 
oncologists use both positive and negative language to convey the news. They would rather 
prefer that a friend or relative is present and that the communication takes place in a private 
arrangement.  Patients usually appreciate when the oncologist summarises the contents of his 
communication, checks understanding thereof and listens to and addresses their fears and 
concerns.34 Maintaining or sustaining hope is a very important factor for the patient when 
prognostic information is disclosed. Patients seem to be more flexible in their formulation of 
hope and do not necessarily interpret it  in terms of a biological cure, as their treating 
oncologists do. They derive it from the interaction with their oncologist, even if the information 
is unfavourable.32 
1.10 The oncologist’s role in communication 
It has been reported that most oncologists find it difficult to discuss prognostic information 
with their patients, especially when their disease becomes incurable.32 They are aware of their 
responsibility to discuss their patients’ prognoses and the role it will play in the planning of 
advanced care and the setting of goals. There is evidence that oncologists, when 
communicating information regarding poor prognoses to their patients, experience unpleasant 
and troublesome emotions of unhappiness and frustration and even exhaustion. This can lead 
to variable physician behaviour in disclosing prognostic information.34 
It is important that oncologists must have frequent and objective discussions on treatment 
options with their patients throughout the course of their disease. Comprehensive information 
should be given about their disease status and treatment options. During these discussions the 
amount of detail should be tailored to the individual patient and due consideration should be 
given to the patient’s wishes. When discussing disease specific anticancer treatment, it is 
important to mention the aim of treatment (whether curative or palliative), the likelihood of 




information together with optimistic information instead of following only an optimistic 
approach can lead to better understanding and informed consent. The financial impact of 
disease specific treatment should also be discussed.35  
Communication hurdles may be encountered when the decision to stop anticancer treatment is 
to be or has been made. Patients often do not grasp what their oncologists tell them. Their 
physical weakness and the mental stress associated with their advanced disease can impede 
their ability to understand what they have been told. This often causes irrational decision 
making. The stress associated with the bad news can also cause the patient to transfer the 
responsibility to take the decision to an immediate family member or even to the oncologist. 
This may lead to treatment that is different to what the patient wants. Oncologists may also 
find it difficult to recommend that curative treatment be stopped as it may be perceived as an 
admission of failure. It would be much easier and more acceptable to the patient and his family 
if another round of chemotherapy is suggested, even though it is a mere  catching at  straws.36 
Given all the complexities associated with cancer care, the vast variety of anticancer treatments 
and the high expectations of the patient and his family, it is obvious that communication with 
the patient and his family is a significant part of the oncologist’s role in caring for patients with 
advanced cancer and an important topic for training.27 
1.11 Advanced care planning 
When a patient’s cancer has progressed and is no longer responsive to anticancer treatment, 
decisions have to be taken regarding the aim of further medical treatment. This aim could be to 
prolong survival, alleviate distressing symptoms or to improve quality of life. The patient’s 
preferences regarding the aim of treatment and the balance between benefits and side effects 
of treatment are very important factors that need to be taken into account when taking these 
decisions. It is important to discuss treatment preferences and possible directives for advanced 
care already in the early phases of a patient’s disease. This approach will ensure the 
involvement of the patient in medical decisions that will influence the final phases of his life.37 
Advanced care planning is a process which, although voluntary, is advisable to be undertaken 




discussion of advanced care planning must include the patient’s preferences, feelings or belief 
about personal goals or aspirations for care, his disease and prognosis, different types of 
treatment that are available and their benefits, harms and risks and possible decisions that 
need to be taken about his future care and treatment.38 
An important outcome of the discussion will be the identification of options for future care and 
treatment, or the refusal thereof in specific circumstances.  The options decided upon should 
be recorded and be communicated to those who will be responsible for the patient’s care or 
treatment, be it family or care givers. This step is necessary as progression of the disease may 
result in the patient losing his capacity to take rational decisions due to the possible occurrence 
of delirium and cognitive impairment. Alternatively, the patient may decide or be encouraged 
to nominate someone known as a “proxy decision maker” to be consulted and to take decisions 
on his behalf when he is unable to do so.38  
Guidance and participation by the physician, family participation and the use of structured 
material to foster discussion and documentation are essential factors which will ensure the 
success of the process.39 Discussions on advanced care may also bring about an increased sense 
of control with the patient which will help him to anticipate the decisions that will have to be 
taken as his illness progresses. This will also reduce anxiety in proxy decision makers which, in 
turn, will improve the teamwork of the professionals.38   
The issues mentioned above again emphasise the importance of addressing advanced care 
already during the early phases of the disease. This action may in some cases be very difficult as 
it may confront the patient with the reality of imminent death for which he may not yet be 
ready. It may also affect the patient’s particular hope for a cure for his disease. It is therefore 
important that the oncologist only enter into discussions regarding advance care planning when 
the patient and family are ready to listen, hear and talk about this topic. Patients with little or 
no interest should be questioned about it once a year or sooner when their condition 
deteriorates. Patients who are showing some interest should be given written information, 
websites or educational materials with a view to discussing these issues at future 
appointments. 40   The failure to plan for advanced care or to prepare clear directives may result 
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in unnecessary aggressive cancer care once the patient has lost capacity to take decisions 
thereon. This can lead to inadequate care and resultant poor quality of life for the patient as 
well as complicated bereavement for family members and care givers.41 
An important matter which should be addressed in advanced care planning and directives is the 
issue of active resuscitation. It is generally accepted that active resuscitation is inappropriate 
for patients suffering from advanced metastatic disease. Patients who experience an in-hospital 
arrest have a 13% to 15% response rate to a resuscitation attempt and will eventually die in 
hospital.43 Patients who are told that their chances of surviving six months are more than 10% 
often want life prolonging care. On the other hand, if the chances of surviving six months are 
less than 10%, patients often opt to decline active resuscitation and choose palliative care 
only.42 By disclosing an accurate prognosis and illness trajectory the treating oncologist will help 
patients suffering from advanced stage disease to make sensible choices with regards to active 
resuscitation. This will also put both care givers and family members of patients who might not 
be aware that the disease has become incurable on an equal footing regarding the current 
disease status and treatment aims.43 
Ideally, advanced care planning is a frequently reviewed and updated process of structured 
discussion and documentation which is woven into the regular healthcare process. Its aim is to 
ensure that the wishes of the patient are respected in decisions regarding his further treatment 
and care when he is no longer able to participate in such decisions.39 
1.12 The multidisciplinary team approach 
The challenging needs of patients whose diseases are not responding to curative treatment 
require a range of expertise to ensure that the patients’ end-of-life care fulfills all the wishes 
and desires of the patients and those close to them. Palliative care plays an important role in 
addressing these needs. It embraces different frameworks and approaches to adequately 
provide in every need of the patient. Thus, team work has become an essential part of palliative 
care through the years, drawing heavily on wide-ranging disciplines, knowledge, experience, 
skill and creative thought. Palliative care teams may consist of nurses, doctors, social workers, 
psychologists, chaplains, healthcare volunteers and a multitude of other treatment modalities. 
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Oncologists who engage in teamwork benefit from the support and wisdom of such a diverse 
team which provides a valuable basis for collaborative care.44 
1.13 Advantages of teamwork 
Numerous studies have shown that the provision of healthcare through a team effort is much 
more effective than the provision thereof through a single practitioner. By following the team 
approach both quality and quantity of services are improved. Teamwork enhances 
communication and coordination which leads to a more efficient utilisation of the available 
professional expertise. These factors are conducive to beneficial outcomes such as reduced 
hospital admissions, less time spent in hospital, decrease in costs and improved accessibility for 
patients. More can be achieved through a team effort than can be realised through the sum of 
the capabilities of the team members operating individually.45  
It has been shown that the diversity of clinical expertise in a multidisciplinary team was 
responsible for clinical decisions which caused considerable improvement in patient care and 
organisational effectiveness. As such it is a source of work stimulation and reward and leads to 
a work environment wherein team members support each other and give valuable feedback. By 
working together problems and stressors as well as successes are shared. This may lead to 
more effective resolution of conflicts which, in turn, further contributes to improving quality of 
care.45     
1.14 Burnout of oncologists 
1.14.1 Oncology: A complex and demanding profession 
Oncology as an occupation comprises diagnosis of complex medical conditions, administration 
of advanced individualised anticancer treatment regimes and the provision of critical support to 
patients suffering from challenging life limiting diseases. However complex, caring for patients 
with cancer can be very rewarding to the treating oncologists. The combination of the advances 
in science which have led to improved prognoses for patients, the progress in the field of 
palliation and the opportunities to connect with patients and to show compassion can enhance 




Yet, despite these real occupational benefits, caring for patients with cancer is a very 
demanding and stressful task. Oncologists are faced almost on a daily basis with complicated 
decisions. These decisions relate to life and death issues such as the provision of cytotoxic 
anticancer treatment with a narrow therapeutic window which has a limited ability to improve 
the survival prospects of many patients. Such constant dealing with suffering and death can 
cause depression, cynicism and a sense of futility. In addition, the oncologist must keep up to 
date with rapidly advancing treatment regimes and keep abreast with a steadily increasing 
volume of information. Moreover, oncologists have to deal with escalating productivity 
requirements, reduced autonomy and the ever expanding administrative responsibilities 
required of all physicians. This growing burden on the oncologist leads to burnout, a syndrome 
characterised by a lack of enthusiasm for work, depersonalisation and a loss of meaning in 
work. According to studies this syndrome affects 25% to 35% of medical oncologists, 38% of 
radiation oncologists and 28% to 36% of surgical oncologists.46 
1.14.2 Causes of burnout 
Although burnout is well documented in physicians of all specialties, oncologists are at 
particular high risk due to their constant exposure to the death and suffering of their patients. 
In addition, many other factors can cause emotional exhaustion and burnout in oncologists. 
Recent studies have shown that, excluding deaths and suffering of patients, the major causes of 
burnout amongst oncologists are heavy patient load, keeping current with the latest literature, 
delivering bad news to patients and finding a balance between work and personal life.47 In the 
past oncologists used to own their practices, hired their own staff and firmly controlled their 
patient load, working hours and work pace. Nowadays they are employed by private 
companies, hospital groups, cancer centers or academic institutions and have much less control 
over these working conditions. Productivity targets are set by business management and 
remuneration is calculated in accordance with the number of patients seen. Expensive 
anticancer treatments need to be authorised by medical aid schemes. Compilation of 
motivations for such authorisations adds to the daily burden of administrative work and, in turn 
causes extra stress.46 In addition, difficulties in finding a balance between the oncologist’s 
personal and professional life is another common cause of distress. Studies have shown that 
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inadequate time away from work is regarded as the single major cause of burnout in 
oncologists.47 
In contrast with the comments by palliative care clinicians regarding the personal and 
professional satisfaction they experience when they succeed in  relieving the suffering 
experienced by their patients, they may ultimately  realise that, due to burnout, they are not so 
caring and motivated as they once were. They may also become conscious thereof that they no 
longer enjoy their work, that they have lost that special connection they once had with their 
patients and that they have given up on personal activities that used to rejuvenate them. Such 
a realisation can precipitate an existential searching and loss of professional direction.47  
1.14.3 Alleviating burnout 
Due to the fact that most oncologists will experience some degree of burnout during their 
career, it is important to emphasise that recovery from burnout is possible. It often requires an 
honest appraisal of personal and professional factors that may be responsible for burnout and a 
concerted effort to find ways to address these factors and to effect the necessary changes.46 
Several practical suggestions can be followed by the oncologist to prevent burnout. Good, 
uninterrupted sleep is important to deal with stressors and to promote clear thought. Sharing 
night and weekend calls with colleagues should therefore be routine and necessary. Short 
periods of rest during the working day are also necessary to prevent fatigue and to improve 
productivity. Extra time should be allowed to connect with patients. Such interaction may not 
only be refreshing to the oncologist but may also reconnect him with some of the original 
reasons which determined his choice of profession. Physical activity and hobbies are good for 
promoting a sense of well being and laughter and humor is good for personal and staff 
morale.48 
The prevalence of burnout can also be reduced by forming clinical health teams where team 
members can clinically and emotionally support one another.48 It is important that a supportive 
environment and working relationships are upheld within the clinical team. Regular team 
meetings are necessary to evaluate and reflect on complicated situations encountered by 




respect each other’s expertise and to provide meaningful support to each other. These 
meetings can also be used as an opportunity for the members to express work related feelings 
and to openly discuss problems of the workplace.49 Each team member needs to develop a 
sense of self awareness which will alert him  when his stress levels are rising and which will 
enable him to recognise what encourages and exhausts him in his work. Effective training and 
mentoring by experienced clinical care workers can aid immensely in developing professional 
competence within the team.51 
Burnout is a common feature in oncologists which has profound personal and professional 
consequences. Given the serious consequences that can be associated therewith, oncologists 
owe it to themselves, their patients and their families to commit to measures to alleviate 
burnout and promote personal health.46 Time management and positive adaptive strategies are 
essential for a successful and happy practice.48  
1.15 Conclusion 
Despite rigorous efforts to prolong life in their field of practice, oncologists inevitably encounter 
patients whose disease does not respond to curative treatment. While important advances 
have been made in the treatment of cancer over the past decade, more or less half of all 
current cancer patients will eventually succumb as a result of their disease or associated 
complications. Therefore, caring for patients as they die is a prominent part of an oncologist’s 
daily practice. This can generate arduous stressors and demanding challenges which may 
eventually affect the quality of care provided.5 It is for this reason that the researcher will 
evaluate in this study the current practices followed by private oncologists when managing 
patients whose disease does not respond to anticancer treatment. The purpose of this 
evaluation will be to identify needs and to develop recommendations to essentially optimise 
quality of care and to ensure support for the treating oncologist.  
It has been described that, regardless of all the fixations and preoccupations of oncologists in 
their efforts to cure their patients, no experience will give greater satisfaction or provide firmer 
confirmation of the soundness of their choice of occupation than by bringing comfort and 




a private enterprise specialising in cancer care, the researcher has witnessed firsthand many 
challenges  associated with cancer care in the private sector. The high expectations of private 
patients and their families together with the stress associated with the requirement to increase 
the throughput of patients to enhance the company’s profitability are some of the frustrating 
factors to be dealt with on a daily basis. Although high standards of care are maintained it is the 
researcher’s view that the main focus of cancer care in the private sector is primarily on 
evaluation, staging and the initiation of lucrative anticancer treatment while palliative and 
supportive care are not receiving the attention it deserves. One of the purposes of this study 

















CHAPTER 2: LITERATURE REVIEW 
2.1 Introduction 
Patients diagnosed with advanced, incurable cancer present a major challenge to their treating 
oncologists. Oncologists may be faced with complex emotions associated with the impact of a 
life limiting disease and with difficult decisions to be taken on treatment which has a limited 
chance of being beneficial. In addition, the presence of distressing physical symptoms and the 
challenge of maintaining hope despite bleak prospects are equally taxing.52  Numerous studies 
have been conducted on patients suffering from advanced disease with regards to issues such 
as symptom management, quality of life, patient and family experiences, of an ethical nature 
and pertaining to communication. However, little qualitative work has been published, 
especially in South Africa, regarding the current practices and identified needs of oncologists 
treating such patients.  Important aspects of the treating oncologist’s management of patients 
suffering from incurable cancer have been researched from the literature. Search engines used 
for the literature review included PubMed, Google Scholar and EBSCO HOST and key words 
used included advanced cancer, incurable cancer, palliative care, palliative chemotherapy, end 
of life care, communication in oncology, qualitative study of oncologists, multidisciplinary 
approach, palliative care team, oncologist burnout, advance directives, advance care planning 
and palliative care in South Africa. 
2.2 The oncologist’s experience of managing patients with advanced disease 
2.2.1 Attitudes towards palliative care 
Despite all the latest advances in cancer treatment, the mortality of patients diagnosed with 
cancer remains high. Cherny and Catane, both reputable authors in the field of palliative care, 
reported on the European Society of Medical Oncology’s (ESMO) survey on oncologists’ 
involvement in and attitude towards palliative care.1 The rationale and aim of the study were 
clearly stated. It was prompted by the fact that the care of patients with advanced disease 
represents a major part of the work load of oncologists in Europe and the world and is 
associated with stress and other complexities. Hence, the aim of the survey was to gather 
information which could be used to improve the quality of supportive and palliative care 
rendered by the oncologists. The survey tool used had been developed by a focus group of 
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oncologists who were members of the Palliative Care Working Group of the ESMO. It was 
validated also by oncologists of the Working Group in collaboration with the executive of the 
ESMO. The population was clearly identified as ESMO oncologists. A total of 738 responses 
(82.5%) were received from 35 European countries and from five other continents which 
adequately allows for generalisation of the results. 
The results gathered from the survey were clearly and appropriately presented. Of the 895 
members who responded to this survey 69% reported that their practices included patients 
with advanced disease. Of the latter respondents 74% indicated that they derived satisfaction 
from their involvement with end of life care. Most of the responding oncologists acknowledged 
the importance of the provision of palliative care to patients with advanced disease and during 
the dying process. However, many admitted that they had not been adequately trained for the 
task and, in view thereof, had not participated in palliative care.  Only a minority of oncologists 
involved palliative care specialists, hospice services, home based palliative care and 
psychologists in the care of these patients. The majority of the oncologists were more 
comfortable with the management of physical symptoms such as pain, fatigue, nausea and 
vomiting than with the management of psychological symptoms such as depression and anxiety 
and with the provision of end of life care.  
The survey confirmed that most oncologists who participated were positively inclined towards 
palliative and end of life care. However, it is a cause for concern that, despite this positive 
attitude, most oncologists did not receive adequate training in palliative care and were not 
equipped to deal with psychological aspects and end of life care. Skills in these areas are 
essential when managing patients with advanced diseases. The authors mentioned that 
possible bias might have been present in that the majority of respondents were clinicians with 
an interest in palliative and supportive care. The fact that oncologists with active interest in 
palliative care are not comfortable in dealing with non physical palliative care related problems 





2.2.2 The ability of oncologists to identify psychosocial distress in cancer patients 
Sollner et al conducted a study to determine oncologists’ ability to identify cancer patients who 
suffer from significant distress, who do not have proper social support and who are in need of 
psychosocial counseling. Their premise was that oncologists should play a vital role in the 
identification of cancer patients who are experiencing psychosocial distress and in the 
prevention of such distress.  Their literature review, which was comprehensive and up to date, 
identified a considerable number of recent relevant studies aimed at the evaluation of   the 
skills of oncologists to identify psychosocial problems experienced by their patients. They 
identified 298 cancer patients, who were receiving radiotherapy, by means of validating 
screening methods as experiencing psychosocial distress and being in need of support. These 
patients were assessed simultaneously by eight oncologists for psychological distress; 
assistance received from social networks and need for psychosocial support. The fact that the 
study was performed at a single radio-oncology unit does affect generalisation of results. The 
results showed that the oncologists were highly able to identify patients who experienced 
moderate distress. However, their ability to recognise patients experiencing severe distress was 
low. Of the 30 patients in the group who were experiencing severe distress the participating 
oncologists were able to identify only 11. These results, together with the fact that 20% to 40% 
of all cancer patients are emotionally distressed led the authors to conclude that a real need 
exists for the development of measures aimed at enhancing the ability of oncologists to identify 
psychosocial distress in their patients and to ensure their referral for proper support and 
counseling. These measures could include the development of screening instruments to detect 
distressed patients or the training of oncologists to be aware of psychosocial distress in 
patients.53  
Passik et al studied the ability of physicians to recognise depression in a large group of 
ambulatory cancer patients. Signs and symptoms of depression were often missed because 
oncology examinations focus mainly on physical issues and symptom management. Emotional 
and psychological symptoms were frequently perceived as normal consequences of a terminal 
illness and, therefore, were overlooked. Physicians participating in the study were asked to rate 




requested to complete the Zung self-rating depression scale which had been described by 
several studies as a reliable and valid instrument. It was found that the participating oncologists 
often inaccurately assessed their patients’ depression symptoms. Interestingly, patients with 
depression also reported higher levels of pain and disability. This shows that untreated 
depression may intensify many oncology outcomes which, in turn, may affect quality of life and 
even possible overall survival.54   
2.2.3 Integration of palliative care into standard oncology practice 
Studies have suggested that palliative care should be integrated into standard oncology 
practice when a patient is diagnosed with advanced cancer or metastatic disease. Bakitas et al 
conducted a qualitative study on oncologists to determine their perspective on concurrent 
oncology palliative care and to understand their perspective on advanced cancer care. It was a 
well constructed study with a sample size of 35 oncologists. However, no information of the 
interviewers was given. It was only noted that they were trained by the authors. Also, nothing 
was mentioned about how the participants would be protected from harm, such as sensitive 
information which could elicit emotional responses. Ethical considerations were not 
mentioned.55 
According to the authors, this was the first study in which oncologists’ experiences with 
advanced cancer patients in a concurrent oncology palliative care environment were described. 
It was found that the participating oncology clinicians treated patients with advanced cancer in 
a more holistic way and focused on quality of life rather than duration. This approach differed 
slightly when the treatment aim was curative in that patients were encouraged more to 
tolerate toxic side effects of chemotherapy. The clinicians valued the transition to palliative 
care but also emphasised the importance of timing and sensitivity. The introduction of early 
palliative care in concurrence with oncology treatment, the interdisciplinary approach and 
palliative care assistance with difficult discussions with patients and families were all viewed 
favourably by the majority of clinicians. This study showed that the participating oncologists 
strongly believed that concurrent palliative and oncology care should be the standard of care 




Temel et al also hypothesised that early integration of palliative care with oncology treatment 
would enhance the quality of life of advanced cancer patients, decrease the occurrence of 
depression symptoms and would require less aggressive  end of life care. The study design was 
clearly identified as a non-blinded randomised controlled trial where newly diagnosed non-
small cell lung cancer (NSCLC) patients were assigned to receive either standard oncology care 
or standard oncology  care integrated with palliative care. Quality of life and patient mood were 
assessed with valid and reliable scales namely the Functional Assessment of Cancer Therapy–
Lung (FACT-L) scale and the Hospital Anxiety and Depression Scale. The results demonstrated 
that patients who received integrated palliative oncology treatment showed an improvement in 
overall survival of two months when compared with patients who received oncology care only. 
It was suggested that this could be due to earlier hospice referrals with better symptom 
management which could have led to disease stabilisation and prolonged survival.  This 
particular care model also resulted in improved documentation of the patients’ resuscitation 
preferences and in less aggressive end of life care.3  
The fact that the study was performed at a single tertiary institution and that only participants 
who were able to read and respond to questions in English had been recruited, limited the 
application of the results to other care centers or other ethnic groups. Temel et al also did not 
mention the cause of death of the patients, such as chemotherapy related deaths, infection or 
dehydration. Had the causes of deaths been known, the data then available could possibly have 
supported early integration of palliative care. In such an event it could have been inferred that 
the deaths of patients with advanced cancer who died at home possibly due to dehydration or 
infection could have been prevented if home based palliative care had been implemented.  
Nevertheless, the conclusion was clear and comprehensive: Patients with metastatic NSCLC 
who received early palliative care in their disease experienced significant improvements in both 
quality of life and mood as well as longer survival. 
Muir et al evaluated the integration of an embedded palliative care clinic in a private outpatient 
oncology practice. This study is important because, consistent with trends, oncology practices 




administered through this practice. This investigation was also considered a pilot study as, 
according to the author’s knowledge, embedded palliative care clinics in a private outpatient 
oncology unit had not been described before. Patients attending these clinics also presented 
with a high volume of multiple symptoms and a potential prevalence of psychosocial distress. 
The objectives of the study were to assess quality care outcomes for patients, satisfaction 
provided, the volume of palliative care consultations and time saved for the oncologists. 
Symptom burden and relief were measured by application of the Edmonton Symptom 
Assessment System and by physician acceptance of palliative care services through a provider 
satisfaction survey. The volume of referrals and billing information were used to determine 
time saved for the oncologists. The embedded palliative care clinic was initiated at one half day 
per week and consisted of a certified palliative care physician and a palliative care fellow. It 
might have been more effective had the palliative care clinic involved more members of the 
palliative care team, such as a social worker, counselor or spiritual advisor to provide extra 
psychosocial and spiritual support. Nevertheless, the results were positive and showed that 
embedding a palliative care clinic in a private outpatient oncology unit is feasible. This service 
has the potential to improve symptom control and care for patients and also the effectiveness 
of the time spent by the treating oncologist.56  
The above mentioned studies demonstrated that early integration of palliative care with 
oncology treatment should be the standard of care. Some oncologists may regard the early 
referral of patients for palliative care as a failure to cure the patient. Traditional medical schools 
focus primarily on curative measures which can make the transition from curative to palliative 
care difficult to accept. This was identified in a study performed by Melvin et al as one of the 
barriers to early integration of palliative care.57 Fortunately the importance of  early integration 
was strongly confirmed by oncologists participating in the above mentioned studies and the 
results promised to alleviate distressing symptoms and improve quality of life of patients with 
advanced disease. Implementation of this practice in private oncology outpatient units with the 
aid of embedded palliative care clinics not only enhanced quality of care for the patient but also 




2.3 Communication with patients presenting with advanced disease 
Communication is a crucial part of caring for patients with advanced cancer. Such patients 
present with complicated physical symptoms and potential psychosocial issues. The emotional 
impact of their disease together with the effects of toxic chemotherapies which offer limited 
benefits and the challenge to balance hope with realistic goals affect the interpretation and 
integration of information by patients. Thus, communication often is a very challenging feature 
of an oncologist’s profession.52 Oncologists regard the following situations which commonly 
occur  during cancer care as particularly challenging from a communication perspective: 
Transition from curative treatment to palliative care; cessation of anticancer treatment; 
continuing with or withdrawing from life-prolonging medical treatment not knowing whether it 
is or is not life prolonging; discussions about death and dying; and dealing with the emotional 
responses of the patient and his family members. In these circumstances skillful, discrete and 
sympathetic communication which comprises listening, questioning, exploring and feedback are 
essential to build realistic hope. Experience and appropriate training can measurably increase 
the oncologist’s competence in this particular field.58     
2.3.1 The oncologist’s perspective 
Cherny reported on a study undertaken by the ESMO on European oncologists’ attitude 
towards information disclosure to patients with advanced cancer.52 Oncologists were requested 
to complete an online survey aimed at evaluating their attitudes and clinical behaviour relating 
to disclosure of information to such patients. The research tool that was used had been 
extensively peer reviewed to establish its validity before commencement of the study.  
Although 298 completed questionnaires were returned the response rate of 7.9% was quite 
low. The fact that the survey was conducted in English might be one explanation for the low 
response rate. The data collected during the survey showed variability in behaviour between 
physicians as well as variability in behaviour of a physician with regard to different patients. The 
data further added to preexisting knowledge that oncologists found it very difficult and were 
sometimes unable or unwilling to disclose information to patients regarding diagnosis, 
prognosis and the likely responses to treatment, even if such information was requested. The 
survey however did not provide information on the reasons why oncologists had found it so 
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difficult to disclose such information. These findings recommended the encouragement of the 
development of positive attitudes amongst oncologists towards the disclosure of relevant 
information to their patients.  
Jackson et al conducted a qualitative study of oncologists’ approaches to end of life care. 
Eighteen oncologists underwent a face to face survey and in-depth semi-structured interview 
during which they were asked to describe factors relating to the most recent in-patient death in 
their medical oncology service. The main aim of the study was to better understand how 
oncologists provide end of life psychosocial care and how this care affects job satisfaction and 
burnout. This understanding can be best achieved by using the exploratory methods associated 
with a qualitative study design, therefore justifying the authors’ choice of this particular design. 
The authors also used quantitative methods in the form of close ended questions as part of the 
interview. The Maslach burnout inventory was used in combination with the semi-structured 
interview to assess emotional exhaustion, depersonalisation, and personal accomplishment of 
the treating physicians. This information will assist physicians in relating the story of their most 
recent patient death. By using a combination of both quantitative and qualitative study designs, 
the authors tried to get a deeper understanding of the physicians’ experiences in the care of 
dying patients. Although the authors mentioned that a certificate of confidentiality was 
obtained to protect respondents from liability associated with their disclosures, no other ethical 
considerations were mentioned, such as the informed consent process or help in cases of 
possible burnout identified amongst participants. Furthermore, the fact that the study was only 
performed at two specialised referral institutions may limit generalisability of the findings to 
oncologists practicing in other units. Nevertheless the findings were clearly described and 
showed that oncologists who embraced both biomedical and psychosocial aspects of care were 
able to communicate more clearly about end of life care, felt more satisfied with the care they 
provided to terminally ill patients and their families, did not regard progression of the disease 
as due to personal failures and also felt less burnt out. They also understood that 
communication about end of life decisions with patients and their families is a process involving 
numerous discussions over time. Usually, a single conversation on these difficult decisions 





The timing of such discussions were also emphasised by Cherlin et al in their study relating to 
communication between physicians and family caregivers about end of life care. Three key 
subjects for patient-caregiver and -physician communication were identified and described 
during the study: Communication that the patient’s disease is incurable; communication 
pertaining to life expectancy and communication regarding hospice referral. A comprehensive 
literature review was conducted which showed substantial limitations of the reviewed studies 
performed in the field of patient-caregiver and -physician communication. Previous studies 
focused mainly on hospice discussions but not on the timing of such discussions, on patient 
experiences with inadequate attention being paid to the experiences of family caregivers and 
on the investigation of family caregivers of patients who were not in their final phase of life. As 
in the case of Jackson et al, the study was designed to provide for the concurrent 
implementation of both qualitative and quantitative methods to gain a deeper understanding 
of the complex phenomena associated with communication about incurable illness, life 
expectancy, and treatment options. The results showed that many caregivers reported that 
they had not been informed by the physician that the patient’s disease had become incurable, 
had never been provided with information on the life expectancy of the patient and that 
possible hospice admission had never been discussed with them. They also stated that the first 
discussion relating to the possibility that the disease might be incurable and to possible hospice 
referral only took place about a month before the patient’s death. The open ended interviews 
however showed ambivalence in family caregivers’ expressions on what they wanted to know 
and on the difficulty they experienced in accepting bad news. These findings then lead the 
authors to conclude that ineffective communication regarding end of life issues could be caused 
either by a reluctance of the physician to enter into discussions thereon with patients and care 
givers or in a reluctance  of the family caregiver to be confronted with bad news.60  
Audrey et al also focused on communication by oncologists with their patients. They employed 
qualitative research methods to describe patients’ experiences of palliative chemotherapy and 
whether the survival benefit of receiving such chemotherapy was discussed with them by their 




Thereafter, the consultation with the oncologist where palliative chemotherapy had been 
discussed was recorded and observed to capture non-verbal communication. The patients were 
then interviewed again at least once in the weeks that followed. Oncologists who consented to 
the recording and observation of consultations were also interviewed towards the end of the 
study. Thirty seven oncologist-patient consultations were recorded. Analysis of the recordings 
focused on the quantity of information regarding the survival benefits of palliative 
chemotherapy divulged by the oncologists to their patients. It was found that most patients 
were not clearly informed about such benefits. This could influence informed consent and 
decision making on further treatment. If oncologists only concentrate on the symptom relief 
and quality of life benefits of palliative chemotherapy and not on survival benefits, patients 
might assume an improvement in their overall survival, which might not materialise. It was 
recommended that oncologists, in their discussion of palliative chemotherapy with their 
patients, sensitively describe the benefits and limitations which must include survival gain. A 
positive outcome of this study was that participating oncologists acknowledged that palliative 
chemotherapy regimens were not necessarily the answer for the treatment of patients with 
advanced disease. Together with their patients they hoped for a better solution in the near 
future. However, by avoiding unrealistic expectations and by focusing their treatment decisions 
on current evidence, oncologists can improve their ability to assist patients in making informed 
decisions regarding treatment options.61 
Friedrichsen and Milberg addressed the physicians’ perspective regarding losing control when 
breaking bad news to patients with advanced cancer. The aim of this qualitative study was to 
evaluate all the problems experienced by physicians during communication with terminally ill 
cancer patients concerning the termination of tumor specific treatment due to incurability of 
the disease. The medical directors of ten clinics in one county in Sweden were requested to 
select physicians in their respective clinics for participation. This may be seen as selection bias 
as the medical directors may choose physicians who they think might be more appropriate for 
this particular study. Thirty physicians were interviewed during this study. However, the fact 
that only Swedish-speaking doctors were allowed to participate does affect generalisation of 




The physicians interviewed were asked to describe the way in which the information was 
presented to patients and to discuss what made the information positive or negative, what 
issues presented and how they dealt with it.   They identified their fear of losing control, their 
behaviour and possible patient reactions as the main problems experienced during the 
provision, to their patients, of information on the transition from disease specific treatment to 
palliative care. However, due to the sensitive nature of the discussions regarding patients 
whose disease had become incurable, it would have been appropriate to mention possible 
referrals for counseling and support to those participants who might be in need of it.62   
It was apparent that an academic approach, thorough theoretical knowledge and a sound 
scientific background were important for a meaningful discussion of reasons for treatment 
decisions. Theoretical knowledge and experience, though, will not prevent emotional outbursts 
by patients during these conversations. These emotions should be recognised, acknowledged 
and legitimised by the physician and support should be offered. To be able to maintain 
emotional control physicians were advised to go through further training in clinical practice in 
palliative care and in spirituality.62 
It is clear from the above studies that communication with patients with advanced disease is a 
complex component of their treating oncologists’ profession. Oncologists find it difficult to 
disclose information regarding diagnosis, prognosis and treatment response rate to their 
patients and have a fear of losing control while doing it. Providing information regarding 
survival benefits of palliative chemotherapy was also identified as a problem as well as delayed 
discussions of incurable illness, life expectancy and hospice referrals. Development of 
communication skills through training and experience, a holistic approach to patient care, 
further training in spiritual and palliative care as well as encouragement of positive attitudes 
towards patient communication are recommended. That will contribute to the improvement of 
patient-oncologist communication which is a critical determinant of the quality of advanced 




2.3.2 The patient’s preference 
Bad news is seen as any type of information which has the ability to negatively influence a 
patient’s view of his future. It may consist of information regarding diagnosis, disease 
recurrence or progression or treatment failure in the oncology setup. Good communication 
skills are necessary when presenting this information to decrease patient distress. However, the 
majority of physicians do not have a strategy for the delivery of bad news and, based on expert 
opinion, most communication skills do not have a strong theoretical basis or take the patient’s 
preference into account. Furthermore, communication features preferred by patients were 
associated with less psychosocial distress and improved patient satisfaction.   
Fujimory et al performed a study on Japanese cancer outpatients. The aim of the study was to 
identify patients’ preferences regarding the disclosure of bad news about their disease. The 
authors appropriately used a quantitative study design to assess descriptive data in order to 
explore the components of these patients’ preferences and to find variables associated with 
communication style preferences. A survey was conducted to determine patients’ preferences 
of communication styles of their physicians when delivering bad news. The design of the survey 
was based on previously conducted patient-consultant interviews, on a systematic literature 
review and on discussions amongst the authors. However, it was not mentioned whether the 
survey had been validated. The criteria for the inclusion of participants were well described. 
Yet, the fact that only patients able to speak and write Japanese were allowed to participate 
does affect generalisation of the results. Similarly, the fact that only those patients who were 
regarded by their physician to be capable to complete the questionnaire were chosen to 
participate, could be considered as selection bias. Nevertheless, the results were clearly 
described followed by a comprehensive discussion.63 
It transpired that the majority of patients preferred a communication style where both positive 
and negative information regarding their condition were given in a supportive manner. 
Continuation of physician care with a future treatment plan was important and vagueness was 
the least preferred. Physician-patient engagement was important, therefore, when bad news 
was delivered. Although most of the preferences of Japanese patients are similar to those of 




physician, for instance, is regarded as very important by Japanese patients. This emphasised the 
importance of understanding an individual’s communication preferences to improve patient-
physician communication.63 
Hagerty et al conducted a study on 126 patients with metastatic disease whose disease had 
been diagnosed incurable six weeks to six months before recruitment, eliciting their preference 
for prognostic information. The literature review, which was comprehensive and up to date, 
showed that, although most of the literature pertaining to communication covered the 
breaking of bad news, not much guidance was available for physicians on how to communicate 
prognosis, especially in the newly diagnosed metastatic disease context. This led to a well 
formulated aim for the study, namely to determine the preference of metastatic cancer 
patients for prognostic information and to explore predictors of these preferences. A written 
survey was done to determine patient preference of prognostic information and the results 
were clearly set out.64 
The majority of patients wanted detailed prognostic information such as disease symptoms, 
treatment options and side effects, longest survival time with treatment, five year survival rates 
and overall survival. Although most patients preferred positive information, more than 65% of 
the patients also wanted less positive information about their disease. A desire for broader 
information such as how the disease would influence their daily lives was also indicated. From 
the results it was concluded that most patients with advanced disease wanted detailed 
information about their prognosis but preferred to negotiate the extent of the information and 
the timing of the communication.  The results further highlighted the importance of recognising 
the patient’s emotional needs and cognitions when discussing prognostic information.64 
Physician-patient communication can also become problematic when the patient becomes 
terminally ill. Yun et al performed a study to investigate the attitudes of cancer patient’s as well 
as the attitude of their family members towards the diagnosis of a terminal cancer. They found 
in their literature review that patients often were not well informed when their disease had 
become terminal and when the aim of treatment had changed from curative to palliative. This 




circumstances and to make important life supporting decisions. They constructed a 
questionnaire for cancer patients and for families who have relatives with cancer. This 
questionnaire was to be used to determine the attitudes of cancer patients and their families 
regarding the diagnosis of terminal cancer. Although the questionnaire was based on previous 
studies regarding the disclosure of bad news, it was not mentioned whether it was validated. 
Patient and family members were not allowed to share information. Patients who were 
accompanied by family members were interviewed in a separate room. Thus, patients were 
prevented to answer according to family expectations.65    
An important finding was that 96.1% of the patient group wanted to be informed whether their 
disease became terminal. This differed significantly from the 76.9% of the corresponding 
proportion in the family group. More patients than family members wanted their physician to 
give this news and to do so immediately after the diagnosis was made. These findings should 
encourage physicians not to withhold information about terminal illness from their patients in 
an effort to protect them from the truth. Physicians must also take note that the patient and 
family unit may have different attitudes regarding disclosure of such information.65 
The above mentioned studies emphasised advanced cancer patients’ needs for detailed 
information about their disease. It is important that this information contains both positive and 
negative facts together with a well structured treatment plan and must be conveyed in a 
supportive manner. Information should not be withheld to protect the patient. The physician 
should understand the individual preferences of the patient and recognise his cognitions and 
emotions. He should also consider the family of the patient when informing them about the 
patient’s illness but should also realise that patient and family may have different needs for and 
attitudes towards such information. 
2.4 Considerations regarding chemotherapy in advanced cancer patients 
Indications for the use of palliative chemotherapy in patients with advanced disease are 
constantly on the rise. Benefits such as prolonged survival and quality of life for patients with 
chemo-sensitive tumors confirm that palliative chemotherapy should be considered as a 
treatment option in cases of incurable disease. However, to minimise harm, the challenge for 
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the treating oncologist is to balance the benefits of tumor response with the toxic side effects 
of the drugs. Factors that need to be reflected on in each palliative chemotherapy case are 
performance status, tumor sensitivity, survival prognosis, side effects profile and co-
morbidities. As the disease progresses despite palliative chemotherapy, the survival benefits 
and symptom relief may be affected and the harmful effects of the treatment may increase. 
This may lead to recurrent hospital admissions and may even shorten life expectancy.66 Thus, to 
allow his patients to die with dignity and to simultaneously improve their survival through 
palliative chemotherapy, the treating oncologists should evaluate continuation or cessation of 
chemotherapy with caution and should organise related healthcare resources appropriately.67    
Nappa et al hypothesised that at least one month of post treatment is needed to increase life 
expectancy. They analysed the data on all Swedish patients with epithelial cancer who passed 
away between 2007 and 2008 and who received palliative chemotherapy within a year of their 
death. One of their aims was to identify potentially harmful effects which may be caused by the 
administration of palliative chemotherapy during the last month of life. They found that 
patients who received palliative chemotherapy during their final month of life had a significant 
shorter length of survival, measured from the start of palliative chemotherapy to their death. 
Such patients also had frequent hospital admissions and died less frequently at home. 
However, it could not be concluded whether these harmful effects were a result of disease 
progression or were side effects of the chemotherapy. Nevertheless, these results emphasised 
the importance of assessing each patient individually before prescribing palliative 
chemotherapy. Guidelines may be useful to assist oncologists to determine if their patients are 
fit for more treatment and are likely to survive long enough to benefit therefrom.66  
Keam et al investigated the appropriateness of chemotherapy and care of advanced cancer 
patients near the end of their lives. They evaluated 298 Korean patients with metastatic cancer 
who died of their disease with regards to end of life care and chemotherapy received. A 
significant proportion of patients were found to have received inappropriate, aggressive 
chemotherapy up to the end of life. It was found that these patients also visited emergency 




9.1% of patients whose treatment had been stopped were referred to hospice services. This 
could be due to the lack of proper hospice services and poor coordination between hospice 
programmes and hospitals in Korea. The fact that the study only represents a single centre in 
Korea does affect generalisation. Nevertheless the results lead to a comprehensive conclusion 
that the treating physician should continuously evaluate the appropriateness of prescribing 
chemotherapy to a patient with advanced metastatic disease and highlight the importance of 
the patient’s early referral to support services to improve quality of care.67 
The effect of an aggressive approach to the administration of chemotherapy to advanced 
cancer patients in the final two weeks of life was also investigated by Saito et al. They identified 
7879 Medicare enrolled patients over the age of 65 who, between 1991 and 1999, passed away 
after surviving at least three months after they had been diagnosed with advanced NSCLC. They 
found, in general, that receiving chemotherapy had been associated with a survival benefit of 
two months. However, patients who had received chemotherapy in the final two weeks of life 
experienced no survival benefit. They were also much less likely to receive hospice care, and 
then only for three days or less. This notwithstanding, prescription of chemotherapy for 
patients with advanced disease is still recommended, even without a survival benefit, if it is 
indicated that the treatment will improve the quality of life of the patient. The findings of this 
study suggested that the aggressive approach of chemotherapy near end of life not only had 
little effect on survival but also had a negative effect on quality of life. It is therefore imperative 
that oncologists base their treatment decisions on the circumstances pertaining to each 
individual patient, considering both expected risks and benefits of chemotherapy.68 
Major advances have been made over the past 15 years in the treatment of patients with 
advanced NSCLC. Additional active agents made second and even third line treatment options 
for NSCLC patients a common practice. However, overall survival increased with only 1.5 to 2 
months with these treatment advances. This put the patient at risk of receiving chemotherapy 
near the end of life. Murillo and Koeller conducted a retrospective chart review of deceased 
advanced NSCLC patients who received chemotherapy to characterise the chemotherapy given 




received first and second line chemotherapy while 26% received third line, 10% received fourth 
line and 5% of patients received fifth line chemotherapy or greater. Of these patients 43% 
received chemotherapy within one month of death and 20% of patients within two weeks of 
death. These findings demonstrated an increase in the use of chemotherapy near the time of 
death in patients with NSCLC. The availability of more treatment options, the inability of 
physicians to predict the life expectancy of patients with NSCLC and possible pressure by the 
patient or his family demanding additional treatment, based on information obtained from the 
internet or other sources, may all contribute to these prolonged chemotherapy treatments.69 
The choices of treatment for advanced cancer patients at the end of their lives have become 
more complex. This is due to the increase in the variety of anticancer treatments, higher 
expectations of treatments, less severe side effects of therapy and improved supportive care. 
As a consequence, these complex choices can markedly influence the lives of the patient and 
his family members as well as the cost of the patient’s healthcare.  Matsuyama et al conducted 
a search of relevant literature published from 1980 to 2006 in a number of countries. The aim 
of this search was to determine the availability of information regarding prognosis and 
treatment efficacy to advanced cancer patients and to establish how these patients arrived at 
decisions on chemotherapy and other types of supportive care. They concluded that patients 
with advanced cancer were inclined to opt for chemotherapy even if only a minor health 
benefit might materialise. These patients were also found to be less concerned about adverse 
effects of treatment than their healthcare providers. It was unclear if the provision of 
information regarding prognosis and treatment choices would have affected the decision 
making process. Although patients indicated a desire to be provided with such information 
most patients did not receive it. These findings may explain the increased use of chemotherapy 
in advanced cancer patients near the end of life. The authors further found that no decision 
aids were available to assist metastatic cancer patients to make their treatment choices. The 
provision of unbiased, honest information regarding prognosis, treatment options, outcomes 
and consequences as well as decision aids would have assisted advanced cancer patients with 




It was clear from the studies and reviews referred to above that patients with advanced cancer 
received more palliative chemotherapy near the end of their lives. Such inappropriate 
treatment caused frequent hospital admissions, less hospice referrals and even a shorter length 
of survival from the start of palliative chemotherapy to their death. Reasons for this type of 
treatment could be the availability of more treatment options, pressure exerted by patients 
and their families, inadequate information regarding prognosis, outcome and treatment side 
effects given by the treating oncologists and the patients’ willingness to undergo chemotherapy 
even if the outcome would have little benefit for their health. This information emphasises 
some patients’ urge to avoid death at any costs and the importance that the treating 
oncologists guide their patients in making informed decisions by providing adequate 
information regarding disease prognosis, treatment outcome and side effects.  
2.5 Attitudes towards advance directives 
The development and implementation of advance directives are regarded as a basic aspect of 
medical care and are widely advocated by many medical societies. It is accepted that it will 
assist the patient, his family or loved ones as well as his treating physician to take decisions 
regarding his treatment and care when he (the patient) is prevented by circumstances caused 
by his illness to take such decisions. In this way his autonomy near the end of his life is 
preserved. Especially patients suffering from advanced malignant disease, who will inevitably 
be confronted with decisions regarding the end of their lives, will benefit from the use of 
advance directives.71  
Kierner et al assessed the attitudes towards and wishes regarding advance directives among 
hospitalised patients suffering from advanced malignant disease.  Patients who participated in 
the study were verbally given information regarding the purpose of advance directives and on 
how such a document should be compiled. They were then asked if they were interested in 
drawing up an advance directive. Patients who were not interested were asked to complete a 
questionnaire to determine their reasons for not showing interest.71 
 Despite all the benefits associated with advance directives only a very small percentage (10%) 




disinterest were that the time to consider such directives was inappropriate; that they were too 
young and too optimistic to contemplate such directives; and that they had full confidence in 
the ability of their treating physicians to take such decisions when necessary. Patients who 
agreed to consider advance directives showed a high incidence of depression and anxiety which 
were associated with a poor performance status. The reason for this was however unclear. A 
possible explanation for the patients’ depression was given that the issuing of advance 
directives could have brought them in touch with the reality of their terminal disease. 
Alternatively it could also be disease progression which could elicit signs of anxiety and 
depression. Nothing was mentioned, though, about steps that were taken to refer these 
patients whose depression and anxiety were identified during the study, for proper 
management of their symptoms. Furthermore, hospitalised patients suffering from advanced 
disease are usually seen as vulnerable participants in medical research due to their physical 
condition. Additional precautionary measures should be taken, therefore, to ensure that these 
patients were competent and fit enough for participation and informed consent. Ethical 
considerations and measures to ensure suitable participants were not mentioned, however. 
The only criteria mentioned for exclusion was unconscious patients.71 
A similar study was undertaken by Van Oorschot et al.   Oncology patients who were receiving 
radiotherapy treatment were provided with and completed a standardised questionnaire. In 
contrast with the findings of Kierner et al, the attitudes of patients towards advance directives 
in the Van Oorschot study were found to be positive. At the time of the survey 23.6% of the 
patients had already signed an advance directive while 53.3% showed a real interest in 
compiling and signing such a directive. Only 9% did not want to sign an advance directive while 
4.9% were not familiar with the concept of advance directives. Patients who showed interest in 
advance directives considered that it might facilitate the physician’s decision making process 
and reduce the burden on their relatives. In addition, every second respondent acknowledged 
that advance directives would rather enhance the interaction between patient, relative and 
physician than providing rigid prescripts for a concrete situation. It is important, therefore, that 




advance directives. Such directives could not only facilitate later decision making but could also 
improve the physician-patient relationship and communication.72  
Guo et al examined the prevalence of advance directives among oncology patients with 
malignant spinal cord compression. The data of 88 patients with spinal cord compression 
presenting for rehabilitation consultations at a cancer centre in the USA were retrospectively 
reviewed with regards to advance directives. Although patients with malignant spinal cord 
compression have a well documented median survival of 3 to 6 months, only 20 patients (23%) 
reported having a living will; 27 patients (31%) reported the existence of an identified 
healthcare proxy; and 10 patients (11%) had a “do not resuscitate” order. Ozanne et al also 
found in their study of the existence of advance directives in patients with metastatic breast 
cancer that the majority of patients did have advance directives and had had discussions with 
their family members or friends about end of life decisions. However, only a minority of these 
patients shared this information with their oncology care providers. These findings emphasised 
the lack of urgency among these patients to have an advance directive despite their short 
median of survival. This may be an indicator of delayed palliative care and sub-optimal doctor-
patient communication regarding end of life goals and terminal care. Physicians should grasp 
the opportunity to discuss advance care planning and end of life care when their patients 
present with malignant spinal cord compression or metastatic disease. This will give patients 
and their families time to process the information, improve doctor-patient communication and, 
eventually, to improve end of life care.73,74  
Advance directives play an integral role in the management of patients with incurable disease. 
Although the implementation thereof often is perceived as a difficult issue to manage, the 
positive outcomes could enhance the quality of the patient’s end of life care. Advance 
directives improve doctor-patient communication and prepare the patient and his family for 
what lies ahead. It reduces the fears, stress and uncertainties of family members, patients and 
oncologists. When the inevitable occurs everyone is on equal footing as far as management and 
care are concerned. Kwon et al also found in their study of the advance directives prepared by 




want to be resuscitated or to have their life prolonged by invasive, painful procedures. They 
were prepared to undergo supportive measures that would reduce pain and improve quality of 
life regardless of whether it would prolong life or not.75 In their study regarding the satisfaction 
level associated with the completion of advance directives by patients with advanced disease 
Pautex et al further established that participants showed lower anxiety and depression levels 
after completion of the directives.76  
It is important, therefore, that patients with advanced disease should be made aware of the 
need for and be encouraged to complete advance directives. Pautex et al described that this 
will lead to a reduction of fear and to an improvement of communication between patients, 
proxies and health professionals and, ultimately, to an enhancement of the quality of end of life 
care.76 
2.6 The palliative care team approach 
Often care for patients with advanced disease is described as sub-optimal.77 Patients and 
families identified inadequate pain relief and symptom control as well as unnecessary invasive 
life sustaining interventions at the end of life as major shortcomings. In the same vein 
information regarding prognosis and treatment options is also frequently perceived as 
insufficient.78 It is believed that these shortcomings in end of life care can be countered by 
making use of interdisciplinary palliative care teams. Such teams are able to provide a full 
spectrum management of the patient and his family’s physical, psychosocial and spiritual needs 
while treatment is directed in accordance with the patient’s needs and wishes.79  
Gade et al conducted a multicenter, randomised controlled trial on inpatients suffering from a 
life limiting disease. They conducted a comprehensive literature review which accentuated the 
suboptimal standard of care for patients with advanced disease and the limited evidence of 
positive effects which an inpatient palliative care facility could have on these patients. Hence, 
the aim of their study was set out as follows: To measure the impact of an interdisciplinary 
inpatient palliative care consultative service on symptom control, patient satisfaction and on 
quality of care.79 
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They also investigated the costs of healthcare services received during the period of six months 
after the patients’ discharge from hospital. These costs were compared with the costs of 
normal inpatient hospital care. They found that the patients managed by the inpatient palliative 
care team reported greater satisfaction with their care experience and with the communication 
with their care providers. In addition, they had less ICU referrals on readmissions, longer 
periods of hospice stay and a higher incidence of preparation and acceptance of advance 
directives. The costs of their post-discharge healthcare were also lower.  There were no 
differences in overall survival. These findings provided evidence which confirmed the positive 
impact of palliative care consultations on the levels of patient satisfaction with care, on hospice 
utilisation and on healthcare costs.79  
Jack et al investigated 100 cancer patients who had been admitted to hospital for symptom 
control. Fifty patients received intervention from a hospital based palliative care team while the 
remaining 50 received standard hospital care. The impact of care on symptom control was 
researched by using the Palliative Care Assessment symptom assessment tool. This tool had 
been extensively assessed in terms of validity and reliability.  This assessment was repeated on 
three occasions. As in the case of the trial conducted by Gade et al, both groups showed 
improvement in symptom control. However, the group in which the palliative care team 
intervened showed better symptom control, particularly for pain and anorexia. Jack et al 
conducted further studies on how intervention by hospital palliative care teams improved the 
insight of cancer patients into their disease. Again, in a group of 100 cancer inpatients, 50 
patients who received intervention from the palliative care team were compared with 50 
patients who received standard hospital care. This comparison was also repeated on three 
occasions. The patients’ self reported understanding of their disease was tested. It was found 
that those patients who received input from the palliative care team showed greater insight in 
their diagnosis and prognosis when compared with the patients who received standard hospital 
care. It was concluded from the findings of both studies that the interventions by the palliative 
care teams not only improved symptom control but also that the team members had an in-




skills to communicate, treat and provide support and, hence, enabled team members to 
comfortably and effectively care for a dying patient.80,81  
An important central component of palliative care is teamwork. Establishing teams well versed 
in palliative care can be a challenging venture. Junger et al studied the factors which the 
members of a team in a palliative care unit associated with success and regarded as necessary 
to ensure positive team work results. Members of the palliative care team of the University 
Hospital of Aachen were subjected to semi structured interviews one year after the team was 
formed. They found that communication, team philosophy, commitment and work climate 
were crucial elements necessary to enhance cooperation within a team. Communication was 
not only regarded as information exchange to keep team members up to date and thereby 
enhancing work flow. The informal exchange of ideas, subjective perceptions and speculations 
as well as humor were viewed as essential elements for effective team functioning. The need 
for openness and flexibility among team members, opportunities to discuss goals as well as the 
negative impact of unclear goals and procedures were new aspects which surfaced during this 
study. Commitment, sustained performance and the experiencing of work satisfaction by team 
members were shown to be strongly associated with an optimistic approach by the team and 
strong identification with the team’s goals.82 
The above mentioned studies showed that involvement of a palliative care team in the 
management of patients with advanced cancer had a positive impact on patient care and 
provided the treating oncologist with much needed support. It improved patients’ satisfaction 
with care and symptom control and resulted in decreased health care costs due to fewer 
hospital admissions and earlier hospice referrals. In addition, the improved communication 
regarding diagnosis and disease prognosis led to a better insight by the patients in their disease.  
Therefore it is strongly recommended that oncologists should make use of a palliative care 
team in their units to share the load of dealing with all the clinical problems and complex 
psychosocial issues associated with patients suffering from advanced cancer. Communication 




goals, commitment and a positive work climate is crucial for the team to function well and 
enhance patient care.  
2.7 Oncologist burnout 
Managing patients suffering from an advanced incurable disease can cause a great deal of 
stress to their treating oncologist. Burnout amongst oncologists and oncology healthcare 
workers is a common phenomenon and is well documented in the literature.  
Allegra et al conducted a survey to determine the level of burnout in the oncology community 
in the United States. Their literature review focused on the occurrence of stress and burn out in 
the medical profession and described previous surveys performed on oncologists to determine 
the presence, cause of and remedies for burnout. Their aim was to reassess the level of burnout 
amongst oncologists in the U.S.A and to understand any changes that may have occurred in 
recent times. Participants were given the opportunity to complete the surveys via email or at 
live meetings. Seven thousand seven hundred and fifteen medical and hematologist oncologists 
participated in the study but only 22.6% completed the survey. They were distributed over the 
major geographic areas of the U.S.A and spent the major portion of their work on patient care 
activities. Overall, 61.7% of the participants stated that they were experiencing feelings of 
burnout with the primary three signs being frustration, emotional exhaustion and lack of job 
satisfaction. The main causes for burnout were reported as being overworked, lacking time 
away from work and financial remuneration concerns. Participants considered more time away 
from office, the attendance of medical conferences and fewer patients to be the main remedies 
to counteract burnout. Interestingly, neither the area of the country where the participants 
worked nor the number of partners in the oncology practice had any influence on burnout. The 
results of the survey indicated that, although stable, the rate of occurrence of burnout among 
oncologists in the U.S.A is still perceived as high. Oncologists need to be encouraged to increase 
their time away from work as well as to attend professional meetings to increase professional 
pursuits. By alleviating burnout amongst oncologists, the quality of care provided to patients 




The above mentioned findings of Allegra et al more or less correlated with the results of a 
similar survey which had been conducted by Whippen et al. One thousand physician 
subscribers to the Journal of Clinical Oncology were randomly selected to participate in the 
survey. Fifty six percent of the respondents reported experiences of burnout in their profession. 
Similar to the findings of Allegra et al, the causes of burnout were identified mainly as a lack of 
time away from work and, secondly, as frustration. A feeling of failure, a heavy work load, 
remuneration issues and the administration of palliative or terminal care were also described as 
strong contributing factors to burn out.   More vacation and the need for more personal time 
away from work were indicated to prevent burnout. Due to the high response rate to the 
questionnaire (60%) and the high incidence of burnout among the respondents, the authors 
concluded that more research on this topic was necessary.84 
Dougherty et al found in their survey of 60 oncology personnel members at an inpatient 
palliative care unit that 63% of the staff reported high levels of stress experienced at work. 
However, the small sample size and the fact that the survey was done at a single palliative care 
unit does limit generalisation of the results.  Reported stress levels were determined by the 
indication of stress symptoms on the completed questionnaires, such as being emotionally 
drained and experiencing feelings of reduced accomplishment. These questionnaires were not 
validated, though. The main causes of work related stress were high workload, inadequate time 
to grieve the death of patients, insufficient institutional support in a stressful work situation, 
lack of resources and the inability to choose one’s workplace. More than half of the 
respondents believed that work related stress had a negative impact on patient care and more 
than 80% considered that high levels of work stress affected their ability to give emotional 
support and compassionate end of life care. Ethics rounds with a clinical ethicist, yearly staff 
retreats and morbidity and mortality meetings to discuss and reflect on difficult cases  were 
some suggestions made to reduce work related stress.85 
Burnout can seriously affect the treating oncologist’s personal health and his interaction with 
his patients and colleagues. If left untreated, it could have a significant negative impact on the 




hospice and palliative care physicians, practicing in the United States to determine the 
strategies they employ to counteract burnout and to improve job satisfaction. The most 
common strategy reported was enhancement of physical well being followed by supportive 
professional relationships, transcendental perspective and spirituality, communication with 
others, hobbies, clinical variety, personal relationships and personal boundaries. Sufficient time 
away from work, passion for one’s work, humor, laughter and realistic expectations as well as 
remembering patients who passed away were also suggested.86 Italia et al found in their study 
of doctors and nurses working in an adult and pediatric oncology unit, that burnout syndrome 
which exists among the staff can be effectively treated with art therapies.87 Granek et al 
interviewed 20 oncologists to gather suggestions on how their units or institutions could 
support them to deal with the loss of patients. Suggestions that were made included training 
and provision of information, acknowledgment and validation of grief, institutional psychosocial 
support and vacations and sabbaticals.88  
Working in cancer care can be extremely stressful due to the frequent exposure to pain and 
suffering of patients who, due to the fact that their disease has become incurable, are in the 
process of dying. Surprisingly studies have shown that palliative care staff experiences the same 
psychological distress as staff working in other medical specialties. Yet, the latter experiences 
less burnout.89 Ablett et al conducted a qualitative study to describe the work experience of 
palliative care nurses to identify those personal traits which enable them to be resilient and 
maintain a sense of well being while caring for patients with advanced disease. Ten palliative 
care nurses (nine female and one male) were recruited from a hospice in North West England. 
The fact that many of the hospice workers knew the first author as a clinical psychologist may 
be regarded as researcher bias. The results of the study produced 10 themes which the nurses 
used to describe their work experience. These themes showed a high degree of commitment 
and sense of purpose towards their work. Interpersonal factors such as resoluteness and a 
sense of coherence were identified as strong promoters of resilience which enabled staff to 
manage the stress associated with working in palliative care. To promote resilience the training 




According to this literature review burnout is a real and serious condition which is common 
amongst oncologists, yet less common amongst palliative care workers. It affects the physical 
strength and mental health of treating oncologists which can lead to poor interaction with staff 
and patients. Ultimately it results in a deterioration of quality of care. It is crucial that the 
treating oncologist should acknowledge warning signs of burnout, such as frustration, 
emotional exhaustion and feelings of worthlessness, and should be acted on appropriately.  
Support systems should be in place, relevant information should be readily available and special 
rounds and meetings pertaining to difficult cases should be regular events in each oncologist’s 
treating unit. In addition, personal strategies such as time away from work, physical exercise, 
hobbies, art, humor, spirituality and making time to remember patients who passed away 
should be applied to prevent and treat burnout. By applying appropriate strategies and by 
utilising institutional support systems to manage and prevent burnout, the personal wellbeing 
and job satisfaction of the treating oncologist could be enhanced. This will undoubtedly lead to 
an improvement in the quality of care provided. 
2.8 Work done in South Africa 
There are few South African studies on palliative care for patients with advanced cancer. The 
management of patients with life limiting disease in South Africa and Uganda was investigated 
by Selman et al. The quality of life of patients with incurable, progressive disease, who received 
palliative care were researched and described.91 They  also explored  the information needs of 
patients with progressive, life limiting disease and their family members.92 Harding et al also 
performed a study on advanced cancer patients in South Africa and Uganda but focused on the 
determination of symptom prevalence and burden amongst patients.93 They found that pain 
management and psychosocial matters were the most prominent issues and that  psychosocial 
and spiritual well being  and pain control was regarded as equally important determinants of 
quality of life. Lack of information given to patients and their family members were identified as 
a problem too. Harding et al also did some work on the challenges of conducting research in 
Africa94, on palliative care in the African context95 and on assessing and improving palliative 




Gwyther, who participated in the studies done by Selman et al and Harding et al in Uganda and 
South-Africa, reported on the status of palliative care in South Africa.97 Sebuyira et al 
commented on the Cape Town palliative care declaration regarding home grown solutions for 
Sub-Saharan Africa.98 
All the above mentioned studies concentrated mainly on the field of palliative care given to 
patients with advanced, life limiting disease in Sub-Saharan Africa.  
2.9 Conclusion 
 Managing patients with incurable disease is an integral and complicated aspect of an 
oncologist’s daily profession. Apart from the difficult clinical oncological issues treating 
oncologists are regularly confronted with, complicated additional challenges such as dealing 
with complex psychosocial issues associated with the treatment of distressing physical 
symptoms experienced by their patients, with having difficult discussions regarding treatment 
side effects and disease prognosis, with decisions whether to continue or cease treatments and 
discussing advance directives with patients and their families.  As a consequence oncologists 
are continuously being exposed to possible burnout syndrome. 
As outlined in the above literature review, numerous studies have been conducted on the 
complicated aspects associated with the treatment of patients with advanced cancer. Some of 
the worrying factors identified in the literature are the inadequate training of oncologists in the 
field of palliative care, their inability to identify psychosocial distress in cancer patients and the 
fact that they find it very difficult and are sometimes unable or unwilling to disclose information 
regarding diagnosis, prognosis and the likely responses to treatment to their patients, even if 
such information is requested. Furthermore, it is indicated that more patients with advanced 
cancer receive inappropriate palliative chemotherapy near the end of their lives, that there is a 
general lack of urgency regarding the development of advance directives by patients and that 
there is a high incidence of burnout amongst oncologists. The complexities of these non-clinical 
issues which are inevitably involved with the caring for the terminally ill cancer patient 
constitute an important component of the oncologist’s profession. It needs   to be further 
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researched to facilitate a better understanding thereof. The formulation of strategies to 
mitigate these difficulties will eventually improve job satisfaction as well as quality of care. 
As outlined in the literature review, numerous studies have been conducted on all the 
important individual aspects associated with the management of patients with an incurable 
disease. However, the holistic management of such patients in a private oncology institution 
has been inadequately researched and is to some extent lacking in South Africa.  
Therefore, the researcher will not only focus on the integration of palliative care in an oncology 
practice but also on other important aspects that forms an integral part of the management of 
patients suffering from incurable cancer. These aspects include communication with cancer 
patients and their family members, the use of advance directives, the implementation of a 
multidisciplinary approach, factors influencing treatment decisions and the difficult demands 




CHAPTER 3: Research methodology 
3.1 Introduction 
The researcher decided to conduct his study on the current practices of oncologists working in a 
private oncology clinic in South Africa and who are managing patients with solid tumours which 
no longer respond to anticancer treatment. The important individual aspects of the 
management of patients with incurable cancer have been well researched and documented, as 
outlined in chapters 1 and 2 above. However, not much work has been done on the holistic 
treatment of these patients, especially in the private oncology sector in South Africa. A concise 
description of the research methodology employed to conduct this study is set out below. 
3.2 Rationale for the study 
Patients suffering from advanced disease which no longer responds to anticancer treatment 
present their treating oncologists with major stressors. These may range from the management 
of distressing physical symptoms to complex psychosocial issues. In addition, oncologists in the 
private sector are faced daily with exacting challenges such as the high demands of patients and 
their families, the increasing pressure to administer more patients with lucrative anticancer 
treatment and with difficult discussions regarding disease prognosis, cessation of anticancer 
treatment and advance directives. Eventually the combined effect of all of these factors affects 
the quality of care provided and may lead to possible burnout of the treating oncologists. This 
set of circumstances commonly prevailing within the private oncology sector prompted the 
undertaking of this study.  
3.3 Aim of the study 
To evaluate the current practices followed by oncologists in the private sector of Cape Town, 
South Africa, in the management of patients with advanced cancer which no longer responds to 
anticancer treatment and to identify the needs associated with such management.   
3.4 Objectives of the study 
3.4.1 To identify the current practices followed by oncologists in the private oncology sector in 





3.4.2 To identify the information and training needs of these oncologists which must be met to 
enable them to effectively manage these patients. 
3.4.3  To identify support services needed by oncologists who manage patients with 
progressive and terminal illness. 
3.4.4 To identify processes and procedures that may contribute towards the improvement of 
care to patients with incurable disease in private oncology centres. 
3.5 The study design 
The researcher selected a descriptive qualitative study for data collection through in–depth 
semi structured interviews with private oncologists.  
3.6 Philosophical background 
The aim of the study is to evaluate the treating oncologists’ experiences with patients whose 
diseases have become incurable. By following the flexible and explorative methods associated 
with qualitative research, a deeper understanding of such experiences and of the meaning the 
oncologists attribute thereto can be developed. Furthermore, qualitative research draws from 
the philosophy of phenomenology in that it focuses on the structures of experiences of 
phenomena and the interpretation thereof and, thus, provides a holistic view of the 
phenomena under investigation. This phenomenological approach is well suited to explore 
affective, emotional and often intense human experiences which would be appropriate in this 
particular study. On an ontological level, qualitative perspective states that there are multiple 
realities or interpretations of a single event, in this case, the oncologists’ experience of the 
management of patients with advanced disease. Knowledge can be constructed adequately 
from these experiences through the use of qualitative research methods. During the study 
attention will be focused rather on the building of new theories or concepts regarding the 
experiences of the treating oncologists than on the deductive testing of current hypotheses. 
Therefore, the process will be inductive, which is a typical important characteristic of 
qualitative research.  The findings of the study will be presented by means of a rich descriptive 




3.7 Study site 
Five satellite units of the private oncology company, GVI Oncology (GVI), were used by the 
researcher as study sites. These satellite units are situated in the Western Cape Province. They 
are the Rondebosch Unit in Rondebosch, the Vincent Pallotti Unit in Pinelands, the Panorama 
Unit in Parow, the Cape Gate unit in Brackenfell and the Vergelegen Unit in Somerset West.  
3.8 Study population 
The study population comprises radio-oncologists who are managing patients with solid tumors 
and who are attached to private South African oncology institutions based in Cape Town.  
3.9 Sampling method 
The researcher opted for a non-probability, purposive sampling method to recruit appropriate 
participants in the private sector that would render satisfactory data regarding the 
management of patients with incurable cancer. To enable purposive sampling, the researcher 
recruited his participants according to the following inclusion criteria: 
 Participants must be qualified radio-oncologists. 
 They must be actively practicing in the private sector in South Africa. 
 They must have at least four years of clinical experience working as radio-oncologists in 
the private sector. The researcher regarded four years as adequate for an oncologist to 
have gained sufficient experience in the management of patients with incurable disease.  
 Patients with solid tumors must be their main scope of treatment. 
 They must be able to understand and speak English. 
 They must be willing to undergo a face-to-face interview with the researcher. 
The researcher submitted a request for permission to conduct this research project to GVI 
Oncology (see appendix A). A copy of his research proposal as well as proof of ethical approval 
(see appendix F) of the project was attached  to this request. The researcher received 
permission per email (see appendix D) from the research committee of GVI Oncology to 





Oncologists who were consulting at the selected treatment units and who fitted the inclusion 
criteria were approached and invited by email to participate in the study (see appendix B). After 
confirmation of their intended participation had been received, also by means of an email, a 30 
minute appointment at a convenient time was booked with each oncologist’s secretary to 
conduct the interview. All the oncologists who were approached were willing to participate and 
gave informed consent therefor. Although no incentives were offered to participate in the 
study, the researcher did, however, give each participant a small gift of appreciation for their 
time after the interview had been completed. 
3.11 Sample size 
The researcher estimated that 15 participants would be required to obtain sufficient data 
regarding oncologists’ experiences with patients with incurable disease. The researcher 
regarded this number of participants as adequate as data saturation was experienced after 
interviewing 15 participants. After the 15 interviews the collected data did not shed any new 
light on the issue under investigation. Therefore, the sample size was large enough to ensure 
that all the important perceptions of the studied issue were covered. A larger sample size could 
have produced repetitive data which eventually could have become superfluous. 
3.12 Data collection 
The research protocol proposed face-to-face, in-depth interviews to collect data from the 
participating oncologists about their experiences regarding the management of patients with 
incurable disease. These interviews were mainly semi-structured but also contained a 
structured part which provided for the collection of sociodemographic data from the 
participants. 
3.12.1 Data collection tool 
An interview guide (see appendix C) was drafted which contains topics which have a bearing on 
the research theme. The guide was developed by the researcher in the light of the literature 
reviewed in chapters 1 and 2 above, after consultation with colleagues, in view of the 
researcher’s own clinical experience in the private sector and after discussing the interview 




The first part of the interview guide consists of factual, sociodemographic type questions which 
were used to initiate the interview. The information required included the sex of participant, 
age of participant, clinic where the participant is working, number of years practicing as a 
private oncologist, tumor specialty and percentage of the participant’s patients who receive 
advanced or palliative treatment. 
The second part of the interview guide deals with important aspects of the treating oncologist’s 
management of patients suffering from incurable cancer. Each topic is presented as a general, 
open ended question followed by a list of probes, areas or  issues associated with the topic  
that were to be explored by the researcher during the interviews. Topics that were addressed in 
this study included the oncologist’s experience of the management of patients with advanced 
disease, the oncologist’s communication skills, factors influencing treatment decisions, the use 
of advanced directives, the palliative care team approach and oncologist’s burnout.  These 
topics emerged during the literature review as themes regularly associated with the 
oncologist’s management of terminally ill cancer patients. The literature review also revealed 
that numerous articles have been written on these topics, which are indicative of their 
importance.   The topic guide concluded  with a section pertaining to the support necessary for 
patients with advanced disease. Some recommendations aimed at the improvement of the 
services to be rendered to such patients were also included. 
3.12.2 Data collection procedure 
After ethical approval and permission from GVI to perform the research had been received, the 
researcher approached oncologists who met the inclusion criteria with requests to participate 
in the study. This was done by means of an email in which the purpose of the study was 
explained and ethical approval and GVI’s permission that the study may be conducted at the 
oncologist’s treatment unit were confirmed. The researcher started by first approaching 
oncologists at his (the researcher’s) own treatment unit, namely Rondebosch, followed by 
oncologists working at Vincent Pallotti, Panorama, Cape Gate and Vergelegen treatment units. 
After each oncologist had expressed in writing willingness to participate in the interviews, 
appropriate time slots of 30 minutes were booked with each oncologist’s secretary. Thereafter 
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the researcher met the participating oncologists in person in his/her treatment unit on the 
allocated time of the interview. The meeting took place in the oncologist’s consulting room. 
At the commencement of each meeting with a participant, the researcher introduced himself 
and his workplace and outlined the aims, objectives and anticipated content of his study. The 
participant was informed that the interview would be performed in English and that it would be 
digitally recorded. The participant was further assured that there is no right or wrong answer 
and was encouraged to give as much information as he/she considered appropriate, welcoming 
examples from his/her clinical experiences. The participant was assured of the confidentiality of 
all information given and of his/her identity. However, some personal details of the participants 
such as age, gender and years experience in oncology needed to be disclosed for the purpose of 
the study. The interview could be stopped at any time at the request of the participant and the 
estimated duration of the interview would not exceed 30 minutes. The participant was 
informed that the study results would be published as an article in a medical journal and that 
he/she would receive a copy of it once the study would have been completed.  
After discussing all the aspects associated with the interview process, the participant was given 
an opportunity to ask questions to clarify uncertainties. Thereafter each participant was 
provided with a consent form (see appendix E) and was asked to sign informed consent before 
the interview was started. The consent form was counter signed by the researcher as well as a 
witness from the clinical team. The completed consent forms were scanned and stored in the 
researcher’s password protected computer. 
After the preliminary procedures outlined above had been dealt with, the interview was 
proceeded with and digitally recorded by using an unobtrusive dictation recorder. Only the 
researcher and participant were present, thus ensuring privacy and confidentiality. The 
interview started with predetermined structured questions regarding sociodemographic 
information of the participant. This was followed by open ended questions and probes using 





The semi-structured interviews were introduced with a request for basic descriptive 
information regarding the participant’s experience with the management of patients suffering 
from incurable disease. The information gathered from this question laid the foundation for 
further questions to access the participant’s experience and opinions regarding the study topic.  
Initially the researcher depended rather heavily on the guide to perform the interview. 
However, the researcher soon became comfortable and allowed the interview to run its course 
with only a few references to the interview guide to make sure all questions had been covered. 
The average duration of the interviews was approximately 16 minutes.  
After the interviews, verbatim transcriptions of the digitally recorded interviews were stored on 
the researcher’s password protected computer. These transcriptions will be submitted to the 
Faculty of Health of the University of Cape Town where it will be archived for audit purposes. 
Personal transcription of the interviews by the researcher enhanced his knowledge and 
understanding of the information obtained and assisted him to identify which information was 
relevant. The recorded interviews will be destroyed soon after completion of the study. 
Although most of the interviews went smoothly without any major problems, the researcher 
did experience some difficulties during the data collection process. The oncologists’ overloaded 
work programmes made it difficult to book appointments for the interviews. Appointments also 
had to be limited to 30 minutes slots to accommodate the oncologists’ work schedules. Some 
interviews were even cancelled and rescheduled at short notice which seriously disrupted the 
researcher’s work plan. Three interviews were interrupted by telephone calls which the 
oncologist had to take and the recording microphone was faulty during one interview. The 
problem was restored but the interview had to be re-recorded. The researcher also had 
difficulties to accommodate interviews with oncologists not located at the Rondebosch unit in 
his working schedule.  




3.12.3 Data analysis 
The researcher made use of a thematic analysis method to analyse the collected data. The data 
analysis was done in combination with the data collection. Each interview was transcribed by 
the researcher directly after each interview had been performed. This enabled the researcher 
to enhance his recollection of the collected data while reviewing the interview material to 
identify tentative themes or categories as well as to refine questions to improve the interview 
process and the quality of data collected. The researcher identified six main themes during the 
transcription process using the process of coding as well as using the topic guide of the semi 
structured interviews as a reference. Based on his work experience, the researcher identified 
these themes as important and relevant topics which are generally associated with the 
management of patients with advanced disease. The responses given during the interviews 
clearly confirmed that the participating oncologists also regarded the themes as important and 
relevant.  
The process of coding was repeated after all the interviews had been completed in search of 
other themes that would serve as subcategories. Categorisation continued until all relevant sub 
themes were identified and labeled. These particular themes were presented by abbreviated 
descriptive codes. A coding list which contains the symbol for each code, its name as well as a 
definition for each code was compiled. Colleagues, which included the practice social worker 
and medical officers together with the researcher’s supervisor, were requested to review the 
main themes and subthemes for credibility. 
The researcher used a basic word processing software namely MS Word as well as Microsoft 
Office Excel and adapted it to manage and analyse his qualitative data. All the themes and 
subthemes together with relevant quotes from the interviews were copied from the word 
documents containing the interviews and pasted on a Microsoft Office Excel sheet. This enabled 
sorting of the data which, in turn, facilitated description of the themes and subthemes. The 
Department of Family Medicine at the University of Cape Town accept it as appropriate 
practice,  that the particular spreadsheet, together with all the word documents containing the 




computer and is available for audit if required. These data must be stored for a minimum 
period of five years after which they will be deleted.  
Conclusions were formulated after studying the particular coded themes as well as any patterns 
and connections within and between them, and bringing them all together. These conclusions 
were brought into context with the main theme of the study with a descriptive, narrative 
approach, after interpretation thereof in light of the literature research. A network display was 
used to visualise the findings. This display will serve as the conceptual framework for the study. 
Recommendations were made after the conclusions had been formulated. 
3.13 Researcher reflexivity    
As an oncology medical officer in a private clinic of this nature in South Africa, the researcher 
has witnessed firsthand the difficulties and shortcomings associated with the management of 
such patients. The researcher realised that there is a need for an evaluation of these practices. 
Such evaluation may stimulate interest which may lead to the improvement of the quality of 
care rendered to patients with incurable cancer.   
According to the researcher’s work experience the focus of cancer care in the private sector is 
primarily on evaluation, staging and the initiation of lucrative anticancer treatment. Seemingly, 
palliative care and supportive treatment do not receive the attention they deserve. After 
conducting this research project on oncologists in the private sector the researcher were able 
to determine the validity of his view. In qualitative research, the researcher brings his own 
experience and perspectives to the research; part of the research process is to hold an 
awareness of one’s own bias as a researcher and to acknowledge this in the analysis and 
reporting of research. For this study, the researcher was aware that working as a medical 
officer in the same field and for the same company as his study population could put him at risk 
of projecting his own beliefs and values on the study material and manipulate the findings to 
suite his views. The researcher therefore gave a thorough explanation of the contents of the 
topic guide and emphasised his supervisor’s involvement to improve objectivity in data 




dispute regarding the authenticity of the collected data. Potential bias was also considered 
during data analysis. 
The study design was of a qualitative nature which  comprised interviews with the participating 
oncologists during which researchable questions were asked. By combining explorative 
interviews with qualitative interviews the interviewer were able to identify important variables 
in this particular area of research. Further exploration of these identified variables through 
penetrating questions led to the development of new concepts or hypotheses regarding the 
relevant theme which, in turn, may require additional investigation.99 After each interview with 
a participant, the researcher studied the contents thereof to identify aspects that need to be 
altered to improve the interview process. The questions were reviewed to determine if they 
were judgmental or leading and their formulation was reviewed where necessary to enhance 
the generation of information. The interview was also examined to determine whether the 
participant had been unduly interrupted by the researcher or had been allowed sufficient time 
to formulate his comments. In addition, the researcher made sure not to comment on or to 
judge any participant’s views, even though he might not have agreed therewith. 
This qualitative study design furthermore corresponded well with the researcher’s interests and 
abilities. He has a keen interest in human behaviour, is a careful observer, possesses 
appropriate communication and people skills and has a well developed writing ability. By 
following a qualitative study approach, the researcher did spend a substantial amount of time 
in the field and was often in very close contact with the participants. This gave the researcher 
the opportunity to observe the participants in their clinical context and his first hand exposure 
to the collected data did enhance his knowledge of the study material considerably.100  
3.14 Ethical considerations 
The researcher submitted his research proposal to the Human Research Ethical Committee of 
the Faculty of Health of the University of Cape Town for ethical approval. The Committee’s 
approval had been obtained before the study commenced. Before the interviews were 
performed the researcher had obtained fully informed written consent from the participants 




interviewees’ right to privacy was respected by assuring their anonymity and the participants 
were assured that no physical and emotional harm will be caused during the interviews. The 
researcher treated the participants with respect and dignity as individual human beings and did 
not attempt to manipulate them. The interviewees were allowed to withdraw from the 
interview at any time, as described in the informed consent document. 
Each interview was followed by a debriefing session during which the participants were given 
the opportunity to ask questions or to make comments and to make sure that no harm has 
occurred. GVI Oncology has according to policy an oncology social worker present at each unit 
as well as a contracted outside independent counseling service available free of charge for 
counseling of staff in distress. These services were available for the participants in case the 
interview caused any distress or if burnout was suspected. Information leaflets regarding 
burnout and the management thereof were also available for the participants at risk 
All recorded interviews as well as interview transcripts were stored on a password protected 
computer. All recorded interviews were destroyed after the transcription process. Participants 
were informed that they would get comprehensive feedback with regards to the outcome of 
the study. All participants will receive written feedback via email, academic sessions and 
conference meetings. A peer reviewed article will also be available on the findings of the study. 
3.15 Conclusion 
The researcher has decided to conduct his study on the evaluation of the current practice of 
oncologists working in a private oncology clinic in South Africa, managing patients with solid 
tumours whose disease does not respond to anticancer treatment. After considering the 
different study designs available, the researcher has elected a basic, cross-sectional qualitative 
approach using in–depth semi-structured interviews with private oncologists to perform his 
research. The research was performed at the outpatient treating units of the private oncology 
company, GVI Oncology, and treating oncologists were used as study population. The 
researcher used a face to face, cross-sectional, semi-structured interview with the aid of a topic 
guide as data collecting tool and employed the process of coding to organise and manage the 
collected data. Ethical considerations were taken into account when the study was performed. 
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The final results, conclusions and recommendations of the study will be distributed amongst 
the oncologists and clinical staff of the treatment units where the study was performed and an 
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CHAPTER 4: Research findings 
4.1 Introduction 
The researcher conducted a qualitative study which was focused on the current practice of 
South African oncologists in private oncology units with patients whose disease had become 
incurable.  The researcher employed face to face, cross-sectional, semi-structured interviews 
with the aid of a topic guide to obtain data from fifteen participating oncologists regarding 
important aspects of this particular topic.  The data gathered by means of these interviews is 
presented in this chapter through a narrative approach. Themes and sub-categories produced 
by the process of coding will be described and supported by relevant quotes from the reported 
interviews. A network display is used to visually present the findings deduced from the data. A 
summary of the demographic information of the oncologists who participated in the study is 
given in the paragraph below. 
4.2 Demographic data of participants 
Fifteen radio-oncologists participated in the study which was performed in five outpatient 
oncology units situated in the Western Cape Province of South Africa. The participants 
comprised seven female and eight male oncologists with an average age of 47 years. Each 
oncologist had a minimum of four years practical experience in the private oncology sector.  On 
average the participants had twelve years experience in the private sector. The participants 
specialised mainly in solid tumors with experience in melanoma, urogenital, breast, head and 
neck, thyroid, gastro-intestinal, lungs, gynecological and neurological tumors. Three oncologists 
consider themselves to be generalists in the field of oncology. On average 45% of the 
participants’ practices consist of patients suffering from metastatic disease.  
The interviews were conducted at five Cape Town satellite units of the private oncology 
company, GVI Oncology. These units include the Rondebosch Unit in Rondebosch, the Vincent 
Pallotti Unit in Pinelands, the Panorama Unit in Parow, the Cape Gate unit in Brackenfell and 
the Vergelegen Unit in Somerset West. Each unit has three practicing oncologists who 
participated in the study. The interviews were held during a seven month period with the first 




duration of the interviews was approximately 16 minutes with the shortest interview of 9 
minutes and the longest interview of 22.10 minutes. The demographic data is displayed in the 
table and graphs below: 








































2 2012/08/07 00:12:19 47 Female Rondebosch 14 Melanoma 50% 
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9 2012/09/28 00:21:10 52 Female Panorama 18 Breast 10% 











12 2012/10/31 00:22:10 55 Male Cape Gate 19 Generalist 50% 
13 2012/11/22 00:11:24 41 Female Vergelegen 5 Generalist 50% 
14 2013/01/17 00:09:25 56 Female Vergelegen 11 Generalist 60% 









Figure 1 – Gender of Oncologists Interviewed 
 
 






4.3 Identified themes 
Six themes with relevant sub categories have been identified and are summarised and 
described below.   
Table 2 – Themes and Sub-Themes 
                                    THEMES AND SUB-THEMES: THEME 1-3 
Theme 1: Oncologists’ 
experiences regarding the 
management of patients with 
advanced disease 
Theme 2: The difficult 
discussion when a patient’s 
disease has become incurable 
and when it has to be 
decided whether anticancer 
treatment should be stopped 
Theme 3: The decision to 
stop anticancer treatment 
1.1  Familiarity of oncologists 
in dealing with patients with 
advanced disease 
2.1 The approach of the 
oncologist 
 
3.1 Oncologists’ approach to 
palliative chemotherapy 
1.2 Challenges in managing  
patients with advanced 
disease 
2.1.1 The importance of being 
open and honest 
 
3.2 Factors influencing the 
oncologists’ decision to stop 
anticancer treatment 
1.2.1 Treating young patients 
with advanced disease 
2.1.2 Early notification of 
patients of their disease 
status 
3.2.1 Disease factors 
 
1.2.2 Treating patients who 
are in denial 
2.1.3 The importance of a 
relationship based on mutual 
trust 
3.2.2 Patient factors 
 
1.2.3 Treating patients to 
whom the oncologist became 
attached to 
2.1.4 The importance of 
realistic hope 
 
3.2.3 Financial factors  
 
1.2.4 Dealing with the 
patients’ family members 
2.2 The contents of the 
discussion 
3.2.4 Influence exerted by the 




1.2.5 Time constraints 
associated with the 
management of patients with 
advanced disease 
2.3 Difficulties experienced by 
oncologists with the 
discussion 
3.2.5 Influences of working in 
the private sector 
1.3 Rewards associated with 
managing patients suffering 
from incurable disease 
2.3.1 Loss of hope when the 
patient is informed that his 
disease is terminal 
3.3  Strategies to work with 
the patient and his family 
1.4 Personal characteristics 
needed to manage patients 
with advanced disease 
2.3.2 Discrepancy between 
the patient and family 
members 
 
 2.3.3 Oncologist perceived as 
a failure 
 
 2.3.4 Dealing with emotions 
of patients and family 
members 
 
 2.3.5 When patients are 
reluctant to accept their 
disease status 
 
 2.3.6 Time constraints 
associated with the discussion 
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4.3.1 Theme 1: Oncologists’ experiences regarding the management of patients with 
advanced disease 
This theme explored the oncologists’ experiences on the management of patients whose 
disease has become incurable. The oncologists shared their feelings and experiences in this 
regard. The frequency in which they dealt with such patients, the difficulties and advantages 
associated therewith as well as the personal characteristics necessary to work effectively in this 
field were all topics that emerged during the interviews.   
4.3.1.1 Familiarity of oncologists in dealing with patients with advanced disease 
Nine participants indicated that they acquired extensive experience in the management of 
patients whose disease had become incurable and that it constitutes a major portion of their 
daily work. 
 “I probably do have a wealth of experience just by virtue of fact that, sooner or later, you 
know, a great proportion of our patients land up that way.” (4) 
 “Well, I’ve obviously have dealt with that a lot over the years cause we are with patients 
from their diagnosis all the way through, through the adjuvant and when they get a 
recurrence and then go through palliative active therapy and then eventually the difficult 
conversation of…of changing to best supportive care approach. So I have a lot to do with 
that.” (8) 
 “I have a fair amount of experience in this. Most of our patients, well, probably half of 
our patients are palliative patients and then you always get to the point where you stop 




Two oncologists mentioned that possible reasons for the high load of patients with advanced 
disease in their practices could be due to inadequate palliative care services as well as a lack of 
proper screening programmes in South Africa. 
 “We do developed quite a lot of experience just by virtue of the fact that there is not 
always very developed, sort of palliative care in…in our units.” (5) 
 “The majority of the patients that’s referred to us are advance because the screening 
programs in South Africa are inadequate and because we don’t have adequate palliative 
care facilities that’s incorporated in the practice.” (11) 
One oncologist who specialised in breast cancer concurred with the above view and submitted 
further that adequate screening programmes, as implemented by her team, reduced the 
number patients with advanced cancer treated in her practice. 
 “When I started about twenty years ago it was a…the majority of my patients and in 
time spending more than fifty percent of my time managing those patients, but through 
the advances of breast cancer, we now do genetic profiling, prognostication, we 
identify the high risk patients better so the appropriate patient gets better adjuvant 
therapy and the response rate and outcome so much better…..so our unexpected 
metastatic disease is very, very low, local recurrence is low. I end up now doing less 
than 10 percent of my work is metastatic, uhm, the majority is adjuvant therapy.” (9) 
4.3.1.2 Challenges in managing  patients with advanced disease 
Seven oncologists mentioned that treating patients with advanced disease can be a very 
difficult task. Demanding challenges, such as time constraints, futile treatment efforts and the 
emotional burden associated therewith are some of the reasons given why this field is not so 
popular amongst them. 
 “I probably dislike it more than I like it in that it usually means a failure of my 
discipline.” (3) 
 “It’s not a field that I particularly like because it’s quite difficult to support the 




 “I’m not averse to the field, I find as I get older I struggle more emotionally with it, I 
seem to be less able to detach myself from the process.” (11) 
  “I think it’s quite a challenge, I think number one, it takes quite a bit of time, that as a 
full time oncologist you often don’t have…So, it’s time consuming and also, I think, 
emotional challenging.” (15) 
Thirteen oncologists mentioned some of the difficulties associated with the management of 
patients suffering from advanced disease which included the following: 
a) Treating young patients with advanced disease 
Seven participants admitted that the management of young patients can be very emotionally 
demanding. These patients’ will to improve their condition and their determination to fight 
their disease exert additional pressure on the treating oncologist. 
 “Younger patients tend to be I think, more emotionally  demanding,  I think because 
obviously there’s more of a …(pause)… need to hope that you are going to provide 
curative therapy…so that sometimes is emotionally more burdensome to some degree.” 
(1) 
  “It affects me a lot if the patients are young, you know, you’ve walked a path with them 
through their disease and, you know, … (pause)… that’s quite distressing.” (12) 
One oncologist admitted that dealing with older patients are easier as they often are prepared 
to accept their disease status more readily. 
 “It’s easier for me to manage a palliative patient that’s older than a younger patient 
with children. So just emotionally also easier, because with older patients often they’re 
quite comfortable with just having symptoms managed.” (15) 
Three oncologists mentioned that they relate more to younger patients, especially to those 





 “I struggle with young…with woman with children. I can’t…cause it’s just because you 
relate in terms of where you are. I had my children at thirty six and forty two so I find it 
quite difficult.” (11) 
  “Younger patients that…that I can identify with who still have small children for 
example, I find that quite emotional and difficult.” (13) 
 “I had a young twelve year old girl who died of a glioblastoma, it’s very traumatic, you 
know. A lot of our staff also, they recognise their own kids who’s almost that age. So 
that’s very traumatic. I think it hits home. We expect an older person to die; you don’t 
expect a child to die from a tumor.” (6)  
 
b)  Treating patients who are in denial 
Two oncologists commented on the challenges that are associated with patients who do not 
acknowledge the severity of their disease and, consequently, always insist on more treatment. 
 “Where we also struggle with is in patients who do not kind of reach the level of 
acceptance that you anticipate. So we sometime struggle with patients who … (pause)… 
you know from a denial perspective fail to really … (pause)… see or acknowledge where 
the disease is headed or going and that is sometimes quite emotionally burdensome.” 
(1) 
  “It’s quite an emotional thing. The patient always want to feel something can be done 
and you’ve got to be honest and they sometimes lose interest in you.” (7) 
 
c)  Treating patients to whom the oncologist became attached to 
Two oncologists described the difficulties they experienced with the management of patients to 
whom they had become attached and whose disease became incurable. Such difficulties were 
especially prominent when the patient reminded them of a family member or a close friend. 
 “There are always patients that’s kind of…you…you kind of relate to better than others 




somebody in your family or there’s some…something along that way where you…you 
kind of bond more with them. So obviously there is a sense of sadness when those 
patients deteriorate.” (2) 
 “The difficulty is with patients that I’ve been caring for, for a long time, usually in the 
adjuvant setting that then develop metastatic disease. Hmm, and I think about them 
sometimes at two am. Hmm … (pause)… and I’m sad.  It’s difficult to actually look after 
them.” (3) 
 
d)  Dealing with the patients’ family members 
Three oncologists admitted that dealing with family members of patients suffering from 
incurable disease can be both emotional and time consuming. 
 “I think being in charge of looking after patients who are dying and their families and in 
particularly their families is emotionally very draining…and from the point of view of 
emotions and from the point of view of being very time consuming as well in a busy 
day.” (4) 
 “Sometimes it doesn’t goes well or there is a lot of distress in families and that…that can 
be quite tough you know.” (5) 
 
e) Time constraints associated with the management of patients with advanced disease 
Four oncologists commented on the time constraints associated with the provision of proper 
palliative care to patients suffering from advanced disease. The support of family members and 
added paperwork exacerbated inroads made on their available time. 
 “You also have the sense that you want to try and be there sort of emotionally or just 
physically be around for family and..and make them feel that you kind of there for them 
in that process, and I think that’s often difficult cause of the time constraints involved.” 
(5) 
 “It’s very time consuming to do proper palliative care.” (6) 
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“The burden of added paper work and unfortunately palliative patients add more paper 
work because you end up getting a lot of referrals and motivations.” (15) 
4.3.1.3 Rewards associated with managing patients suffering from incurable disease 
Despite all the difficulties and challenges associated with the management of patients with 
advanced disease, five oncologists commented on rewards associated with this challenging 
field. Being able to control a patient’s symptoms, interacting with the family and involving them 
in the patient’s care and receiving the family’s acknowledgment  were mentioned as being 
quite rewarding. 
“…it’s quite rewarding in a way if…if everyone is well prepared and it’s a process that 
you feel like you’ve managed well and everyone’s been able to anticipate and 
everything is in place and everyone kind of on the same page and patient’s kind of well 
controlled…and generally the families or patients are kind of appreciative of all of that 
and that’s quite rewarding.” (5) 
“I think it’s very rewardingly even if you can just relieve someone’s pain.” (6) 
“Yes, it’s a field that I like cause I want to have the patient as comfortable as possible 
and involved the family to help with the terminal care as well.” (10) 
“I enjoy the challenges that it comes with and I enjoy the chances it gives you to 
interact with the patient and their families.” (4) 
4.3.1.4 Personal characteristics needed to manage patients with advanced disease 
Two oncologists commented on the personal characteristics that are needed to effectively work 
with patients with incurable disease. Inner resilience, compassion, understanding and 
emotional strength were identified as needed traits. 
“People who are drawn to specialties like oncology and palliative care usually have the 
ability to cope on an emotional level.” (1) 
“You have to have sort of a inner kind of resilience to be able to work in oncology and… 
but I think you also have to have a degree of compassion and understanding.” (2) 
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4.3.2 Theme 2: The difficult discussion when a patient’s disease has become incurable and 
when it has to be decided whether anticancer treatment should be stopped 
Oncologists shared their experiences regarding the difficult but inevitable discussion they have 
to have with every patient whose disease has become incurable and on the decision whether 
treatment should be stopped. The oncologists’ approach to this discussion, difficulties 
experienced by both oncologist and patient, people that should be present at the discussion 
and further management of these patients emerged from the interviews. 
4.3.2.1 The approach of the oncologist 
Fourteen oncologists commented on their approach towards this theme. 
a) The importance of being open and honest
Nine oncologists emphasised the importance of being open and honest with their patients. The 
situation should be explained in a sensitive and gentle way and in understandable language. 
Ample time should be made available to allow for a thorough discussion of the patient’s needs 
and adequate opportunity for questions should be given: 
“So really just simply telling the truth in as gentle way as you can but without leaving 
the patient muddled.” (3) 
“I try to be sensitive to where the patients are emotionally and very honest with very 
basic information and then leave spaces for the patient to ask questions so I would take 
my cues from the patient in terms of what..how much detail they want.” (11) 
“I try to be as open as possible to my patients and, you know, when I get to a point 
where I see, you know, that they’re not responding anymore, you know, I’ll be open to 
them and say look, you know, it’s no use us carrying on with this kind of treatment and, 
you know, there is no..no other treatment and therefore, you know we need to look at, 
you know, your needs.” (12)  
b) Early notification of patients of their disease status
Two oncologists mentioned the importance of informing advanced stage cancer patients who 
are on active treatment at an appropriately early stage that a decision on a change of their 
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treatment from curative to palliative will be unavoidable. This usually helps to improve the 
transition from curative intent to symptom palliation and gives the opportunity to discuss the 
initiation of palliative care services. 
“I think where it is clear that someone has disease that is metastatic or incurable, you 
really need to try and incorporate that in your discussion upfront. So, all my new 
patients, I typically make a clear cut distinction between those that are being treated 
with curative intent and those that are being treated with palliative intent, and I find 
that that makes the transition easier.” (1) 
“If a patient has an incurable cancer, even if they are on active treatment, I’m very 
conscious of making them aware of the fact that their cancer is incurable and that at 
some stage down the line, they will require the input of a palliative care team. You know, 
lot of patients’ perceptions of the palliative care service is one that is given in the last 
week or two of life. And so I try to debunk that myth as much as possible by explaining 
that most of their work is done as an outpatient and most of their patients are manage 
for long periods of time prior to any terminal event.” (4) 
c) The importance of a relationship based on mutual trust
Four oncologists highlighted the fact that a patient-oncologist relationship based on mutual 
trust substantially facilitates this discussion. Each patient’s level of education and sophistication 
should also be taken into account:  
“It varies from patient to patient because you obviously have to take into account the 
patient’s uhm……level of education and ability to appreciate the sophistication or the 
patient’s sophistication I suppose as a word.” (4) 
“It’s much easier if you’ve walk the road with the patient because then you sort of get to 




d) The importance of realistic hope 
Two oncologists referred to the importance that the patient should be given some form of 
realistic hope that, although curative treatment is going to stop, their care will still continue but 
that the focus now will fall on quality of life. 
 “…and encourage them that in the time that remains to…to still live life, so it’s not all 
about taking away hope and the end is now but it’s almost like a transition phase in 
terms of their life.” (2) 
 “You need to give them the impression that there is always or not the impression, the 
understanding that there is always something else to do, we’re just going to do it 
differently, not giving them active chemo treatment but we can manage pain, we can 
manage nausea whatever the case may be.” (13) 
4.3.2.2 The content of the discussion 
Eleven oncologists commented on the content of this discussion with their patients. Four 
oncologists usually discuss the different treatment options that are available, emphasising the 
pros and cons of each specific treatment regime. Patients are made aware of the decrease in 
efficacy and the increase in toxicity that is associated with each following line of chemotherapy.   
 “I mean, generally how I approach it is, is trying to explain, hmm, sort of, ja, pro’s and 
con’s to treatment and risks and benefits and try to explain to patients for most 
treatments you get, sort of, diminishing returns the more different types of treatment 
you….you give them. They become less likely to have a benefit and more likely to give 
them side effects.” (5) 
 “Then you progress through the different treatments and as you progress through the 
different lines, you also start to communicating the chances of response, say for instance 
first line metastatic is 50 percent, second line is 30 percent, third line is 10 percent and if 
they know the chances to get a response is one out of ten.” (9) 
Six oncologists indicated their preference to use the results of special examinations, such as CT-
scans and blood tests, to demonstrate to their patients that their disease has progressed. From 
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there, the conversation progresses naturally to treatment options, prognostication and future 
care plans and follow ups. 
“I usually like to have some kind of hard and fast data or pictures or tumor markers or 
something that I can show them. So it’s nice to have a CT scan that shows progression of 
disease in the face of the third or fourth line of chemotherapy and..and so you not just 
talking about, like think it’s not working, it’s kind of some definitive proof that it is not 
working.” (2) 
“I’m talking particularly about survival data and possible symptoms that could happen. 
I’d be honest and say, you know, we’ve seen your X-ray. As you know you start with 
advance disease with a poor prognosis and unfortunately you’re not responding to the 
tumor therapy anymore and then just wait….” (11) 
“But I’m just completely opened and honest and tell them, you know, this is what your 
scan has showed, you know. Unfortunately there are no other chemotherapy lines of 
treatment, so we, you know, we gonna have to withdraw active treatment but we’ll 
follow up regularly. Tell them what to look for.” (6) 
Two oncologists emphasised the importance of communicating to their patients the necessity 
to shift the focus of treatment from prolonging survival to improvement in quality of life when 
their disease has become incurable. 
“Hmm, so generally that’s the way I…I convey it. I say, you know, we’ve done as much as 
we can to keep the cancer under control, now we need to shift our focus to making sure 
that whatever time is left, is a…uhm…lived in as good or quality as possible.” (4) 
“…and then just focusing on the fact that we need to, that we can still be actively 
involved in their management but more focusing on their quality of life.” (8) 
One oncologist suggested that written information could also be provided to patients and their 





 “But I mean there is a lot of information, you know, available, because you often do 
have, you know, somebody with medical training, who do not understand that part of it. 
Then I say I’ve got stuff on my computer I can offer you to read, you know, and then I 
print it out and give it to them. Because that often is a major problem in the end of life 
scenario.” (12) 
4.3.2.3 Difficulties experienced by oncologists with the discussion 
Twelve oncologists commented on the difficulties they experienced when they had discussions 
with their patients on the incurability of their disease and the possible termination of 
treatment. The following issues were identified: 
a)  Loss of hope when the patient is informed that his disease is terminal 
Four oncologists mentioned that loss of hope and the inability of patients to accept their 
disease status are complicating factors that need to be dealt with. 
 “It’s not always a easy conversation to have, uhm, and ja, it’s…if patients are insightful, 
uhm, it’s obviously an easier conversation to have. But..uh.. ja, lot of them want to live 
forever, you know, they don’t have the understanding that there’s nothing else out there 
for them.” (2) 
 “The news for the patient is catastrophic often. Uhm, and it’s not nice to be the bearer of 
bad news so that’s probably the main reason why it’s difficult.” (3) 
 “I think it’s often difficult depending on the patients and their families, I mean if they got 
a huge amount of hope or…or you can see they’ve got a huge amount of their, sort of 
moral invested in carrying on with treatment, any treatment, those are…I find those very 
difficult discussions, you know, where you know that the fact of not giving treatment or 
withdrawing treatment is going to be a really…you get the feeling it’s going to be quite a  







b) Discrepancy between the patient and family members 
Three oncologists mentioned the challenges that emerge when divergent views are held by the 
patient and family members regarding the disease that has become incurable. Problems that 
occur include a difference between the family’s requests and the patient’s wishes regarding 
further treatment as well as mixed messages received by family members who do not attend 
the consultations with the patient. 
 “You may also have a discrepancy in what the patient’s wishes are and the family’s 
expectation is.” (1) 
 “I have had one or two patients, I’ve got one at the moment that I always see alone and 
that’s very difficult because you get mix messages from the family but the patient has 
never brought anybody with her.” (15) 
 
c) Oncologist perceived as a failure 
Two oncologists mentioned that they sometimes experience feelings of failure when their 
patients’ disease does not respond to the treatment they prescribe. They find it difficult accept 
their inability to fulfill their patients’ expectations to be cured. 
 “I think that…(pause)…one when….as doctors we’re not used to admitting…a… that 
nothing can be done from a active treatment point of view and I think even, you know, 
that..a…we…so we sometimes see it as a failure on our part. A failure to…to live up to 
the expectations that the patients have, so it’s a difficult conversation from that point of 
view.” (4) 
 “It’s quite a challenging field because, you know, patients have expectations of you and 





d) Dealing with emotions of patients and family members
Four oncologists admit that informing patients that their disease has become incurable is 
usually followed by intense emotions from both patient and family members. Such emotions 
are difficult to manage. 
“Oh, I don’t think I’ve…I particularly enjoy that kind of conversation, telling the patient 
that there’s nothing more active we can do apart from supportive care and what that 
entails, because it’s a very emotional time for the patient so its…its quite stressful 
dealing with that.” (8) 
“Often the patients are OK but the families are the ones that need assistance.” (12) 
“The patients’ reactions to that information make it more or less difficult for oneself.” 
(13) 
e) When patients are reluctant to accept their disease status
Five oncologists mentioned the difficulties associated with the situation where patients are 
reluctant to accept that their disease has become incurable. Four oncologists referred to their 
patients’ loss of hope and their tendency to give up once the decision to stop treatment has 
been made. The patients usually find it very hard to come to grips with the facts of their disease 
status. 
“And the other thing that patients tend to interpret the discussion is giving up hope in 
some degree that many patients cling on to treatment as some form of hope that we can 
continue to treat the disease actively.” (1) 
“I don’t think the patients have a huge role there, because the facts are there to support 
stopping treatment as much as they may be not be comfortable with that as a concept.” 
(2) 
“For other patients its quite hard because they actually…they see stopping treatment 
as…as kind of giving up or…or, you know, it’s kind of…sort of associated with the fact 




One oncologist mentioned how especially young patients can cling on to the smallest things 
which may provide some hope regarding the outcome of their treatment. 
 “For a patient, even a one percent chance does make sense. So…not for everybody but 
for young patients specifically sometimes they would do anything to stay alive longer 
and sometimes without really insight about the toxicity, they’re so focused on the 
response and treatment that…that they are dictated by.” (9) 
 
f) Time constraints associated with the discussion. 
Three oncologists mentioned the need for sufficient time to be allocated to allow that a proper 
discussion could be held with the patient at the stage when his disease is no longer responding 
to treatment. Time constraints develop when the disease progression is detected unplanned 
during normal follow up examinations or where patients have difficulty in processing the 
information given. 
 “It’s very difficult and sometimes it takes two or three conversations before they will 
realize what you’re saying because we tend to put very nice little words like metastasize 
and patients have no clue what it is. It’s a difficult one.” (14) 
 “I think sometimes the unfortunate thing is that it’s often not a planned discussion. So 
the patient comes for discussion of a scan or something like that and then incidentally 
you end up with a palliative care discussion where you having to decide that you’re 
going to stop treatment. So in your day that’s often not scheduled as a longer 
consult….and to reschedule that kind of appointment I think causes more anxiety, so it’s 
best to just do that.” (15) 
g) Issues regarding treatment decisions concerning patients fit for treatment 
Two oncologists identified issues which complicated the decision to continue treatment. One 
oncologist mentioned the difficulty associated with continuing treatment on a patient who did 




 “It gets more difficult in like breast or ovarian cancer where there’s actually quite a lot of 
options although you know that if they haven’t responded to like two or three in 
succession, they probably not going to respond to anything else but, you know, you still 
got another two or three treatments you could theoretically give them.” (5) 
Another oncologist referred to the difficulty experienced when patients refuse continued 
treatment if the treatment aim is enhancing quality of life and not life extension. 
 “They want to know if it is going to improve their length of life not only their quality of 
life and then they say no, they don’t want it. So that’s quite a difficult decision.” (6) 
4.3.2.4 People participating in the discussions 
Eleven oncologists commented on the people who usually are present with the patient when 
the news is broken that the patient’s disease has become incurable. Ten oncologists suggested 
that the patient should be supported on that occasion by at least a close family member or 
caregiver.  
 “I try to make sure that there is a family member like with my first consultations also. I 
think it’s extremely important that you actually have someone in the family or close 
relative, I think it’s actually quite unethical to hand patient information like this on their 
own.” (11) 
 “It’s rare that a patient come completely on their own, uhm, and if they do and there is a 
family member sitting inside, I usually suggest that if they comfortable with it that that 
person come along to be part of the conversation.” (13) 
One oncologist was of the opinion that the discussion itself should determine who is present or 
not and that one should just go with the natural flow of it. 
 "For me it’s not really necessary to say who is included, I think the anatomy of that 
conversation, uhm, will define whether the patient bring in family or not or continuing 
the conversation or stop the conversation or start crying and you call on to the social 
worker for that, or start crying and you just stop the conversation because obvious is 




Seven oncologists mentioned the importance of involving a social worker during the 
conversation to support the patient and to ensure that the patient fully understands the 
contents of the conversation 
 “The social worker is going to be part of the meeting, because sometimes, you know, you 
get carried away in your medical jargon and terminology and the patient might not 
understand, so she actually stops you and said but what does that mean.” (6) 
On the other hand, four oncologists were of the opinion that the social worker should only be 
involved after the conversation if it is deemed necessary or during the conversation if it is 
specifically requested. 
 “Occasionally the oncology social worker is called in for that conversation, but that’s 
quite seldom that it happens at the same time, they would usually see the oncology 
social worker afterwards.” (8) 
 “Very occasionally I’ll call in one of the sisters or social worker to join the consult but I 
seldom would initiate that kind of conversation with a sort of third party if it’s not 
related to the family, uhm, in the room.” (2) 
4.3.2.5 Follow up plans given to patients after the discussions 
Five oncologists have commented on their follow up plans for their patients after the patients 
had the conversation during which they were informed that their disease had become 
incurable. Although the anticancer treatment has stopped, their care of the patient will still 
continue. The oncologists may withdraw to a certain degree and may not be the sole provider 
of palliative care. However, they will still see the patients on a regular basis but the aim of 
treatment will be symptom management. 
 “I still arrange to see patients for follow up, uhm, on a monthly basis and usually leave a 
open door policy so that they never feel that we’ve discharge them from my care but 
they have the opportunity to give us a ring and a shout whenever they need to.” (1) 
 “You will still remain as their carer and you now need to shift your focus away from 




 “I think we should still be involved although we don’t need to be the sole provider of the 
palliative care.” (8) 
 “I’m on the sides, I’ll draw in the GP, I’ll get a nursing carer at home, I’ll get hospice, 
hmm, and then, in a way, hand over (pause) the main responsibility.” (9) 
4.3.3 Theme 3: The decision to stop anticancer treatment 
The oncologists’ approach to palliative chemotherapy, the factors that influenced the 
oncologists’ decision to stop anticancer treatment in patients whose disease has become 
incurable as well as strategies to deal with these influences emerged from the interviews. 
4.3.3.1 Oncologists’ approach to palliative chemotherapy 
Four oncologists commented on their approach on giving palliative chemotherapy to patients 
with advanced disease. Two oncologists admitted that, as they gained more experience, they 
became more conservative regarding palliative chemotherapy. Their aim would rather be more 
on symptom control and enhancement of quality of life than on cytotoxic chemotherapy. 
 “As I’m getting older, I tend to be more, uhm, conservative and I would like to stop 
earlier because I believe the toxicity versus quality of life balance is really important and 
sometimes no treatment is also a good management.” (9) 
 “Having been in oncology so long, you know, I’ve gone past the where you try and cure 
everybody and you know, try and give everybody as much as possible and I actually was 
thinking about it yesterday, you know, how my mindset has actually changed through 
the years and how I’ve become much more, uhm, I don’t know if it’s realistic but more 
less active in, you know, in treating patients.” (12) 
Two oncologists expressed themselves strongly against continuation of chemotherapy if it is not 
appropriate or indicated by international guidelines 
 “Obviously you follow international treatment guidelines, you don’t…you can’t thumb 
suck what you want to offer patients so if you fail the second line therapy and there is no 




 “I don’t feel comfortable offering a further line of chemo if I thought that it’s not 
appropriate. So, uhm, it’s not going to be easy to twist my arm, I’m fairly conservative. 
So, and I think I’m known in the community to be the conservative one (laughing).” (15) 
4.3.3.2 Factors influencing the oncologists’ decision to stop anticancer treatment 
The following factors were identified as having an influence on the oncologist’s decision to stop 
anticancer treatment. 
a) Disease factors 
Eleven oncologists stated that a patient’s disease which becomes non-responsive to treatment 
is a very important indicator that chemotherapy should be terminated. 
 “I think the first factor would be lack of response, so, if the patient is no longer 
responding to the treatment that would be factor number one.” (1) 
 “Whether to stop treatment or not is whether it's working or not. If it’s not working then 
there’s no point in continuing.” (4) 
One oncologist emphasised the importance of being aware if the patient responded to his first 
line of chemotherapy as this might improve his chances for further treatment response. 
 “I think my approach to that to decide first of all if the patient is treatable, is it a 
responder or non-responder because that is the crossroad in my mind. A non responder, 
and there are many trials from the British Columbia group showing that if you fail first 
line your chances or overall survival is about 12-18 months while if you’re a responder, 
some of those live for 10 years.” (9) 
Another oncologist pointed out that cancer type, prognosis of the patient as well as treatment 
options available for that specific cancer should also be considered when deciding on the 
continuation of chemotherapy. 
 “It’s what cancer they have and what the sort of prognosis for that is and you know, 




Seven oncologists admitted that patient tolerance to treatment is an important indicator of 
whether treatment should be stopped or continued. The patient’s ability to tolerate the toxic 
side effects associated with treatment is an important factor. 
“Patient tolerability, uhm, so if it’s quite clearly a regimen that is not well tolerated that 
would also be the indication to stop.” (1) 
“Tolerance, so if there are quality of life issues and the patient is having severe toxicities 
that can’t be manage.” (3) 
Seven oncologists pointed out that the patient’s preference whether treatment should be 
stopped or continued must be considered and respected. 
“Well, the most paramount factor is the patient’s choice.” (4) 
“You know lot of the patients make their own decision and it’s just for us to reinforce and 
to say that it is acceptable.” (6) 
The patient’s performance status should also be taken into consideration when a patient is on 
treatment. It should be determined if the patient’s physical condition is well enough to tolerate 
anticancer treatment. This was pointed out by six oncologists. 
“I think it’s just general health of the patient, if they are still in a good physical 
condition.” (10) 
“I think for me the most important thing is performance status often. If you’re 
performance status isn’t good then I don’t even talk chemotherapy.” (15) 
One oncologist mentioned that a sub-deterioration in a patient’s condition due to an acute 
event unrelated to his cancer could also influence the decision to continue treatment. 
“Other issues would be sub-deterioration in patients’ conditions. Sometimes they can 




continuing with their therapy…and I’ll use the example of a myocardial infarction or 
pulmonary embolism etcetera.” (1) 
 
c) Financial factors  
Six oncologists mentioned that insufficient funding for treatment can also influence their 
treatment decisions. Declining of requests by medical aid schemes for the funding of certain 
treatment options available for patients is regarded as a severe problem in the private sector. 
Conveying this news to the patient can also be quite taxing for the oncologist. 
 “I think the (pause) to some extent in the private sector, the decision to stop may be 
financial, so I think that will be the…. the key indication is to where that becomes 
relevant uhm is that the patients may not be able to afford it, or their medical aid may 
decline treatment.” (1) 
 “Sometimes I have got to tell them that the medical aids won’t fund anything, that’s 
maybe the worse conversation, tell them there is something available but there is no 
funds for it.” (7) 
 
d) Influence exerted by the family of the patient 
Five oncologists admitted that the family members of patients can have a great influence on 
both the patient and the oncologists when a decision needs to be taken regarding further 
treatment options. Some patients are influenced especially by their siblings who can make the 
decision a difficult one for the treating oncologist. 
 “I think that, you know, one can come under a lot of pressure from family to continue 
with treatment even if you believe it to be futile.” (4) 
 “It’s the siblings, the kids or the brothers and sisters that want different goals and want 
to influence the patient and ultimately, you know, it’s the patient’s will, you must think 
what is best for the patient, that’s the ultimate goal, but in real terms it’s quite difficult, 




Three oncologists pointed out that more sophisticated patients and their family members can 
sometimes cause pressure by confronting them with information gathered from the media or 
overseas sources regarding advanced or new treatment options. 
 “Generally the patients in the private sector are more sophisticated, their families have 
access to more data and so there’s…there’s….one has to (pause) one spends a lot more 
time debunking myths and…and…and explaining that even though the newspapers and 
magazines may say something is a miracle cure, it may (a) either not be appropriate or 
(b) not available.” (4) 
 “Well, they often do put pressure on you, you know. They’ve got information from 
internet, you know, which they bring and they say, you know, but what this and what 
that.” (12) 
 “I think there is pressure and often pressure from overseas children with new 
information and new drugs and things that are available.” (15) 
Four oncologists admitted that often the family members together with the patient will put a 
great deal of pressure on the oncologist to continue treatment even if the patient is not fit 
enough or the outcome would be futile. 
 “ There have been times where I’ve wanted to probably bail out, rather, because my 
judgement of their quality of life is that it’s poor and they’re not really benefiting despite 
the fact that they might have stable disease radiologically, uhm, and then there has 
been pressure from the patient as well as the family and then I have continued.” (13) 
 “Patients and families tends to be..rather wants to push on, wants to continue on. I very 
often had to convince people not to have treatment as suppose to the other way around 
because they are always looking for something more, something extra.” (10) 
 
e) Influences of working in the private sector 
Ten oncologists admitted that the private sector does offer more treatment options to choose 




pressure on the oncologist as the affluent patient is provided with the opportunity to continue 
with chemotherapy. In the government sector treatment often is stopped due to limited 
resources.  
 “I think patients perceive the private funding having…sort of being endless. You know, 
there must be something out there that we can still try.” (2) 
 “Yes, uhm, having work in the state previously, one would definitely stop with active 
treatment sooner and possibly after given radically treatment one may not actively 
palliate with..with chemotherapy or radiotherapy because the resources aren’t available. 
Uhm, in private the resources are more available so yes, certainly there is more active 
treatment that is given to patients.” (3) 
 “I think that there is more lines of treatment available and those lines become less and 
less likely to work as you go along, but because you have them at your disposal, it’s 
sometimes very easy to offer a patient another line of treatment rather than having a 
difficult conversation with them about whether their treatment is futile or not.” (4) 
 “I think you have more options in private, so, I think they would stop a lot earlier in 
government hospitals because there are not so many options and they favor the patient 
where you thrive for cure, when stage four palliative, you try to buy time.” (9) 
Two oncologists mentioned that although all these treatment options are available in the 
private sector, the availability thereof should not influence the oncologist’s treatment decision. 
 “I don’t think it has a huge impact. I think it’s more just on what’s appropriate for the 
patients.” (5) 
 “We’re in a very strict managed care environment, so, I mean, very few doctors can offer 
patients whatever they want, I mean it doesn’t exists.” (11) 
4.3.3.3 Strategies to work with the patient and his family  
Five oncologists mentioned that a good, honest relationship with the patient and effective 




patient or his family that treatment be continued. Managing the family effectively is also just as 
important as managing the patient. 
 “I do my best not to….not to be influenced by the family…but to explain to them that, 
just like the doctor mustn’t feel like they’re failing the patient if the treatment is not 
working, the family shouldn’t feel like they’re failing the patient because the treatment 
isn’t working either. Uhm, and so managing the family in these situations is as important 
as managing the patients.” (4) 
 “I think when you’re honest and you build a trust relationship from day one and the 
family and the patient understand that I am here for you. I always say to my patients in 
the first consultation, remember, I am in your team and every face you see in this unit 
also aims to help you with this whole journey through your cancer treatment, so then, 
then there is a trust relationship and then..then it’s much easier to communicate 
openly.” (11) 
 “It’s rare that, you know, if you had the conversation with them properly, that 
they….that they insist on more treatment.” (13) 
One oncologist emphasised the importance of not wasting limited resources on futile treatment 
options. 
 “We as doctors have a responsibility not only to our patients, but also to society, not to 
spend limited resources on futile treatments….and the most important thing in that 
scenario is to make the patients aware of the fact that just because there is a drug out 
there, it doesn’t mean that that drug is going to work, and even if that drug works, it will 
not cure their cancer. It may prolong their current situation but not at any great benefit 
to them.” (4) 
Two oncologists mentioned that in some exceptional cases flexibility may need to be applied 
when considering continued treatment. 
 “But you know there’s also exceptions, you know. Some people wants to see their 




you  have to just try and  push them to keep them alive until then, you know, cause 
that’s…that’s what they living for, they are holding out for that.” (6) 
 “There have been times where I’ve wanted to probable bail out, rather, because my 
judgement of their quality of life is that it’s poor and their not really benefiting despite 
the fact that they might have stable disease radiologically….and then there has been 
pressure from the patient as well as the family and then I have continued.  I’m thinking 
of one case in particular. But for him his quality of life was acceptable. So, you know, 
sometimes you also need to allow that flexibility in terms of the judgement in quality of 
life. It’s not only my impression but theirs that counts as well.” (13) 
4.3.4 Theme 4: Advance directives 
The oncologists’ views on the development and implementation of advance directives as well as 
the timing of a discussion on this subject with their patients and any difficulties experienced by 
themselves and by the patients in this regard emerged from the interviews. 
4.3.4.1 Oncologists’ views on advance directives 
Seven oncologists admitted that discussing advance directives with their patients is usually 
neglected and is not routinely done in their practices. In most cases the oncologists are of the 
opinion that advance directives imply that, on further deterioration of a patient with advanced 
disease, active resuscitation will not be appropriate. 
 “Neglected, it’s not something that we would routinely discuss.” (3) 
 “I think that uhm, we as oncologists are often guilty of just presuming that it is implied 
as far as advance directives goes and never actually having the….the actual conversation 
about whether a patient should be resuscitated or not in a futile situation.” (4) 
 “I don’t particularly discuss it with patients. I mean, I don’t ask them whether they have 
a living will. I don’t specifically stipulate that if you were to be in a situation where you 
needed resuscitation that we wouldn’t, I suppose I assume that it implied.” (13) 
Four oncologists considered the discussion of advance directives with their patients as positive. 




pressure on the oncologists when decisions need to be taken on whether a patient needs to be 
actively resuscitated or not. 
 “It’s something I try to encourage because I…I always say to patients it’s better to plan 
for the path ahead and know what their wishes are. So, you know, if it’s quite clear that 
someone has….is reaching or reached the terminal phase of their illness, it’s a…it’s a 
topic that we try and broach fairly early because it’s good to know what the wishes of 
the patient is so that we’re not caught out in a sort of urgent scenario.” (1) 
 “The problem becomes when you…when someone maybe who was previously doing 
relatively well from their cancer and then suddenly has a deterioration and you’re not 
sure whether you can reverse it or not, or they get a bad pneumonia out the blue and 
you…and you got no idea how they really felt about…about what they would want done 
if they needed to go to ICU or…and that…so.” (5) 
Seven oncologists commented that the issue of advance directives is usually broached by the 
patient and his family. Hence they will only participate in such a discussion when the subject is 
raised by the patient. 
 “It does come up but usually at the initiative of the family or the patient.” (3) 
 “I think…from my point of view, the patient will drive it. They sometimes will say, uh, 
please, don’t keep me alive and I commonly will answer, I know that about you. You 
know, it’s almost like a non written…agreement if you understand that patient, where 
obvious the one pushing for treatment is never gonna get to that point, they will do 
anything to stay alive, so it comes as part of the personality I think.” (9) 
 “We’ve had one or two patients who have directed us that they have a living will but 
normally no, I haven’t discussed it. I would discuss it if the patient brought it up.” (15) 
Three oncologists admitted that they will not resuscitate a patient who suffers from advanced 
disease even if advance directives were not discussed with the patient. Still, they will manage 
treatable causes of distress. 
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“I practice that even if patients don’t sign it. Uhm, you know, I think there comes a point 
where patients has got advance disease and they’re beyond salvage. One could be 
supportive in therapy, care in the ward or whatever but (pause) ja, I think…..just in terms 
of  out of respect for the person you don’t want to go on treating or resuscitate 
somebody who clearly hasn’t got a life that’s worth living.” (2) 
“Some patients will tell me that they do have a living will, uhm, but I treat them the 
same as if they had one or not. I never gonna use advance…I never gonna put somebody 
on life support, on a ventilator, uhm, just to keep them alive if there’s no hope of them, 
uhm, responding to any treatment. I will use…I will put them in ICU, I will support them, 
put them on a ventilator if it is a chemotherapy related complication, uhm, that 
they…that they can get through and then have…have further survival, uhm, but not if its 
due to their disease and if there is no proper responding.” (8) 
4.3.4.2 Timing of the discussion 
Four oncologists admitted that their discussions with their patients regarding advance 
directives will usually take place when the patients’ conditions have deteriorated to such an 
extent that possible arrests are anticipated. 
“It’s not something that I usually deal with unless the patient has had an acute 
worsening and sort of comes into the ward and it’s anticipated in fact that they may 
arrest, then certainly I would discuss it…but otherwise sort of, until we get to that stage, 
not really.” (3) 
“I don’t bring it up as a matter of routine unless there appears to be a clinical scenario 
and the…and the patient’s family are requesting, ….or look  like they may request for the 
patient to be resuscitated.” (4) 
Three oncologists mentioned that they usually have this discussion when their patients’ 
diseases become resistant to treatment. 




 “When they have advance metastatic disease, not responding, I would say after second 
line of chemotherapy. Maybe it is too late but that’s usually when I...when I start 
discussing it with the patients.” (10) 
Two oncologists suggested that the discussion be had in the earlier phases of a patient’s 
disease. This will provide the opportunity to discuss future management plans, should the 
patient’s condition acutely deteriorates and, for instance, requires measures such as IV 
hydration and nasogastric feeding. 
 “I think we probably should do it more earlier, you know, if it gets to the point where 
there’s, you know, those kind of things, particular with regards sort of feeding or 
intravenous fluids, if they have, can say that if there’s no good prospect of recovery, I 
don’t want to be put on a drip or be fed nasogastrically then, that would probably you 
know, help a bit.” (5) 
4.3.4.3 Difficulties associated with the discussion of advance directives 
Two oncologists mentioned that time constraints present problems with the discussion of 
advance directives. Due to acute deterioration of a patient’s condition limited or no time is 
often available for such a discussion. 
 “Most time you don’t have the time or we don’t catch it in time so patients deteriorate 
really quickly. But, uhm, it’s important to know if someone, ah, you know, needs to be 
resuscitated, if they want to be resuscitated, especially in the private hospitals because 
everyone is for resuscitation.” (6) 
 “But it’s once again a time thing, there’s so many other things to discuss that you 
actually tend not to get around to that.” (15) 
One oncologist held the view that the readiness of patients for this discussion may also be a 
complicating factor.  
 “Not everyone is necessarily ready…uhm…I’d say very few percentage of our patients 




4.3.5 Theme 5: Oncologist burnout 
The exploration of this theme investigated the presence of burnout amongst the participating 
oncologists. The emotional and physical effects of working with patients with advanced disease, 
strategies to overcome burnout as well as support systems available at their units emerged 
from the interviews. 
4.3.5.1 The effects of working with advanced disease patients 
Oncologists were requested to discuss the effects that working with patients whose disease has 
become incurable have on them and how it influence their work and daily living. 
a) Emotional effects 
Nine oncologists admitted that working with patients with advanced disease can be extremely 
emotionally draining at times. 
 “Emotionally it’s very draining managing patients with..a…with incurable disease.” (4) 
 “It can be sort of a emotionally, it can be emotionally pretty tough, you know, when 
you’ve got a day when you got to have like three conversations with, with families of 
patients who are sort of terminally ill in the ward, that’s just draining.” (5) 
 “ It has got an emotional impact. I don’t have, let’s say  sleepless nights, I’m not 
depressed or anxious about it, but I mean, I think about the family, I think about the 
patient, you develop a relationship with them, it’s actually quite sad when someone 
dies.” 
 “I think we are in a state of, let’s say post traumatic stress but, uhm, in a way incurable 
because there are just so many traumatic events that the one sort of feeds from the 
other. So I think the doctors may be in a bad way and the staff also.” (7) 
 
b) Physical effects 
Four oncologists commented on the physical effects that working with patients with advanced 




 “The physical aspects of that is that, you know, you certainly, you know, I think, fatigue.” 
(1) 
 “That sort of emotional, uhm, sort of burden that you carry has an impact physically in 
terms of just fatigue.” (2) 
 
c) Effects on daily work 
Two oncologists mentioned that the combined emotional and physical effects of working with 
patients with advanced disease impact negatively on their work performance. 
 “There’s just some days where you don’t always have like the…the sort of emotional or 
the physical reserve, you know, it’s like the end of a long day and it’s kind of six’o clock 
and you want to get home and it’s like do I…do I go and do like one more turn in the 
ward and see how that patient is doing because it would maybe mean a lot to the family 
but then you kind think well gees, I’ve got to get…maybe I need to go and see my own 
family today (sigh & laughing). So it’s quite…it’s like…so that’s sometimes quite hard.” 
(5) 
 “I spoke to a…somebody, his dad was a patient here with one of my colleagues and….he 
said that what was worrying him was he’d looked at the doctor and he could see that 
this man was so tired and so out of energy and he was worried about the impact that 
this very fatigued or depressed doctor is going to have on the outcome of his father’s 
disease and, uhm, ja, I must admit I’m sure patients saw me in that phase of my life as 
well where you cannot say sorry, I feel extremely fatigue and depressed….you don’t 
share that with them, I just withdraw.” (9) 
 
d) Effects on social interactions 
Two oncologists admitted that the emotional and physical effects of working with patients with 
advanced disease make them irritable and frustrated. This often leads to harsh and 




 “I think the most common thing for me is that I become very ,very irritable and…just 
want to jump of the bridge (laughing) not literately, so, uhm, I can see it in my staff 
when one becomes more, you know, irritable, frustrated.” (14) 
 “I find that the place where you’re going to do it the easiest is you end up shouting at the 
kids. So, uhm, and they’re old enough now that they actually say, jeez you know, you 
actually need a holiday or you need a break. But sometimes you end up also getting 
unnecessary irritated with patients and then you realize that this patient is getting to 
you because you’re emotionally not well.” (15) 
4.3.5.2 Strategies for burnout 
Fifteen oncologists commented on their approach to prevent and counteract burnout caused 
by working with patients with advanced disease. The following recommendations were made: 
a) Regular breaks 
Seven oncologists mentioned that it is crucial to get away from the stressors of work to 
recharge. Hence, regular breaks and frequent holidays are essential, although not always 
possible. Taking one afternoon off per working week and the sharing of afterhours calls are also 
regarded as positive strategies. This could be possible in a group practice. 
 “I think also the fact that being in a big practice, you have the opportunity to be off, so, 
you know, you’re not always on call, and when you’re off your off! You don’t come in and 
work over weekends, you know, as far as possible. Uhm, and…to have…the other thing is 
to have regular breaks and that’s not always possible just in terms of cross cover and so 
on.” (2) 
 “I try and spend as much time away from work and when I am away from work I try and 
disengage as much as possible and I take lots of holidays and I break my work week up 
with a round of golf on a Thursday afternoon.” (4) 
 “I think you know, you need to have time off, that’s one thing. So being in a group 
practice, not a solo practitioner. You can’t be on call 24/7, that’s the one thing. I tried 




 “But, I think that for me, I need to take regular holidays. So I actually take four holidays a 
year coinciding with the school holidays….I also find that since I’ve forced myself to take 
an afternoon of every week and not use that afternoon for catching up with admin, 
that’s also good.” (15) 
 
b) Counseling, debriefing and support 
Six oncologists emphasised the importance of the availability of a good support system such as 
family members, counselors or even the practice social worker for debriefing and support. They 
also experienced debriefing amongst fellow oncologists as a good source of support. 
 “We have a social worker who if you really need to discuss issues with to share the load 
at another avenue.” (1) 
 “Just sort of getting my own counseling and sort of talking about it. Particularly at the 
moment I’m having a look at the balance that I have with patients between being caring 
and involved but not too emotionally involved, so it’s sort of work that is going on the 
moment and sort of defining that balance a bit better.” (2) 
 “And then giving yourself like space to talk to difficult things to colleagues, I mean it 
helps if you got people at work that you can sort of debrief about stuff. I think it 
would…its quite hard if you don’t have those.” (5) 
 “I have a good stable marriage which I think makes a big difference and I’m allowed to 
talk about my work at home. The only thing that I’m not allowed to do is to talk about 
death and dying at social functions, so I get…he knocks on my knees under the table.” 
(11) 
 
c) Extra-occupational interests 
Nine oncologists mentioned that outdoor activities and hobbies such as exercising, travelling, 
gardening, sports and spending time with the family are good measures to prevent burnout. 
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“I think if you have got a hobby it’s excellent or a sport that is all excellent ways to do 
that.” (7) 
“I….tend to de-stress by physical exercise, I gym quite a bit, I go for hikes, I’ve been to 
Everest this year and, you know, Kilimanjaro and various…various other hikes. I like to 
cycle regular, so that exercise and getting away from work and doing that, also spending 
time with the kids, uhm, family, that helps me to de-stress.” (8) 
“I try to get away over weekends and put my hands in the soil and dig in the garden or 
whatever and obviously drink too much wine.” (14) 
d) Maintain an emotional distance
Three oncologists referred to the importance of distancing themselves emotionally from their 
patients to prevent burnout. 
“If I meet a patient who is incurable from the beginning, uhm, I tend to be much more 
distant from them so there is no pre-existing relationship, so it’s really about being 
compassionate and providing for their needs but I don’t invest emotionally and am not 
really affected as much.” (3) 
“…you can, sort of a personal point of view…you can keep it a professional, kind of 
distance to it” (5) 
e) Delegating work activities
One oncologist pointed out that the sharing of the workload with other staff members also 
contributes towards the prevention of burnout 
“Sometimes you need to try and delegate tasks, you know. Maybe there’s some things 
that I don’t have to be doing, you know, whether it’s a phone call that like a nurse 
practitioner can make or a motivational letter someone else can write or an email that 




4.3.5.3 Support at work for burnout 
The oncologists were requested to comment on the availability of support present at their 
treatment units for debriefing to alleviate burnout. Eight oncologists admitted that no services 
of this nature are available. 
 “No, no, I think the psychiatrists are also burning out, so no, no support.” (7) 
 “Nothing, it’s actually quite pathetic, I mean the amount of care we provide the patients 
and then who cares for the care takers is like my slogan always.” (11) 
 “Woo, I think that, ja, unfortunately it is something that I don’t think is well managed 
from a doctor’s perspective. I think that if we look at counselors, they been regularly 
debriefed or so on, and on an oncology point of view we actually don’t have that.” (15) 
Five oncologists mentioned that debriefing in the treatment units mostly occurs amongst 
themselves. 
 “My colleagues, they’re very supportive. The partners I work with here in my unit 
specifically in my unit, I talk to them. I don’t see a psychologist, psychiatrist, counselor…” 
(10) 
 “Yes, I think so, we are fortunate that there are three of us, three oncologists. So we sort 
of understand, I think, between us what is going on and we know our private lives as well 
so we know what is going on in our lives…and that’s good support.” (14) 
Two oncologists stated that the only support provided by the institution they are working for to 
alleviate burnout is the granting of leave. 
 “There is nothing provided for the doctors for burnout except leave.” (8) 
 “I think there is a lack of that, you know, we as the oncologists, you know, have lots of 
leave, you know. So occasionally when you get to the point where you know I just can’t 
cope, you take leave.” (12) 
Two oncologists described how time constraints and overloaded working schedules prevent any 




 “I think the staff has debriefing sessions….uhm, but for the doctors there’s….we’re 
probably invited to those sessions but nobody goes, we’re all too busy.” (8) 
 “I remember many days where I was ill, fever, diarrhoea, whatever and you cannot dare 
to phone in and say you’re not coming to the rooms because everybody is booked and 
the patients are waiting for a consultation for two or three weeks or whatever and 
to…to..cause all the chaos at..at the rooms due to the fact that you are not well so you 
rather just come you know. I can’t imagine that I would…I end up in hospital and I was 
literally admitted from my rooms to the hospital (laughing) because there is just 
no..there’s no scope for things like that. Ja, there’s not a lot of support there.” (9) 
4.3.6 Theme 6: The palliative care team approach 
This theme investigated the palliative care team approach implemented at the treatment units 
of the participating oncologists. The oncologists’ general understanding of palliative care, the 
timing of palliative care referrals as well as training received for palliative care emerged from 
the interviews. The current palliative care setup at their units and recommendations to improve 
these palliative care services were also examined. 
4.3.6.1 The oncologists’ understanding of the concept of palliative care 
All fifteen participants were asked to give their interpretation of the concept of palliative care. 
Only one oncologist mentioned that palliative care entails a holistic approach to patient care 
incorporating symptom control, psychosocial and spiritual support together with ongoing 
management of the patient’s disease 
 “…it’s a model of providing care for patients to effectively look after them not only from 
a physical perspective but also incorporate aspects of psychosocial care, looking at issues 
of spiritual care, and incorporate all of that in ongoing management of their disease, 
uhm, focusing on aspects of symptom control, quality of life but also being fairly holistic 
and encompassing of other aspects related to their disease process.” (1) 
Four oncologists held the view that palliative care involves symptom management by means of 




 “My understanding of palliative care is the treatment of patients who have incurable 
disease, uhm, concentrating mainly on the management of the symptoms related to the 
disease as well as the patient’s psychosocial well being. I think that probably covers it.” 
(4) 
 “Oh, it’s quite a broad definition. It’s probably all encompassing management of a 
patient, holistic management, looking at caring for the patient psychological as well as 
symptomatic management, uhm, knowing that you are not offering treatment to 
prolong survival but rather to improve quality….But that palliative care can take the 
form of methods including chemotherapy and radiotherapy but knowing that the patient 
has to be aware that the intent of treatment is not for cure or for improved survival, it is 
for improvement in symptoms .” (15) 
According to six oncologists palliative care consists mainly of symptom management focused on 
quality of life and not cure. 
 “Palliative care for me is essentially symptom control…you know, pain control, 
hypercalcaemia control, syringe drivers, those sorts of things, but to improve quality of 
life and symptom control.” (6) 
 “To make the patient as comfortable as possible, as pain free as possible and to optimise 
quality of life in the terminal phase of the disease.” (10) 
 “Symptom relief, uhm, is probably the most important part of the palliative…and, you 
know, making comfortable in a situation where you can’t really offer any other things of 
helping the patients so comfort and pain relief, you know, oxygen for shortness of 
breath, symptom management.” (12)  
One oncologist believes that palliative care is the ability of the treating doctor to determine 
what is important for the patients when they are receiving treatment. 
 “I think it’s the art of medicine. I think that is really where there’s a difference between 
doctors, in being a good doctor, in being a wise doctor specifically that to understand for 




touch and attention and time. So, ja, palliative care is, I don’t see it only as part of the 
cancer, it’s like diabetes, a management of a patient with a chronic disease.” (9) 
4.3.6.2 The appropriate time to introduce palliative care 
Ten oncologists commented on the appropriate time to introduce palliative care. Eight 
oncologists suggested that palliative care should be introduced fairly early during the patient’s 
disease process to make the transition from curative to palliative care as smooth as possible. 
The introduction of palliative care should coexist with active anticancer therapy to ensure the 
continuum of care. 
 “I think introducing the concept early on is key, uhm, once again so that the transition is 
a fairly easy one. Uhm so I think palliative care, certainly for patients with disease where 
we are not offering cure is something that needs to start from the….from the word go.” 
(1)   
 “I think, palliative care can to some extent run in conjunction with active management, 
it’s not one or the other.” (2) 
 “I think you start palliative care from day one when you actually inform the patient of 
their diagnosis and definitely when they’ve got metastatic disease so symptom care goes 
right through the continuum of care.” (11) 
 “It is a continuum, so it’s not something that starts once you’ve stop active treatment; it 
starts earlier on….and symptom management plays an important part right from the 
start as well as the psychosocial. I think it makes the end phase, uhm, easier.” (13) 
Two oncologists felt, however, that palliative care should be introduced only when a patient 
does not respond to active treatment anymore and has moved into the preterminal phase of 
his disease. 
 “If I say this patient is now palliative I would say no active chemotherapy for sure. The 
patient is not able to live a normal life anymore due to the disease, uhm, and that you 
can foresee that the survival of that patient is, say whatever you think, 3 months, 6 
months or whatever, so I can start to see the end of the line. That is where I think I’d 




with cancer and bedridden most commonly and starting preparing for end stage of life.” 
(9) 
 “I would say when the patient is not responding to treatment.” (10) 
4.3.6.3 Training of oncologists in palliative care 
Four oncologists commented on their training experience in palliative care. They admitted that 
their main training was focused on the active treatment of cancer and not on palliative care. 
Most of what they know about palliative care was self taught from text books and was gained 
through experience. 
 “Emotionally it’s very draining managing patients with incurable disease specially when 
you’re also spending a good part of your day managing patients with active 
management for their cancer which is really the bulk of our scientific and academic 
training was around.” (4) 
 “At the moment we..I…we will just use our text books, you know, like Oxford handbook 
or whatever.” (5) 
 “For a oncologist it’s a….we don’t feel being a expert in the field when it comes to 
palliative care.” (14) 
 “Our palliative care training is also poor. It’s not part of, you know, we’ve been taught 
how to offer chemo and how to give radiotherapy but beyond that, you’re not taught, 
so it’s self taught.” (15) 
4.3.6.4 Palliative care setup at treatment units 
The participants were requested to comment on the availability of palliative care facilities at 
their treatment units. Eight oncologists admitted that there is no formal palliative care teams 
present at their units. 
 “We don’t currently have a separate palliative care facility although that is something 
that we would obviously like to work towards. Uhm, so our palliative care is….fall under 
the same umbrella as our oncology services.” (1) 
 “We have none. We are the palliative care team (laughing).” (4) 
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“We don’t (laughing) we don’t really have a palliative care team, I mean, in the unit we 
don’t have a dedicated palliative care team.” (5) 
“We don’t actually have a palliative care team at the unit.” (6) 
Fourteen oncologists indicated that the provision of palliative care to patients with advanced 
disease is usually a combined effort launched by the staff members already present at the unit, 
namely the oncologists themselves, a social worker, a physician extender, medical officers, 
chemotherapy nurses, radiographers and the administrative staff that deals with the patients. 
“It’s a multidisciplinary team, uhm, consisting of ,uhm, social workers, chemotherapy 
sisters, uhm, radiographers….the clinical staff and admin staff also play a role in terms of 
supporting patients and been aware of their needs, and then also medical officers and 
other oncologists in the group as well.” (2) 
“The team comprises really everybody in the unit, everybody plays a role. One is 
depended on the other, from the receptionists to the doctor really. Those who actually 
will have a conversation about palliative care would obviously be the doctor and the 
oncology social worker and probably the, uhm, the physician extender.” (8) 
“It’s basically the oncologists, uhm, medical officer, a social worker, and then we have, 
what we call physician extenders who are very closely involved and they actually liaise 
quite often with the patients when they come in or walk in or phone with 
complaints.”(11) 
Eleven oncologists mentioned that outside services such as local hospices and the patients’ 
general practitioners are also involved in the provision of palliative care to their patients. 
“The GPs are often involved more so with particular patients and hospice.” (3) 
“And then we make use of outside, uhm, outside things like hospice but they’re not 
actually part of a team within the hospital.” (5) 
“I can’t do palliative care without the GP. In South Africa, the infrastructure is such that 




 “We have very close ties with the hospices in the area….we meet with them once a 
month. One of the sisters comes here and then we discuss all patients that have been 
referred to hospice to give feedback from their side and us to them.” (13) 
 “A large part of our patients from here are from outside the district…there involve the 
patient’s GP.” (15) 
4.3.6.5 Shortcomings in the current palliative care services 
A number of shortcomings experienced in the current palliative care systems at the 
participants’ units emerged during the interviews.  
One oncologist was of the view that the general lack of palliative care facilities in the country 
can unnecessarily prolong anticancer treatment. 
 “I think what happens in a lot of countries and also including in South Africa is because 
of a lack of palliative care facilities we..we tend to hang on to the patients and try and 
offer them treatments up till a situation where you know we get told by the medical aids 
that we treat up till death.” (12) 
Five oncologists mentioned problems they experienced with their local hospice services. These 
problems included communication issues, additional administrative work, unavailability of beds 
as well as a reluctance of patients to be referred to hospices. 
 “There’s still, you know, certainly early on in a patient’s course of their disease, there’s 
still despite all of that quite a….quite a reluctance to accept a hospice referral.” (4) 
 “The hospice is also very thin at the moment so there is a lot of need, much less than is 
available or much more need than what’s available.” (7) 
 “I think there’s a big wall between us and hospice for instance. There’s not really good 
communication. I don’t feel like always phoning them. It’s difficult to get hold of them, 
they make very nasty comments about us (laughing), so there’s not good, there’s no 
good relationships there and it’s a lot of crap, all the admin involved with it.” (9) 





Two oncologists mentioned that the lack of palliative care leadership and the fact that the 
oncologist often is the sole provider of palliative care puts a lot of pressure on the treating 
oncologist. 
 “You know, you’re head of the team and you become responsible and I think my mistake 
was initial to do all of these and you end up burning out yourself and now I just try to at 
least be a good doctor but I feel the team, there is not good leadership in palliative care 
right now.” (9) 
 “But it puts a lot of burden on, you know, on the treating physician because, you know, 
you then do take on that palliative part and, you know, not having facilities, I mean we 
try…you know you admit into the hospital but, you know, the patient cannot stay there 
for long periods of time.” (12) 
Three oncologists expressed concern regarding the lack of palliative care knowledge of some 
general practitioners and ward staff members. 
 “Our patients who land up here, you know, it’s a rotating staff, they don’t have oncology 
training and they don’t always understand, you know, that morphine is to be given, you 
know, on time, and, uhm, so the care is not what it should be.” (12) 
 “You know my honest feeling is that the palliative care should be the family physician’s 
job and not the oncologist’s job and if we could change that it would be great but 
unfortunately in this town, we find that most of the GPs feel uncomfortable.” (13) 
 “And also the interface between palliative care…between general practitioner and 
oncologist, I think there is also quite a gap.” (15) 
One oncologist mentioned that some patients feel abandoned when they are referred to 
general practitioners or to specialists in palliative care. 
 “Unfortunately lots of patients feel that they’ve been abandoned by the oncologist if you 




4.3.6.6 Recommendations to improve palliative care facilities currently available at treatment 
units 
The participants were asked to give suggestions on how the palliative care facilities available at 
their units could be improved.  
a) Involving the patients’ general practitioners 
Eight oncologists suggested that the patients’ general practitioners should be more involved in 
their care. They could assist the oncologists with symptom management and palliative care as 
well as the administrative work associated with advanced disease patients. In order to improve 
continuity of care the general practitioners should receive palliative care training and 
communication between them and the treating oncologists should be enhanced. 
 “We need to enlist general practitioners and provide training in palliative care so that 
they can become more involved in ongoing care of patients… particularly looking at 
symptom control and then terminal care and trying to have as many patients managed 
in their home setting as suppose to an inpatient facility.” (1) 
 “I suppose just communication with the GPs, cause they’re important as well, uhm, and 
that is sometimes you would admit the patient to the ward and not necessarily have the 
GP involved as much, so I suppose we could look at that.” (3) 
 “ And then just around the administrative point of that, we often get requests to do, 
uhm, scripts for morphine example….I also think GPs need to be educated into how to 
prescribe it and that they also have to write motivational letters as we do all the time. So 
the involvement of the GP here is something that I would like to see happening.” (13) 
 
b) Early referrals to hospices 
Three oncologists suggested that patients should be referred to hospices for symptom 
management and support at an earlier stage. 
 “Try and get earlier referrals to hospice because I find once they become involved, they 




dosages of morphine needs to be adjusted twice a day sometimes even, they’re very 
good at that. Uhm, in our busy practice it’s quite difficult to take that private phone call 
twice a day. (3) 
 “We fortunately that we have a good hospice backup, so I tend to want all my patients 
who are being managed palliatively to be referred to hospice so we’re really try and 
emphasise that rather earlier rather than later.” (15) 
 
c) Employment of a palliative care physician 
Five oncologists suggested that palliative care physicians be employed to assist with the 
management of advanced disease patients. Their presence provides the oncologists with 
valuable additional time to devote to anticancer treatment. It will also ensure an early smooth 
transition to palliative care and will guarantee the availability of help and advice regarding 
palliative care issues. They could also act as leaders of palliative care teams and ensure proper 
communication between team members. 
 “I think that our unit and any unit would…would be much richer and would offer a far 
better service, uhm if we had specialist palliative care physicians who were able to, uhm, 
to help us manage our patients. I think it would free up a lot more of our time to deal 
with our active patients and I think the patients would benefit from having a palliative 
care service that isn’t sort of just tagged on to the end of their treatment but is actually, 
you know, an integral part of their cancer journey.” (4) 
 “I think we need a palliative care physician or, uhm….in the UK we had .…they were not 
based at our hospital but they came around….for ward rounds twice a week. They gave 
us advice, we could always phone them about syringe drivers, you know, some people 
are very agitated a few days before they die and what to put in the syringe drivers for 
example.” (6) 
 “And to have a palliative doctor, just somebody in specific areas where we can say this 
guy is doing palliative care and please, he’s managing my terminal patients that would 




psychologist or whoever or just to be captain of the team in palliative care because at 
this stage people are fighting about who’s the captain.” (9) 
 
d) Providing exclusive palliative care services 
Four oncologists suggested that exclusive palliative care services should be provided to patients 
by a multidisciplinary team in a caring environment. 
 “Like there would be units overseas that will have like…you’ll have a clinical round than 
you’ll have like a you know like…either a palliative round or it will be all the allied 
specialties like, you’d sit down at a table with the dietician and the O.T. and the physio 
and the social worker and counselor and you’ll just talk about other aspects to the 
patient and what you all been going through looking after them, which is probably what 
you should try and do for the difficult patients but it’s probably  a time thing.” (5) 
 “What I really would like to see is that there is a facility that one can actually, you know, 
put a patient there and you know that they’re going to be looked after by caring staff. So 
there is a real need for, you know, somebody who’s caring and, you know, quiet 
environment and can, you know, be there with the patients and give them the treatment 
and turn them and do all that you know. So there’s a huge need for that.” (12) 
 
e) Employment and training of medical officers and nurse practitioners   
Five oncologists suggested that medical officers and nurse practitioners trained in   palliative 
care be employed to help with the management of patients with advanced disease or, 
alternatively, that current staff be appropriately trained. 
 “Maybe we must train nurse care practitioners like the St Luke sisters, but I mean for our 
own unit and to manage our own patients here and at home type of thing, uhm, I think 




 “I think if we can equip our medical officers to be…to be trained, that would be superb 
because, I mean, I think, the oncology…the oncology training is such that we should 
actually be focused on active treatment.” (11) 
 
f) The presence of an oncology social worker/counselor 
Two oncologists were of the opinion that the availability of an oncology social 
worker/counselor at the units for counseling and support is invaluable 
 “I think probably would be good to, hmm, make sure that all the patients who need, 
hmm, counseling get to see the oncology social worker.” (8) 
 “I think that no unit can consider running as a fully functional unit without a counselor. 
So I know that in some units there is discussions saying that the counselors actually don’t 
make financial sense because they are not bringing in anything but if you try and work 
as an oncologist without the counselor, you’re not gonna cope, you actually  gonna  burn 
out because they’re taking a big load off your shoulders. So I try and insist that all my 
new patients at least meet her and then especially with the palliative patients.” (15) 
 
g) Making use of palliative care guidelines 
One oncologist emphasised the value of having guidelines pertaining to palliative care issues 
and symptom management available at their units.  
 “If you have your own sort of unit guidelines in terms of how you manage like pain or 
malignant bowel obstruction, that will probably also help, you know. It will teach you 
and it will probably make the care a bit more uniform as well, so that’s maybe 




The information set out in the paragraphs above were distilled through the careful review and 
analysis of data which were collected by means of in depth, semi structured, face to face 
interviews with fifteen radio-oncologists who specialise mainly  in solid tumors. Six main 
themes which all have a bearing on the main topic as well as sub categories were deduced 
from the data through a process of coding. All the themes and sub categories were descibed by 
using a narrative approach based on relevant quotes from the interviews. A summary of the 
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CHAPTER 5: Discussion 
5.1 Introduction 
Managing patients whose disease has become unresponsive to anticancer treatment is a 
complicated but integral part of any oncologist’s daily programme. Despite the satisfaction 
associated with the curing of patients from their disease, with the monitoring of patients in 
remission or with the successful controlling of patients’ advanced disease, there will eventually 
come a time in every oncologist’s career where some patients’ disease will no longer respond 
to anticancer treatment. The results of the researcher’s study provide strong evidence that the 
management of patients with advanced disease in the private oncology sector in Cape Town, 
South Africa presents complicated challenges. These challenges should be addressed 
appropriately to enhance patient care and to improve job satisfaction for the treating 
oncologist. Relevant topics associated with the management of such patients have been 
identified from the data gathered during the study and will be discussed in the sections below. 
5.2 Oncologists’ experiences regarding the management of patients with 
advanced disease 
It was evident from the responses and demographic data that the management of patients with 
advanced disease is common practice amongst oncologists in the private sector. For the 
majority of the participating oncologists it constitutes a major part of their daily work. This 
corresponds with ESMO’s survey on oncologists’ involvement in and attitude towards palliative 
care. Sixty nine percent of the respondents in that survey reported that their practices included 
patients with advanced disease.1 In the present study, the lack of adequate palliative care 
services was commented on while insufficient screening facilities in South Africa were proffered 
as a possible reason for the high incidence of patients with advanced disease.  
The management of patients with advanced disease was perceived as a very challenging 
activity, fraught with complicated issues and difficult problems. The admission by most 
respondents that the management of such patients, which constitutes a major part of their 
daily workload, is not an activity favoured by them is a cause for concern.  This may reflect a 




existence of the notion that this particular aspect of the participants’ careers is emotionally 
draining and may lead to burnout. However, such a perception differs from the results of 
ESMO’s survey in which most oncologists indicated that they derived satisfaction from their 
involvement with palliative and end of life care.1 Possible reasons for this perception amongst 
the participants in the current study could be the variety of difficult issues and challenges 
associated with the management of patients with advanced disease or the lack of training in 
palliative care, as stated by some respondents. Training in palliative care could not only 
improve the management and care of these patients but could also change the oncologists’ 
negative attitude towards this particular field by the development of coping skills which may 
help oncologists to experience the satisfaction that comes with the implementation of palliative 
care.   
The respondents experienced the management of young patients with incurable disease as 
especially difficult to handle. The determination of these patients to keep on fighting their 
disease despite bleak prospects affected the oncologists emotionally. Oncologists with young 
children of their own and who, therefore, were able to relate more intensely to such patients, 
were affected most. Oncologists also experienced the management of patients to whom they 
became attached as very difficult. Similar difficulties were experienced with the management of 
patients who reminded the oncologists of a friend or family member or whose personalities 
were compatible with their own. The various degrees of distress experienced by patients with 
incurable disease and by their family members may also render their management more 
difficult.  A great deal of time and effort need to be spent with these patients and their families 
to address issues and concerns and to provide compassionate support, especially in cases 
where denial is present. Such encroachment on the already limited time available in the daily 
schedules of the oncologists is aggravated by the extra paper work, of which the completion of 
referral forms for hospice and healthcare at home are examples, and administration usually 





Despite all the difficulties associated with the management of patients with advanced disease, 
the respondents did mention some rewards that were associated with this experience. Some 
respondents regarded the interaction with patients and their family members to ensure that 
everyone is well informed as fulfilling. Others experienced the effective control of their 
patients’ symptoms and the management of the complex associated issues as satisfying. One 
respondent was of the opinion that these rewards experienced could be enhanced by the 
improved confidence that would be associated with their further training in the field of 
palliative care. In short:  A dedicated compassionate oncologist who is passionate about his 
work and especially about palliative care would be able to thrive under these taxing 
circumstances.  
5.3 The difficult discussion when a patient’s disease has become incurable and 
the decision whether anticancer treatment should be stopped 
From time to time every oncologist is faced with the difficult decision on whether the 
anticancer treatment of a patient with advanced disease should be terminated or continued. 
These decisions are usually made by the oncologist after a comprehensive discussion with the 
patient and his family members regarding the disease status, the clinical rationale for stopping 
treatment and the approach to be followed with continued care.  It is imperative that patients 
be made aware that further anticancer treatment options may cause more harm than good, 
especially when their disease is advanced. The possible benefits and harm of anticancer 
treatment should be carefully considered and discussed to effectively apply the ethical principle 
of beneficence and non-maleficence. It is clear from the nature of the responses from the 
participants that this topic is regarded as an extremely important and arduous aspect of the 
management of patients with advanced disease  
After having the difficult discussion with their patients regarding their recent disease status, a 
complicated decision needs to be made regarding continuation of anticancer treatment or not. 
The oncologist’s perception of palliative chemotherapy together with influential factors which 
were gathered through the interviews can affect his judgement on this particularly important 
decision.  
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5.3.1 The approach of the oncologists towards the difficult discussion 
Most oncologists believed that an open and honest approach should be followed during the 
difficult discussion regarding the decision to stop anticancer treatment. They felt that 
information should be given in a clear and sensitive manner in understandable non-technical 
language. These findings correspond with the oncologists’ descriptions of communication with 
patient and family regarding end of life care in the study performed by Jackson et al.59 Enough 
time should be set aside for the discussion to enable the oncologist to address all concerns and 
answer all possible questions of the patient and family members. This again accentuates the 
time constraints associated with this particular field which inevitably add to the stress burden 
of the treating oncologist, particularly on a busy day.  It furthermore emphasises the value of 
following the team approach. The assistance of a social worker or palliative care physician could 
relieve much of the pressure on the treating oncologists during these difficult discussions   
Some oncologists expressed the opinion that the issue regarding the cessation of anticancer 
treatment and the commencement of best supportive care should be broached early in the 
disease process of a patient who presents with advanced disease. Such an approach is positive 
as it enables smooth transition from curative to palliative care and provides an early 
opportunity to discuss any issues regarding the initiation of palliative care services such as 
hospice referrals. Early discussions regarding the initiation of palliative care will also enhance 
early referrals to palliative care services which, in turn, will improve quality of care. These 
positive findings differ from the findings of Cherlin et al which showed that oncologists tend to 
inform their patients that their disease have become incurable only late during their disease 
process. This allowed little opportunity for palliative care discussions and hospice referrals.60  
Mutual trust was also believed to be a vital component that needs to be present between 
oncologists and patients to ensure better management of these discussions. A relationship 
between oncologist and patient which is based on mutual trust will enable the oncologist to get 
to know their patients’ personalities and to judge their ability to understand their situation. 
Building trust is usually much easier if the oncologist has been involved with the patient’s care 
over a long period. This will give the opportunity for trust to build steadily and to evolve with 
each consultation. 
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Most respondents emphasised that it is crucial in the management of patients with advanced 
disease that realistic hope be given when anticancer treatment needs to be stopped. Patients 
need to believe that there is always something that can still be done although the aim of 
treatment is no longer seen as curative. This is by no means the end of the road for these 
patients but only a transition into a new phase in their lives, as one respondent aptly stated. 
Unrealistic hope for a cure should rather be displaced with a more realistic hope for a life 
without pain or distress and the realisation of rational aims such as spiritual peace or ordering 
affairs, as stated by Daneault et al.24 These patients should therefore be motivated and 
encouraged to live their lives to the fullest and make the most of the time they have left.   
5.3.2 The oncologist’s approach to palliative chemotherapy 
The oncologist’s perception of and approach to palliative chemotherapy can have a major 
influence on the decision to stop anticancer treatment in patients with advanced disease. It 
may even cause the inappropriate prescription of aggressive chemotherapy. It was reassuring, 
however, to learn that some of the participants’ views regarding palliative chemotherapy 
became more conservative as they gained more experience. They gradually recognised that the 
exposure of vulnerable patients to life debilitating toxicities was unacceptable, especially where 
the aim of treatment is palliation of symptoms. This view was also held by Kao et al in their 
review of deceased oncology patients treated with palliative intent.22  
The notion that gaining experience caused the participants’ approach to become less aggressive 
is appropriate. In the treatment of patients with advanced disease, doing nothing in terms of 
chemotherapy can sometimes be regarded as good management. Thus, these participants were 
of the view that older, more experienced oncologists can play an important role to guide 
younger oncologists, who generally are more aggressive in their treatment decisions, to adopt a 
more thoughtful and cautious approach when deciding on the continuation of treatment of 
patients with advanced disease. Awareness of the value of holistic palliative care, which does 
not necessarily have to include palliative chemotherapy, could thus prevent the prescription of 
inappropriate chemotherapy which could improve quality of care. 
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5.3.3 The content of the difficult discussion 
The content of the discussion that oncologists have with their patients when their disease 
becomes incurable was commented on in detail by the participants. Back, Peppercorn and 
Hagerty et al32,35,64 outlined the information that should be provided to and discussed with 
patients during such sessions. It should pertain to prognostication, possible treatment options 
available with their related efficacies and toxicities as well as to a future care plan which has to 
correspond with the patients’ needs and preferences. The fact that most oncologists discussed 
with their patients the survival benefits of available treatment options together with associated 
toxicities was reassuring. This will enable the patient to take a better informed decision to 
consent to the continuation or cessation of certain anti-cancer treatments and not to 
desperately grasp at treatment options with low possibilities of success. Thus unnecessary 
aggressive treatments which may affect quality of life can be prevented. This finding differs 
from the analysis done by Audrey et al who found that most patients were not clearly informed 
about the survival benefits of palliative chemotherapy.61  
The majority of the oncologists who participated in this study also mentioned using special 
investigations such as CT-scans and blood results to convey the message of their patients’ 
disease status. This method of conveying disease information is sound as most patients in this 
situation experience fear and anxiety regarding their illness which can affect their attention and 
comprehension when information of a sensitive nature is presented to them. In these situations 
the special investigation reports serve as concrete evidence and visible proof of disease 
progression and will help patients to accept and understand their current condition. One 
participant emphasised that the provision of written information regarding their disease status 
and end of life care to patients is an essential element of good doctor-patient communication.    
Some oncologists pointed out that the discussions they had with their patients further provided 
the opportunity to discuss referral to palliative care services and also prevent unnecessary 
exposure to cytotoxic treatment regimes. The importance of regular follow up visits with their 
patients after anticancer treatment had been stopped was further underscored by a number of 
oncologists. This concur with the findings of Fujimory et al which indicate that participating 




Continued physician involvement will ensure that patients will not feel abandoned by their 
oncologists even though anti-cancer treatment has been stopped and main care has been 
handed over to other treating modalities such as hospices or general practitioners. During this 
phase of treatment the oncologist can concentrate, together with the other role players, on 
symptom management and quality of life care.  
Although the data suggested that the content of the difficult discussion that the participants 
had with their patients when their disease became incurable was comprehensive and thorough, 
the participants did not mention whether this was regular practice or only a description of the 
ideal situation. Furthermore, it was evident that certain preferences of patients, as identified by 
Hagerty and Peppercorn et al, had not been attended to.34,35,64 The participants did not 
mention whether they assessed and addressed any fears, concerns or wishes that their patients 
might have mentioned during these conversations. They also did not mention whether the 
extent of the information and the timing of the communication had first been negotiated with 
their patients or whether the patients’ permission had been requested before such information 
was discussed. According to Hagerty et al34  these preferences are important as there has been 
an increasing predilection of cancer patients in developed countries to become more involved 
in the decision making process regarding their care as well as a consequent demand for more 
detailed information regarding their disease’s prognosis. However, such shortcomings can be 
overcome with adequate training and raising of awareness regarding the importance of 
ascertaining patient preferences in good time.  
5.3.4 Factors influencing the oncologists’ decision to stop anticancer treatment 
After having the difficult discussion regarding the advanced state of a patient’s disease, a 
complicated decision needs to be made whether anticancer treatment will be continued or 
stopped. Numerous factors which may influence this important decision were mentioned by 
the participants 
Most oncologists commented that tumor response to anticancer treatment is a very important 
factor to consider when deciding on cessation of treatment. Non responders to previous lines 




to patients who have responded. This important information should be communicated to the 
patient during the decision making process to enhance acceptance of his situation. 
International guidelines should also be followed when prescribing palliative chemotherapy and 
discussed with the patient. Patients might find it easier to accept their disease status when they 
know that no further treatment options are available. 
Patient factors were also reported to have a strong influence on the decision to stop anticancer 
treatment. Especially patient tolerability and performance status should always be assessed 
and taken into consideration when deciding on further possible treatment. If the patient is not 
able to tolerate the toxic side effects associated with the treatment or if their performance 
status are influenced to such an extent that they stay mostly in bed, then continuation of 
treatment should be reconsidered. This approach is especially important when the aim of 
treatment was to improve the patient’s symptoms and quality of life. Each patient should 
therefore be assessed individually before prescribing palliative chemotherapy and the expected 
risks and benefits of the chemotherapy should be taken into consideration, as stated by Napa 
and Siato et al.66,68 Once again, the application of guidelines that will help oncologists to 
determine whether their patients are fit for treatment will be very useful, as recommended by 
Napa et al.66 
Most oncologists also believed that the patient’s preference for treatment should be taken into 
account and be respected, provided that the patient is well informed. This could be 
complicated as some patients’ ability to reason might be affected by emotions, family members 
or the advanced state of their disease. Oncologists should therefore guide their patients in their 
decision making process by taking into account any possible needs or concerns they might 
have. Patients should be made aware of the aim of treatment and possible influences that the 
side effects of the chemotherapy might have on their quality of life. Oncologists should 
reinforce if what the patient has decided, in their view, is acceptable but, at the same time, 
should keep in mind that despite their own views regarding their patients’ treatment decisions, 




Patients, together with their family members, can also have a great influence on the 
oncologist’s decision to stop anticancer treatment. Some participants believed that most of 
their patients can easily be influenced by close family members especially siblings, whose goals 
and wishes may differ from theirs. These family members, who may be in possession of 
information and data gathered from various resources, can exert pressure on the treating 
oncologists to continue treatment even if the outcome might be futile. Additional pressure can 
be exerted by a patient who, in turn, is influenced by his family members who, inappropriately, 
want to keep on fighting. Oncologists should therefore make sure that a family member is 
present when further treatment options are being discussed and that the social workers 
interact with and support the family members. Wishes and concerns of both the patient and 
family members should be addressed to prevent any misunderstandings and to make sure 
everyone is equally informed and in agreement. The oncologist should also adhere to his 
guidelines and honestly disclose all relevant information about prognosis and treatment 
outcomes without being influenced or manipulated by the patient or his family members. Most 
participants believed that a trustful and honest relationship with the patient and his family 
together with effective communication holds the key to alleviating the problems usually 
associated with the decision to stop treatment.    
Most participants admitted that working in the private sector can have an influence on their 
decision to stop anticancer treatment. More treatment options are at the private oncologist’s 
disposal than the oncology regimes available in the government sector. Although these 
treatment options may be less effective, their mere availability may easily influence the private 
oncologist to prescribe them rather than having the difficult discussion regarding cessation of 
treatment and initiation of palliative care. This was also noted by Kao et al.22 Reassuringly, some 
participants acknowledged that these multiple chemotherapy lines available are usually strictly 
regulated and should be prescribed appropriately. Participants also believed that patients 
should be made aware that, although there are more treatment options available, their 
effectiveness cannot be guaranteed. Even if the patient responded to these treatments, the 




Additional pressure is reported when funding for these treatment options from certain medical 
aid schemes are not available. Oncologists are then forced to stop anticancer treatment due to 
lack of funds and not by choice. This may be very difficult to communicate to the patient or his 
family. Additional time, stress and effort may also be consumed to motivate for the approval of 
funds by medical aid schemes for these possible futile but lucrative treatment regimes.  
Although participants believed that great caution should be applied not to waste limited 
resources on these potential futile treatments, some believed that flexibility should be applied 
in exceptional cases such as to provide time to the patient to experience the birth of a new 
grandson or the marriage of a daughter.  Each patient should therefore be assessed individually 
to determine if the necessity and benefits of these treatments are strong enough to outweigh 
the potential side effects and futility associated with them.    
5.3.5 Difficulties experienced by oncologists with the discussion 
Communication hurdles associated with the difficult discussion that oncologists have with their 
patients when their disease becomes incurable, were identified during the interviews. The 
patients’ inability to accept their disease status and their loss of hope if no cure is available 
were regarded as common problems that usually arose during these discussions. The 
participants felt that if they acknowledged to their patients that anti-cancer treatment should 
be stopped, they may be regarded as a failure. They believed that their patients perceived them 
as doctors that will cure their disease and, therefore, they should give everything to uphold this 
perception.  
Patients also found it very difficult to accept information indicating that there are no more lines 
of treatment available for their disease. They will even refuse treatment if the treatment aim is 
enhancing quality of life and not life extension. Young patients, in particular, will grasp any 
opportunity for cure, even if the chances thereof are very slim. This was also evident in the 
study performed by Matsuyama et al which indicated that patients with advanced cancer were 
inclined to opt for chemotherapy even if only a minor health benefit might materialise.70 The 
participants found it difficult to manage the emotional outbursts and reactions by patients and 
their family members when receiving the news;  the different points of view between the 
patient and his family regarding further treatment as well as the mixed messages received by 
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family members who were not present at the consultations. It is of utmost importance that all 
concerned family members attend these consultations together with the patient to address 
issues regarding further treatment options and to prevent any future discrepancies.    
The participating oncologists experienced difficulties in the management of the communication 
hurdles associated with the discussion to stop anticancer treatment. The complexities of each 
hurdle together with the time constraints that are usually associated therewith were proven to 
be quite challenging. These hurdles may further influence the treating oncologists to provide 
inaccurate prognostic information to the patient which may lead to the prescription of possible 
inappropriate aggressive anticancer treatment. Oncologists should perhaps embrace both 
biomedical and psychosocial aspects of care as suggested by Jackson et al. Oncologists that did 
so were proven to communicate more clearly about end of life care; felt more satisfied with the 
care they provided to terminally ill patients and their families; did not regard progression of the 
disease as due to personal failures and also felt less burnt out. They also understood that these 
conversations should take place on numerous occasions during treatment to provide more 
opportunities for closure and emotional support.59   
5.3.6 People participating in the discussions 
Most oncologists prefer that a family member or care giver should be present when they 
inform their patients that their disease has progressed beyond the realms of cure and that 
treatment should be stopped. Discussing bad news regarding the status of his disease with the 
patient can be very traumatic and stressful which can affect the transfer of information. Family 
members or care givers can assist patients by relaying information which may be missed due to 
anxiety or disease related fatigue. They can further act as a form of support for the patient 
when bad news is delivered. Most patients also preferred to have a family member or care 
giver present during these conversations, as reflected in the systemic literature review 
performed by Hagerty et al.34  
The presence of an oncology social worker during these conversations was also regarded as 
important by the participants. Not only will they give extra support to the patient and his family 




unfamiliar. Not all oncologists regarded it as necessary for the social worker to attend all these 
consultations. It might be logistically difficult especially if these discussions occur unforeseen, 
for instance when a routine follow up scan reveals disease progression. Some oncologists will 
only consider possible engagement of a social worker if the discussion indicates that it will be 
appropriate for one to be involved. The oncologist will then, after the discussion, first confirm 
with his patient that he will require the assistance of a social worker before making the 
necessary arrangements with a social worker. The contribution by an oncology social worker 
could also be more beneficial if she is involved earlier in a patient’s disease process, even when 
cure is still the aim. This would enable a smoother transition to supportive care due to the 
better understanding of the disease process which the patient would obtain through the 
extended counseling. It would also allow a more effective use of the social worker’s skills as the 
patient’s illness progresses. 
5.4 Advance directives 
Advance directives play a very important role when a patient’s disease becomes incurable. It 
guarantees that the wishes of patients are respected with regards to future care and treatment 
in scenarios where they are not able to decide for themselves. This is especially evident in 
situations where a patient’s condition deteriorates rapidly and where decisions regarding 
further active treatment need to be taken on behalf of the patient who might be too weak to 
decide. It was therefore disturbing to notice that although a minority of the participants 
believed that discussing advance directives with their patients are important, most of them 
admitted that this is usually neglected and not routinely done. Possible reasons given were 
demanding time constraints associated with these discussions as well as the unwillingness of 
patients to engage therein because they feel they are not ready yet. This was also shown in the 
study of Kierner et al who reported on the poor interest shown by patients in advance 
directives due to inappropriate timing of the discussion.71  
The participants also felt that broaching the subject of advance directives would imply that 
active resuscitation would be inappropriate and, therefore, would not be performed when a 




their patients and manage their symptoms, high care management such as intubation and 
ventilation would only be appropriate if the reason for deterioration of their patients’ 
conditions is unrelated to their advanced disease. If not communicated well, this view can 
potentially cause great stress and uncertainties in situations where a patient’s wishes are to 
continue active treatment or where family members are unaware of the advanced state of the 
patient’s disease. Participants felt that discussion of advance directives with the patient and his 
family can help to prevent these uncertainties and decrease pressure on the oncologists when 
decisions need to be taken on whether a patient needs to be actively resuscitated or not. The 
chances are that most patients with advance directives do not want active resuscitation or 
invasive procedures to prolong their life but only procedures to manage their symptoms and 
improve quality of life. This was confirmed by Kwon et al in their study of the advance directives 
for terminal cancer patients.75 
It was evident from the data regarding the timing of the discussion of advance directives that 
the participants did not approach this subject with urgency. Most participants will wait for 
patients or their family members to raise the topic before discussing it. This approach may 
essentially rule out this discussion because some patients and their family members might not 
be aware of this practice or, if aware thereof, may be reluctant to participate in such a 
discussion in fear of accepting the advanced status of their disease. Some participants will wait 
for their patients’ disease to become resistant to anticancer treatment or for their condition to 
deteriorate to such an extent that an arrest is anticipated before broaching the topic. This may 
complicate the discussion because patients in these situations tend to be more reluctant to 
have this conversation, as proven by Kierner et al.71 International perspectives are that advance 
directives should be discussed early and frequently in a patient’s disease process. Regrettably, 
only two participants held this view. Such an approach will provide frequent communication 
opportunities to discuss the patient’s disease process and to address any concerns or 
uncertainties. It will further give the patient and his family enough time to process the 
information and plan for the road ahead. The discussion regarding the implementation of 
palliative care could also be brought into the conversation which could lead to early referral to 




5.5 Oncologist burnout  
Burnout is found to be quite common amongst oncologists due to the nature of their work. It is 
a serious condition which can affect their physical health as well as their interaction with 
colleagues or family members. If left untreated it could seriously influence their ability to 
provide quality of care. It was alarming to learn how the management of patients with 
advanced disease affected the participants emotionally and physically. Most participants 
commented overwhelming about the emotional strain and physical exhaustion they experience 
when dealing with patients with advanced disease. These symptoms affected their daily work 
as well as family life by causing them to be frequently irritable, frustrated, physically exhausted 
and more prone to emotional outbursts towards colleagues and family members. Emotional 
exhaustion and frustration were proven to be two major signs of oncologist burnout, as stated 
by Allegra et al.83 It is strongly suspected, therefore, that these participants may be 
experiencing a degree of burnout. 
It is reassuring that the participants were well aware of the importance of recognising burnout 
and that they had strategies in place to prevent or overcome it. Most participants believed in 
taking regular breaks and holidays to get away from the stressors of work and to recharge. 
These strategies were also identified by Allegra, Whippen, Swetz and Granek et al.83,84,86,88 A 
good strategy mentioned and which was also referred to by Lyckholm48, is the sharing of 
afterhours calls and having one half day in a working week off for personal matters. This is an 
important advantage of the sharing of an oncology practice with other oncologists and should 
be recommended. Extra-occupational interests such as outdoor activities, hobbies, exercising, 
travelling, gardening, sports and spending time with the family were also regarded as good 
measures to prevent burnout and concurred with the findings of Swetz et al.86 Some 
participants believed that emotional distance from patients, especially if they have advanced 
disease, may prevent burnout while another believed that delegating work may ease the 
pressure. 
Support for oncologists in their efforts to cope with burnout was also seen as important by the 




or from their family members at home. It was alarming to learn that private companies 
employing oncologists as a rule do not provide much support to oncologists to prevent burnout. 
An oncology social worker is present at the units when needed, however, no formal debriefing 
for burnout was provided by the participants’ company. Some participants were appalled with 
this situation and felt that they were let down by their company in that respect. The only 
support given by the company to prevent burnout was to provide leave and sabbaticals. Some 
participants felt that time constraints and overloaded working schedules prevented any 
participation in whatever support is provided to lessen burnout. Overloaded working schedules 
are seen by Shanafelt and Allegra et al as major causes of burnout.47,83 Therefore it is suggested 
that possible ways in which the participants’ institutions could support them in the prevention 
and treatment of burnout should be investigated. It could include training and provision of 
information, acknowledgment and validation of grief and institutional psychosocial support, as 
recommended by Granek et al.88   According to Lyckholm,48  the formation of clinical health 
teams where team members can clinically and emotionally support one another and hold 
regular meetings for debriefing can also be very valuable. Adequate training in palliative care 
can assist oncologists to develop competence and confidence in managing patients with 
advanced disease so that the personal and professional satisfaction in helping these patients 
and their families mitigate against burn out.      
5.6 The oncologist’s understanding of the concept of palliative care 
It was evident from the responses of the participants regarding their understanding of palliative 
care that the majority were not familiar with all the aspects of palliative care as set out by the 
World Health Organisation.27 Most participants felt that palliative care encompasses mainly 
symptom management with a focus on quality of life and not cure while others thought that 
psychosocial support should also be added. Only one participant saw palliative care as a holistic 
approach to patient care incorporating symptom control, psychosocial and spiritual support 
together with ongoing management of the patient’s disease. None of the participants 
mentioned support for the patient’s family in their comments. This unfamiliarity with the field 
could be due to a lack of training received in palliative care. Some participants admitted that 




Most of what they know of palliative care was self taught from text books and was gained 
through experience. These statements correlate with findings of the ESMO’s survey on 
oncologists’ involvement in and attitude towards palliative care. According to the results of this 
survey participants admitted that they had not been adequately trained in the field of palliative 
care.1 
Despite the lack of training in and familiarity with the field of palliative care, reassuringly most 
of the participants suggested that palliative care should be implemented early in a patient’s 
disease process. This will ensure smooth transition from curative treatment to palliative and 
supportive care. The participants also believed that palliative care should coexist with active 
anticancer therapy to ensure the continuum of care. These findings concurred with the study 
done by Bakitas et al where clinicians valued the introduction of early palliative care in 
concurrence with oncology treatment.55 However, none of the participants saw palliative care 
as only palliative chemotherapy or radiotherapy. Unfortunately a small number of participants 
were of the view that palliative care should be introduced only when a patient does not 
respond to active treatment anymore and has moved into the preterminal phase of his disease. 
This once again emphasises the lack of training in and understanding of palliative care. Training 
opportunities should therefore be made available for oncologists to improve their 
understanding of palliative care and to stimulate an interest to ensure proper management of 
patients with advanced disease. 
5.7 Palliative care setup at treatment units 
Numerous studies have shown the advantages of following a multi-disciplinary approach 
towards providing palliative care to patients with advanced disease.44,45 It embraces different 
frameworks and approaches to adequately manage the complicated needs of these patients. 
According to studies performed by Temel and Muir et al3,56 embedding a palliative care clinic in 
a private outpatient oncology unit has the potential to further improve symptom control and 
care for patients while providing support to the treating oncologist. It was therefore alarming to 
note that, despite these positive findings, most participants admitted that no formal palliative 




They do however agree that having a specialised palliative care team present in their units 
would be a positive goal to strive for.  
The provision of palliative care was mainly regarded as a combined effort launched by the staff 
members already present at the units. These staff members included oncologists, medical 
officers, physician extenders, social workers, chemotherapy nurses, radiographers and 
administration staff. Every staff member who has regular contact with patients becomes aware 
of the patients’ needs and provides support in some form or another. However, the actual 
communication about palliative care would be performed by the doctors, the oncology social 
worker and physician extender. Although certain specialties such as physiotherapists, 
counselors or spiritual advisors were missing from the current palliative care setup at the units, 
the participants did mention the utilisation of outside modalities, such as hospice referrals and 
the patient’s general practitioner to assist with the provision of palliative care.  
Although it was reassuring to note that all staff members were involved in providing palliative 
care, no indications were given that these staff members were adequately trained in the field of 
palliative care. Nothing further was mentioned about having regular team meetings to evaluate 
and reflect on complicated situations or provide meaningful support to each other as suggested 
in the literature.49 This will provide opportunity for team members to make combined decisions 
about patient care and to learn from each other’s expertise. It will also provide the opportunity 
to express work related feelings or discuss possible problems in the work place. Effective 
training and mentoring from experienced clinical care workers should also be encouraged to aid 
in developing professional competence within the team, as stated by Meier et al.51  
5.8 Shortcomings in the current palliative care services 
The participants were of the opinion that a number of shortcomings were present in their 
current palliative care services. According to them being the sole provider of palliative care 
does come at a price. The complex responsibilities and hard work associated with this activity 
can put a great deal of pressure on the treating oncologist and may eventually lead to burnout. 
Some participants also felt that the lack of palliative care could unnecessarily prolong 
anticancer treatment in an attempt to support patients till the very end. They further believed 
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that referring these patients to palliative care services such as their general practitioners or 
local hospices might cause some to feel abandoned by their oncologists. However, such 
experience of abandonment could be alleviated by the provision of better integrated palliative 
care with standard oncology care. This was shown in the study by Smith et al.20 
Further reasons for concern were that the current palliative care referral facilities were 
regarded by some participants as inadequate. In their view general practitioners and ward staff 
members lacked palliative care knowledge. According to other participants their local hospice 
services had problems such as poor communication structures, unavailability of beds as well as 
poor support. Interestingly enough only participants working in the northern suburbs of Cape 
Town had these complaints about their hospice service. This may warrant further investigation 
to determine possible reasons for this poor relationship and to develop recommendations for 
an improvement of the situation. As some participants consider hospice referrals as a crucial 
element in the management of patients with advanced disease, good relationships with the 
available hospice services are essential.  
5.9 Recommendations to improve palliative care facilities currently available 
at treatment units 
Numerous studies have shown the importance of the implementation of the palliative care 
team approach in the management of patients with advanced disease in a standard oncology 
practice. Not only does this approach improve patients’ satisfaction with care and symptom 
control but it also provides the treating oncologist with much needed support.3,56,79,80,81 
Therefore, it was reassuring to learn that most participants recommended the provision of 
exclusive multidisciplinary palliative care services  together with the employment of a palliative 
care specialist to assist in the management of patients with advanced disease. The availability 
of these services at the units will provide the oncologists with valuable additional time to 
concentrate on more oncological specific treatment and will ensure that patients experience an 
early smooth transition to palliative care. The notion that the palliative care consultants should 
act as leaders of these multidisciplinary teams was very important because it was evident 




would also enhance communication between team members which is necessary to promote 
cooperation within a multidisciplinary team, as was shown in the work of Junger et al.82  
The strong recommendation that the patients’ general practitioners be utilised more when 
their disease becomes advanced was a positive notion. Most patients have a strong bond with 
their general practitioners and would benefit from their services in the comfort of their own 
home. The general practitioners could further assist the oncologists in the provision of palliative 
care, easing the latter’s work load by controlling symptoms or helping with the administrative 
work associated with their care. Essentially these general practitioners should be trained in the 
field of palliative care as some of them were believed to be uncomfortable with the provision of 
such a service. Once again, good communication between participating general practitioners 
and oncologists would be an important factor in ensuring continuity of care. In addition, the 
early hospice referrals of patients with advanced disease, as recommended by some 
participants, could further assist the treating oncologists in the care of these patients. Early 
hospice referrals would ensure better symptom management as well as possible less hospital 
admissions. Continuity of care could further be enhanced by having regular meetings with 
hospice staff to discuss the patient’s condition or address any workflow issues as suggested by 
some participants. Although resources for specialised palliative care facilities in South Africa are 
scarce, according to some responses, utilisation of these existing outside modalities is a step in 
the right direction. 
Medical officers, nurse practitioners and oncological social workers were also mentioned to be 
essential elements in the current palliative care setup. As with hospice services and the 
patient’s general practitioner, their permanent presence in the units provide additional support 
for the treating oncologist. The social workers’ service was regarded as invaluable and was 
recommended to be utilised more often in cases of patient distress. The training of medical 
officers and physician extenders (oncology nurses who manage patients’ symptoms and 
concerns under the supervision of an oncologist) in palliative care were again accentuated by 
the participants. This will ensure that these staff members will be more comfortable in dealing 




which eventually improve the quality of care. The availability of guidelines pertaining to 
palliative care issues and symptom management at the units, as suggested, will further aid in 
staff training and will probably make  palliative care more uniform. 
5.10 Limitations of study 
5.10.1 Limitations pertaining to the study population 
The study focused only on oncologists practicing in private oncology units in various parts of 
Cape Town. This may limit transferability of the data to oncologists practicing elsewhere in 
South Africa. The fact that the researcher purposefully recruited his sample from participants 
working for the same company and at units in close proximity to his working unit may be 
regarded as selection bias. This may also have influenced the participants’ responses as they 
might have been cautious not to show weakness or vulnerability. Working in the same company 
as the researcher could also have made the participants more obliged to enlist in the study, 
hence the high response rate.  Furthermore, time constraints associated with the participants’ 
working schedule together with interruptions experienced during some interviews could have 
caused rushed or inattentive responses. Unfortunately, some interviews had to be rescheduled 
due to difficult time constraints. Nevertheless, the participants did not at any time give the 
impression that they were rushed or negatively motivated. They were always very eager to 
participate and gave very good feedback on their experiences. 
5.10.2 Relevancy of the data 
Despite these limitations listed, the data gathered did contain valid information regarding the 
management of patients with advanced disease in the private sector of South Africa. Although 
the results might not be representative of other private oncology centers in South Africa, the 
researcher believes that, as the sample included oncologists from several age groups; from 
various fields of specialisation; of different degrees of experience and of both genders the 
results reflect the preference of a broad range of oncologists practicing in the private sector of 





5.11 Summary of findings 
It was evident from the findings that the management of patients with advanced disease is a 
complicated and stressful part of the participants’ work. It not only constitutes a major part of 
the participants’ daily work programme but also contains major challenges such as difficult 
discussions regarding disease status and cessation of treatment; dealing with fear and anxieties 
of patients and their family members; the discussion of advance directives and the provision of 
palliative care, a field fairly unknown to the participants. If these challenges are not managed 
properly it can easily lead to oncologists’ burnout and eventually affect quality of care. Current 
shortcomings have been identified and recommendations have been made by the participants 
to successfully overcome these challenges and to improve the current palliative care services at 
their treating units. By adhering to these recommendations patient care and oncologists self 
care could eventually be improved. Further recommendations made by the researcher will be 











CHAPTER 6: Conclusion and recommendations 
6.1 Conclusion 
The management of cancer patients whose disease has become resistant to anticancer 
treatment is a complicated part of every oncologist’s career. The aim of this study was to 
evaluate this particular practice of oncologists working in the private sector in Cape Town, 
South Africa, and to identify the needs associated with such management. It was evident from 
the data that the participants perceived this component of their work as challenging, filled with 
difficult problems which caused fair amount of stress. These challenges included, amongst 
others, the dealing with young terminally ill patients; with certain patients with advanced 
disease with whom a relationship was formed and to whom they became attached to; with the 
external pressures exerted by family members and with the difficult time constraints associated 
with the management of these patients.  
Adding to these stressors are all the complicated issues associated with the difficult discussion 
which the oncologists must have with their patients when their disease becomes incurable. 
Most participants reported that they manage this discussion fairly well in an open and honest 
way. They provide comprehensive information regarding disease prognosis, treatment toxicities 
and efficacies with the aid of special investigations reports. They also try to incorporate 
discussions regarding palliative care treatment options in a sensitive way to ease the transition 
from curative to supportive care. Some support is however needed to overcome 
communication hurdles associated with these discussions. These hurdles include the 
management of patients in denial; surmounting feelings of failure; dealing with the emotional 
outbursts, fears and anxieties of patients and their family members and with the difficult time 
constraints associated with these discussions.  
Further support is necessary to aid the treating oncologist in his complicated decision on 
whether anticancer treatment should be continued. This decision usually follows on the difficult 
discussion regarding the advanced state of a patient’s disease. Reasons given for stopping 
anticancer treatment included disease resistance, poor patient tolerability and performance 
status, patient preference and insufficient funding by medical aid schemes. Guidance regarding 
136 
the patient’s fitness for treatment and support to overcome pressures exerted by patients and 
their family members are necessary to aid the treating oncologist to prescribe appropriate 
anticancer treatment, especially in the private sector where numerous treatment options are 
available. The value of involving a multidisciplinary team to assist the treating oncologists 
during this arduous discussions and treatment decisions was also emphasised. 
Advance directives play an important role in the management of patients with advanced 
disease. It ensures that patients’ wishes regarding future care and treatment options are 
respected when they are not capable to decide for themselves.  However, this particular 
practice is neglected by the participating oncologists. Reasons for this neglect include difficult 
time constraints and the unwillingness of patients to engage in such a discussion in fear of 
acknowledging the advanced status of their disease. Most participants felt that it implied that 
patients with advanced disease are not in favour of active resuscitation. Therefore, guidance 
regarding the aims and development of advance directives is necessary to promote this practice 
and to ensure that patients benefit from the advantages that are associated therewith. These 
advantages include frequent communication opportunities to discuss the patient’s disease 
process, assurance that fears and anxieties are addressed and the timely discussion of the 
implementation of palliative care support services. It further prevents unnecessary stress and 
anxiety in instances where a patient becomes unresponsive to anticancer treatment and when 
a decision regarding further active management needs to be taken. Eventually, unnecessary 
invasive procedures, of which the outcome is often expected to be futile, will be prevented. 
The current palliative care services at the different treatment units were also investigated. It 
was found that no formal palliative care team exists in any of the treatment units. Patients with 
advanced disease are managed by involving a team consisting of the staff present at the 
treatment units. These staff members include the oncologists, medical officers, physician 
extenders, chemotherapy sisters, radiographers, the oncology social worker and administrative 
staff who interact with the patients on a daily basis. External modalities such as hospice 





However, shortcomings were identified within these particular structures. No real leadership 
existed within the treating team and regular team meetings for case discussions and support 
were not performed. The team also lacked the presence of members of other specialties who 
can make invaluable contributions to the care of these patients. Such team members may 
include a palliative care physician, psychologist, spiritual advisor, dietician, physiotherapist and 
a lymphoedema specialist, to name but a few. The lack of training in palliative care of the 
current members of these teams was also identified.  
The study provided clear evidence of the participating oncologists’ general lack of knowledge of 
and, hence, their need of formal training in palliative care. This can affect their attitude towards 
palliative care and may influence the quality of the care they are providing. 
Problems with the external services involved with palliative care also emerged. These problems 
include poor relationship with the local hospice services at some units due to poor 
communication and the lack of available beds and support. The inability of general practitioners 
to provide adequate palliative care, mainly due to a lack of training, also came to the fore. 
Consequently, some oncologists were reluctant to refer patients to these services. Patients are 
also likely to experience feelings of abandonment when they are referred to these services for 
palliative care. As a result some treating oncologists are, in many instances, the sole provider of 
palliative care, which may add to additional stress. Their lack of knowledge of palliative care 
and lack of formal training in palliative care means that they are ill-equipped to take on the role 
of sole palliative care provider. 
All these above mentioned stressors experienced during the management of patients whose 
disease has become incurable did have a significant influence on the participants’ physical and 
emotional well being. Some participants’ daily work and family life were markedly affected. A 
strong belief prevailed that some of the participants were actually suffering from burnout due 
to the presence of associated symptoms such as emotional exhaustion and frustration. 
Although most participants had some form of strategy to overcome burnout at the workplace, 
little support was given by their employers to ease their workload. Therefore, as a consequence 




oncologists need support to identify, manage and prevent burnout. Not only will such support 
improve the oncologists’ emotional wellbeing but it will also improve the quality of care 
rendered. 
The holistic management of patients with advanced disease by their oncologists in the private 
sector of South Africa is a field which has, as yet, not been well researched. The researcher’s 
study succeeded in its aim and objectives by providing a comprehensive description of the 
important aspects of the treating oncologist’s management of patients suffering from incurable 
cancer in the private sector of Cape Town in South Africa. Theses identified topics represent the 
salient aspects commonly associated with this particular field. Identified needs of the 
oncologists associated with this field were also described. A number of recommendations to 
address the needs mentioned are given and will be discussed below.  
6.2 Recommendations 
It was evident from the findings that the participants lacked knowledge and proper training in 
the field of palliative care. This could be a cause for their negative attitude towards palliative 
care which constitutes a major part of their daily work programme. Further training in the field 
of palliative care is therefore necessary to improve their skills in and change their attitude 
towards this field. Currently, a part time correspondence diploma in the field of palliative care is 
presented by the University of Cape Town which is aimed at the provision of basic knowledge 
and skills in palliative care. It is recommended that GVI Oncology both encourage and create 
the opportunity for oncologists and other relevant staff in their employ to undergo this course. 
To maintain their acquired skills and knowledge, the personnel involved in palliative care should 
further be provided with the opportunity to regularly attend seminars and workshops in this 
field. 
 This study has shown that the difficult discussion between oncologist and patient when the 
patient’s disease has become incurable and the decision whether anticancer treatment should 
be stopped has become unavoidable, is an extremely challenging part of any oncologist’s work. 
The management of such a discussion is, in the majority of the cases, solely based on the 




experience. Therefore, to ensure that such discussions be conducted with minimum distress for 
both oncologist and patient, the availability at all oncology units of suitable guidelines on the 
directing and management of this very important oncologist-patient interaction is essential. 
These guidelines should advise on aspects such as the timing of the discussion; breaking bad 
news to the patient and addressing fears and needs of the patient; the prescription of palliative 
chemotherapy and the determination whether the patient is fit for such chemotherapy; the 
discussion of palliative care referrals and follow up treatment plans; the involvement of social 
workers and family members; and the arrangement of follow-up discussions.   
It has further been shown that the discussion of advance directives with and the development 
of such directives for patients have real advantages for the management of terminally ill 
patients. Therefore, this practice should be promoted amongst oncologists. Again, guidelines 
should be available at treating units to direct the oncologists through the communication 
process with their patients regarding this delicate matter. It would further be beneficial if 
leaflets providing information pertaining to the purpose and contents of advance directives 
could be presented to patients and their family members.  In the preceding two paragraphs 
reference is made to the need for the development of guidelines for oncologist-patient 
communication regarding the nature of treatment after it has become clear that the patient’s 
cancer has become incurable and for the development of advance directives. It is 
recommended that one set of guidelines on every one of these two subjects should be 
developed for GVI Oncology as a whole. It is further recommended that a staff member should 
be made responsible for this task and that the guidelines be developed through a transparent 
process of workshopping.  
It clearly emerged in the course of this study that the most effective palliative care is provided 
at institutions where a multidisciplinary approach is followed which is coordinated through the 
activities of a formally constituted multidisciplinary team under the leadership of a dedicated 
palliative care consultant. It is therefore recommended that GVI Oncology seriously consider 
the establishment of such teams at its treatment units. The formation of teams of this nature 




extent the pressure currently exerted on treating oncologists. It needs to be kept in mind that 
the creation of palliative care teams could be effected without major staffing implications. All 
treatment units visited already have nuclei of relevant professionals whose activities could, 
through a slight adaptation in management, be molded to contribute effectively to the 
provision of multidisciplinary palliative care.   
Neither would it be necessary to newly appoint a dedicated palliative care consultant. A 
currently employed medical officer could, through experience and part time and in-service 
training, be prepared for the function of assisting the oncologists in the management of 
palliative care issues such as symptom control and psycho-social and spiritual support of the 
patients and their family members. The palliative care physician can further assist the treating 
oncologists by dealing with additional matters associated with the provision of palliative care. 
These matters may include completion of referral forms to different treatment modalities such 
as hospice services and medical referrals, the compilation of palliative care guidelines to assist 
in the provision of palliative care at the treatment units, the writing of motivations to medical 
aid schemes for healthcare at home or medication and equipment associated with palliative 
care, the completion of insurance forms and benefits claims of patients and the handling of 
correspondence with referring specialists and general practitioners. In addition the palliative 
care physician can negotiate more effectively with medical aid schemes the provision of 
enhanced benefits for palliative care services and can promote palliative care training and 
awareness amongst fellow staff members as well as amongst external treatment modalities. 
During this study burnout has come to the fore as a fairly common phenomenon amongst 
oncologists. Despite its prevalence conspicuously little was done by the oncologists’ employing 
company to provide support to enable the oncologists to cope with the problem of burnout.  
Therefore, it is recommended that the oncologists should be made aware of and tested for the 
warning signs and symptoms of burnout on a regular basis. Formal counseling services provided 
by independent counselors should be made available to the oncologists. Provision should 
further be made for regular staff meetings for debriefing and support. These meetings would 




enable mutual advice and support between team members. Work experiences, both emotional 
and uplifting, should also be shared amongst staff members during these meetings to promote 
a sense of well being. Opportunity should be created to delegate work to share the load in 
order to alleviate difficult time constraints. Training in palliative care would increase the 
oncologists’ competence and confidence in managing patients with advanced cancer and this 
would mitigate against burn out. Other identified training needs may be addressed to assist 
oncologists in their work.  
It was evident throughout this study that managing patients whose disease has become 
resistant to anticancer treatment was perceived as a daunting task filled with complicated 
challenges. By implementing the recommendations above, this negative perception of the 
participants could be changed to a more positive outlook due to the development of coping 
skills and the provision of needed support. Further improvement of palliative care services at 
these treatment units will ensure that a high quality of care is rendered to patients which will 
send out a message of compassion and care. This will reflect positively on the company’s image 
and may improve their client base. Oncologists who are willing to grasp palliative care and 
improve their knowledge and usage thereof may find that they will reap the rewards that are 
associated with this field, as stated by Twycross. These rewards include achieving symptom 
relief and rendering psychosocial support, gaining benefits from working in a supportive team, 
practicing thorough medicine, gaining inspiration and joy from interacting with patients and 
their family members and experiencing personal growth within the challenges of working with 
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A: Letter requesting permission to conduct research at research site 
Attention: Head of clinical services 
GVI Oncology 




Dear Doctor……………..   Date 
 REQUEST TO PERFORM A QUALITATIVE RESEARCH STUDY AT GVI ONCOLOGY 
I am hereby requesting permission to perform research, which forms part of my studies for a 
master’s degree in palliative care, at your treatment units in the Western Cape. 
The study is a qualitative, cross-sectional study in which private oncologists working for GVI 
Oncology will be interviewed to evaluate their current practice and indentify needs when 
dealing with patients that are not responding to anticancer treatment anymore. 
Fifteen oncologists currently working in the Vincent Pallotti, Rondebosch, Panorama, Cape Gate 
and Vergelegen units will be requested to participate in the study. Each oncologist will be 
approached by email and his/her written consent will be obtained prior to commencement of 
the study.  
A report on the findings of the study will be sent to you and presentations to GVI staff will be 





I look forward to performing my study at your site and will be fixing the date of launch once I 
have full ethical approval. 
 
Please do not hesitate to call me should you have any questions or queries with regards to this 
study 
 
Yours sincerely  
 
Dr JC Grove 
(Oncology Medical Officer) 
 




















B: Information sheet for oncologists participating in study  
Dear Doctor                                                                                Date 
Thank you very much for your willingness to devote some time to read this information sheet 
about my prospective study. I recently enlisted for my master’s degree in palliative medicine at 
the University of Cape Town. Amongst others, the course includes a research dissertation that 
needs to be completed within the next two years. I would appreciate it if you would consider 
participating in my study that will be explained as follows. 
Background and aim of study: 
Patients with advanced cancer who do not respond to anticancer treatment represent major 
challenges for their treating oncologist. This study aims to investigate the current practices of 
private oncologists in the management of patients whose disease does not respond to 
anticancer treatment and to identify support needs. If you consent to take part in the study, I 
will contact you to confirm an appropriate time for an interview that will last approximately 30-
45 minutes.  
The interview will be digitally recorded and your identity will be kept anonymous. You are 
welcome to terminate the interview at any time. You will receive feedback in the form of a 
report on conclusion of the study. 
 
Questions regarding the study: 
Please do not hesitate to contact me telephonically or by email should you have further 
questions regarding the above mentioned study. If you are concerned about any ethical issues, 
please contact Mrs Lameez Emjedi of the Faculty of Health Sciences HREC, E 52, Room 24, Old 













Dr JC Grove 
(Oncology Medical Officer) 




















C: Topic guide for interview 
 General starting question: 
- What is your experience with managing patients whose cancer is no longer 
responding to oncology treatment?  
 
 Communication skills of the oncologists:  
- Describe how you would communicate to your patient that his/her disease is not 
responding to anti-cancer treatment anymore and that treatment should be 
stopped.   
- Explore: Difficulties of conversations 
                Who is involved during consultation( family, caregivers) 
                What information is given to the patient and his/her family 
                 
 Factors influencing treatment decisions: 
- Describe the factors that will influence your decision to stop anti-cancer treatment 
- Explore: The influence of family members on decision 
                The influence of the patient 
                Difficult demands of the private sector 
                 
 Use of advance directives: 
- What are your views on discussing and using advance directives if a patient’s 
disease is not responding to anti cancer treatment. 
- Explore: The views of the patient and family. 
                The advantages of advance directives. 
                Difficulties discussing it with family members and patient 
            Does this discussion result in an advanced care plan? 
 
 The palliative care team approach:  




- Explore:  Oncologist’s understanding of palliative care. 
                 The importance/role of palliative care in the private sector. 
                 When is it appropriate to refer patients for palliative care? 
 
 Burnout of the oncologist and necessary support: 
- Describe how the management of patients with incurable disease affects you 
emotionally and physically. 
- Explore: Strategies to deal with stress 
                 Support systems in place for oncologists 
                 Recommendations to counter burnout  
 















D: Permission from the research committee of GVI Oncology to perform the 
study at the requested treating units 
Dear Jan Chris  
I am copying DR Gouws comment in this mail for inspiration to you, perhaps this could be your 
Doctorate !!!! 
You have permission to continue and please keep us posted  
Warm Regards  
Linda Greeff  
For the Research committee  
“I think it is an important piece of research, I would be happy to have sponsored him to 
interview all Oncologists in RSA, as I believe at least it will make them take note and hopefully 
acknowledge that there is a problem in dealing with this important issue. I accept it is beyond 
the scope of his research. 
Maybe an electronic version once he has identified his initial findings may still be worthwhile to 
get the rest to think about what they do. To my mind it is simply easier to offer another line 
than have that exceptionally difficult conversation and have to deal with the consequences of 










E:  Consent form for interviews 
 
Consent form for interview  
I confirm that I have read and understand the information sheet and have had the opportunity 
to ask questions. 
I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving a reason 
I agree to take part in the above study. 
 
Name ________________________________                             
 
Signature _________________                 Date ___________ 
 
Researcher:   
 
Signature _________________                 Date ___________ 
 
Witness:  Name        
(from clinical team or family member) 
 
Signature _________________                 Date ___________ 
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F: Ethics approval letter 
